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ABSTRACT 
Background 
Non cystic fibrosis bronchiectasis (NCFBE) is an increasingly prevalent disease, predominantly 
affecting the older population in Australia. It is a morbid condition with chronic daily cough and 
sputum production, associated with frequent pulmonary exacerbations. Recent randomised 
controlled trials have shown that macrolide antibiotics decrease pulmonary exacerbation frequency, 
particularly in patients infected with Pseudomonas aeruginosa.  
 
Airway infection with P. aeruginosa is associated with a more severe disease phenotype. P. 
aeruginosa utilises several different mechanisms to cause disease within a host organism, one of 
which is quorum sensing. Quorum sensing is a density-dependent mechanism by which P. 
aeruginosa coordinates population-level behaviour, particularly virulence responses. Further, there 
is evidence that P. aeruginosa quorum sensing modulates host immune response. It is proposed that 
the P. aeruginosa quorum sensing molecule, 3-oxo-C12-homoserine lactone, inhibits transcription 
of PPARγ, an anti-inflammatory nuclear receptor gene expressed widely in the lung. Macrolides 
have been shown to be of benefit in Pseudomonas colonised patients with bronchiectasis. While the 
mechanism for macrolide benefit in vivo is not known, macrolides have been shown to inhibit 
quorum sensing in vitro. 
 
Aims and Objectives 
This project was divided into three parts. The first two parts aimed to assess the effect of 
erythromycin on P. aeruginosa quorum sensing in vitro and in vivo, respectively. The third part 
aimed to further understand the role of modulation of PPARγ gene expression in the P. aeruginosa-
host relationship.  
 
Methods 
In vitro investigations were performed using both P. aeruginosa type strains and clinical isolates. 
The impact of growth media (Luria Broth (LB) vs. synthetic sputum media (SSM)), oxygen tension 
(aerobic vs. microaerophilic), and erythromycin exposure on quorum sensing and dependent 
behaviour were assessed. In vivo analysis was performed on whole sputum collected from patients at 
baseline and after 48 weeks of low dose erythromycin or placebo. P. aeruginosa gene expression 
was assessed in 80 patients, of which 41 were P. aeruginosa-positive. Of these, 26 samples (11 
treatment, 15 control) had sufficient levels of mRNA to allow assessment of quorum sensing gene 
expression. To investigate the relationship between P. aeruginosa and PPARγ bronchoalveolar 
lavage samples from 41 NCFBE patients and 20 healthy control subjects were analysed. Expression 
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of the gene encoding PPARγ was measured by real time PCR and correlated to clinical and 
microbiological outcomes. 
 
Results 
In the in vitro experiments, erythromycin exposure resulted in a significant down-regulation of 
quorum sensing controlled traits in the typed strain PAO1 including: the central quorum sensing 
gene lasI: fold change 1.00 vs. 0.22 p=0.009 (Mann-Whitney); pyocyanin 28.1+/-0.8 µM vs. 5.1+/- 
0.8 µM p<0.001 (Mann-Whitney); and elastase (OD 492) 0.64 +/- 0.05 vs. 0.36+/-0.02 p<0.001 
(Mann-Whitney), however phenotypic changes were strongly influenced by oxygen tension and 
media with generally no or inconsistent impact of erythromycin seen in synthetic sputum media 
(SSM) nor under microaerophilic conditions. Clinical strains of P. aeruginosa demonstrated 
significantly different growth rates compared to PAO1 in both standard media and SSM (F = 40.73, 
p<0.001). Clinical isolates also demonstrated significant inter and intra-strain variability across 
different oxygen tensions (Isolate #181 pyocyanin across different oxygen tensions: p<0.001 
Kruskal-Wallis), different growth media (Isolate #181 pyocyanin in SSM: p<0.001 Kruskal-Wallis) 
and their response to erythromycin: (#181 (control: 27.9 +/- 8.5 µM (SD); erythromycin 6.7 +/- 3.2 
µM p=0.016 (unpaired t-test)) vs. (#115 control: 16.2 +/- 0.35 µM (SD); erythromycin 13.9 +/- 
13.14 µM p=0.783, Mann Whitney U test). To overcome this in vitro variability, assessment in vivo 
were performed on whole sputum, negating the need to culture out individual isolates. In vivo, no 
significant impact on P. aeruginosa levels was observed in patients receiving low dose 
erythromycin compared with placebo (erythromycin: 6.25 +/- 1.48 (SD); placebo 5.38 +/- 1.32; 
p=0.129, unpaired t-test). However, a significant reduction was observed in the expression of both 
lasR (erythromycin: fold change -1.27 +/- 1.37 SD; placebo: fold change -0.34 +/- 0.86; p = 0.047, 
Mann-Whitney) and pqsA (erythromycin: fold change -1.00 +/- 0.87; placebo: fold change -0.091 
+/- 0.90; p=0.016, unpaired t-test) in patients who had received erythromycin, compared to controls, 
with a downward trend in lasI and rhlR expression. Finally, PPARγ expression was lower in NCFBE 
subjects compared with controls (p<0.001, Mann-Whitney U test), and lower in those patients who 
were PCR positive for P. aeruginosa (p=0.012, Mann-Whitney U test). PPARγ expression was 
inversely correlated with P. aeruginosa load (r -0.531, p=0.002), but not total bacterial (r 0.239 
p=0.194) or Haemophilus influenzae load (r 0.297, p=0.325).  
 
Conclusions 
Erythromycin inhibits quorum sensing controlled genes and virulence factors in vitro, in a similar 
fashion to azithromycin, supporting a class effect of macrolides, however there was a strong 
influence of oxygen tension, media and P. aeruginosa strain on this outcome. Due to this influence 
of culture conditions on P. aeruginosa phenotype in vitro, isolate-based assessments consequently 
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make a poor basis for investigating this effect in vivo. In order to overcome this effect, direct 
analysis of gene expression in induced sputum was used and demonstrated that, in P. aeruginosa 
positive patients, erythromycin inhibits important bacterial virulence determinants, independent of 
an effect on total bacterial load. Quorum sensing inhibition in vivo is therefore likely to contribute 
to the clinical benefits associated with macrolide therapy in this population. Finally, 
PPARγ expression in the airways of NCFBE subjects was significantly reduced compared to 
healthy individuals. This reduction correlated with increased levels of P. aeruginosa suggesting an 
intrinsic pathogen-host relationship, which may be quorum sensing dependent.  
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CHAPTER 1: INTRODUCTION 
Non cystic fibrosis (CF) bronchiectasis is a chronic pulmonary condition characterised by exuberant 
airway inflammation and damage caused by chronic airway infection and exacerbation [1]. 
Prevalence and incidence of adult non-CF bronchiectasis in Australia are not known, but likely 
reflect the both USA and UK data, where incidence is 3.3-310/100000, with the highest prevalence 
in the >65 year old age group [2, 3], with associated annual costs of $630 million USD [4]. Infection 
with the opportunistic pathogen Pseudomonas aeruginosa is associated with accelerated lung 
function decline  and increased mortality [3, 6]. Treatment with macrolide antibiotics has been 
shown to decrease exacerbation rates in non-CF bronchiectasis [7-9] and is particularly effective in 
those colonised with P. aeruginosa, a pathogen considered inherently resistant to macrolide [10]. 
 
P. aeruginosa is a ubiquitous, aerobic, gram-negative bacterium. It has a highly flexible genome, 
and consequently a set of environment specific responses that make it a very adaptable organism and 
therefore difficult to eradicate with conventional antimicrobials [11].  
 
Quorum sensing is the mechanism by which P. aeruginosa adapts to its environment [12]. Quorum 
sensing is a density dependent cell-to-cell communication system that relies on the production of 
small, diffusible, signalling molecules. Ten per cent of the P. aeruginosa genome is controlled by 
the quorum sensing system with a significant bias towards virulence and nutrient scavenging genes 
[13]. The production of quorum sensing signalling molecules is tightly regulated and responsive to 
external, environmental stimuli [14].  
 
Due to its intrinsic link with pathogenicity and persistence, quorum sensing has been postulated as a 
potential target for a new generation of antimicrobials with the aim of inhibiting cell-to-cell 
communication [15]. Inhibition of quorum sensing has been shown to reduce P. aeruginosa 
colonisation rates and pathogenicity in mice [16].	However, in the human host, quorum sensing 
inhibition may lead to an increase in persistence [17], possibly through the activation of P. 
aeruginosa efflux pumps or through the induction of quorum sensing cheats [18]. Almost all 
previous studies have focussed on testing clinical isolates recovered from culture, rather than 
“whole” sputum. We know that P. aeruginosa can change its phenotype within 24 hours in culture 
[19], this method therefore may not give the complete picture of what is happening in the bacterial 
community within the human host. 
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Macrolide antibiotics have been shown to inhibit quorum sensing in vitro [20, 21] and may inhibit 
quorum sensing in vivo [17] although, until now, this has not been specifically studied in non-CF 
bronchiectasis.  
 
It is therefore essential that we better understand the complex relationship between pathogen and 
host with regards to P. aeruginosa in non-CF bronchiectasis. We know that macrolide decreases 
exacerbations in non-CF bronchiectasis and also inhibits quorum sensing in vitro. What is unclear is 
whether inhibition of quorum sensing in vivo contributes to the mechanism of benefit of macrolide 
in P. aeruginosa infected non-CF bronchiectasis patients. Understanding these relationships and 
how low dose macrolide therapy modulates P. aeruginosa pathogenesis at a molecular level is 
essential for our understanding of the biology of this organism and the development of new 
treatment and/or preventative strategies in the future. 
  
	 42 
 
 
 
 
CHAPTER 2 
 
LITERATURE REVIEW 
 
 
  
	 43 
CHAPTER 2: LITERATURE REVIEW 
2.1 NON-CF BRONCHIECTASIS  
Non-CF bronchiectasis is a chronic pulmonary condition characterised by irreversible loss of normal 
ciliated airway surface epithelium, dilatation of the airways and reduced airway clearance. It is 
characterized by exuberant airway and sub-epithelial inflammation and damage caused by chronic 
airway infection and exacerbation as described by Cole’s vicious cycle hypothesis [22]. This leads 
to symptoms of chronic daily cough with sputum and shortness of breath [1]. 
 
In Australia the prevalence reported in children under 15 years is 3.7/100000 per annum, increasing 
to 1470/100000 in the indigenous child population [2]. The prevalence in adults is not reported in 
Australia, but most likely reflects the US [2] and UK [3] data which suggests a point prevalence of 
485-566/100,000 (male-female) with the highest prevalence in the elderly, reaching nearly 1% 
prevalence [3], with a 2:1 female preponderance [23]. 
 
Mortality is increased in non-CF bronchiectasis compared with a healthy, aged matched population, 
however Australian data is limited. Small cohort and hospital discharge studies suggest a reduced 
lifespan, with mortality varying between 11.5% per annum (in an Australian hospital cohort) [2], to 
23% at 10 years [1]. The most recent UK study indicates a composite mortality number of 2.14-
2.26, suggesting a doubling of mortality risk compared to the general population [3]. The acquisition 
of opportunistic organisms such as P. aeruginosa contributes to accelerated lung function decline 
[5] and increased mortality [6].  
  
Most cases of non-CF bronchiectasis are idiopathic, however an antecedent viral or bacterial 
pulmonary infection (e.g. pertussis) is often reported. Rare genetic disorders of the cilia also 
contribute to the risk of bronchiectasis as do diseases associated with immune dysregulation, in 
particular rheumatoid arthritis, ulcerative colitis and specific deficiencies of immunoglobulin 
production [1]. 
 
The pathophysiology of bronchiectasis in non-CF bronchiectasis is generally accepted to confirm to 
the vicious cycle hypothesis [22] whereby exuberant inflammation and infection lead to airway 
damage. Elevations in both systemic and airway inflammatory markers have been demonstrated [5, 
24, 25]. There is a link between inflammatory cytokines and chronic infection with many of the 
common bacteria associated with non-CF bronchiectasis. Several studies have shown a linear 
increase in IL-8, MPO and neutrophil elastase with increasing bacterial load [24, 25]. Chronic 
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airway infection and inflammation leads to epithelial damage. Due to this damage, or perhaps 
preceding it, mucociliary clearance is impaired, bringing inflammatory products in contact with the 
epithelium for longer periods leading, potentially, to more airway damage [26].  
 
Clinically, non-CF bronchiectasis patients suffer from recurrent exacerbations, which consist of 
increased shortness of breath, excessive sputum production and cough, along with associated 
systemic features that can include malaise and weight loss. During periods of clinical stability 
sputum production reduces, but the majority of patients will report chronic daily sputum production 
[1, 5]. 
 
The diagnosis is made radiologically, on high resolution computerised tomography (HRCT). HRCT 
criteria for the diagnosis of non-CF bronchiectasis includes lack of tapering of the bronchi, bronchial 
dilatation (defined as an internal diameter of at least 110% larger than the adjacent pulmonary 
artery) and visualisation of the peripheral bronchi within 1 cm of the pleural surface [27]. 
Associated features may include mucus plugging or demonstrable conditions associated with the 
disease including infection with mycobacteria or allergic bronchopulmonary aspergillosis (ABPA). 
Radiological changes are usually distributed through the middle and lower lobes, in stark contrast to 
CF where the disease is predominantly in the upper lobes. Chest X-ray is not sensitive in the 
diagnosis, but may demonstrate mucus plugging and changes characteristic of bronchiectasis, such 
as tram tracking and cysts. 
 
There are no specific blood tests that can diagnose non-CF bronchiectasis. Elevations in 
inflammatory markers such as C-reactive protein (CRP) may indicate chronic or acute infection, but 
they are neither sensitive nor specific, but may predict a more rapid decline in clinical condition [5]. 
 
Lung function testing usually reveals a reduction (<70%) in the forced expiratory volume in one 
second / forced vital capacity (FEV1/FVC), and a reduction in the FEV1, consistent with airflow 
obstruction [5, 28, 29]. 
 
The mainstay of management is optimization of physical condition (exercise, good nutrition etc.) 
along with chest specific sputum clearance techniques such as chest physiotherapy. Early treatment 
of exacerbations with appropriate antibiotics and chest clearance are also useful in ameliorating 
symptoms [2]. Attempts to translate therapies with demonstrated efficacy in CF into non-CF 
bronchiectasis have been disappointingly unsuccessful to date. Despite their efficacy in CF, both 
recombinant human DNase I and tobramycin solution for inhalation have been shown to result in 
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significant deterioration in clinically important respiratory outcomes in non-CF bronchiectasis [30, 
31]. A single blinded trial with nebulised gentamicin [32] suggested an improvement in the time to 
exacerbation, but this was tempered by an associated decline in lung function. Three trials assessing 
the efficacy of low dose macrolide antibiotics to prevent exacerbations have shown a reduction in 
exacerbation rate, making macrolides the only consistently proven therapy in moderately severe 
non-CF bronchiectasis [7-9]. A sub analysis of one of these studies (BLESS [7]) suggested that most 
of the benefit of macrolide was in the P. aeruginosa dominant group [33], despite the consensus 
opinion that this pathogen is resistant to macrolides. 
2.2 MACROLIDE ANTIBIOTICS 
The macrolide antibiotics as a class have been used since 1952 with the development of the 14 ring 
macrolide, erythromycin [34]. Since then several other macrolides have been developed with the 
most commonly used clinical formulations being clarithromycin, azithromycin, erythromycin and 
roxithromycin. As an antimicrobial they are thought to be predominantly bacteriostatic, inhibiting 
protein synthesis within the cell by binding to the 50S subunit of the ribosome [34]. 
 
Outside of their antibacterial effects, the 14 and 15 ring macrolide antibiotics have been shown to be 
effective in the treatment of the inflammatory airway diseases diffuse pan bronchiolitis (DPB), CF, 
non-CF bronchiectasis and chronic obstructive pulmonary disease (COPD) [7-9, 35-38]. The 
demonstration of benefit in non-CF bronchiectasis and CF subjects colonised with P. aeruginosa, an 
organism where macrolide is neither bacteriostatic nor bactericidal, implies a non-antibiotic 
mechanism of benefit [10]. Subsequent in vitro data have described a range of anti-inflammatory 
and immunomodulatory effects and consequently it has been generally assumed that macrolides 
exert their benefits by modulating the inflammatory phenotypes of these diseases [37, 39].  
 
Macrolides are not benign medications, however. Azithromycin and erythromycin treatment has 
been shown to significantly induce resistance in commensal streptococcal species [7, 40]. The 
induction of resistance is increased with the longer half-life macrolides, particularly azithromycin, 
making the less potent, shorter half-life macrolide, erythromycin, a potentially safer drug in this 
respect. The effect of antimicrobial resistance induction (particularly in commensal Streptococcus 
species) is a potential concern for future generations, with fewer and fewer antibiotics being 
developed to target resistant pathogens.  
 
The side effect profile varies somewhat dependent upon the macrolide. Erythromycin is particularly 
associated with gastrointestinal side effects and, due to its interaction with the cytochrome P450 
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system, has the potential to cause drug-drug interactions [34]. Whilst all macrolides can cause 
prolongation of the QTc interval, azithromycin in particular has been associated with increased 
cardiovascular death [41]. Use in the older patient, with more comorbidities and the potential for 
medication interactions, is likely to pose an even greater risk.  
2.3 PSEUDOMONAS AERUGINOSA 
P. aeruginosa is a ubiquitous gram negative bacillus. It is aerobic in most cases but can survive as a 
facultative anaerobe in hypoxic conditions, as found within the bronchiectatic lung. Pseudomonas is 
highly adaptable to its environment, able to withstand nutrient-poor, hypoxic conditions as well as 
extremes of temperature. This species is also phenotypically unstable, forming many distinct strains 
by altering its gene expression and phenotype readily, given appropriate conditions [42-44]. 
2.3.1 Life Cycle 
Simplistically, P. aeruginosa has two distinct phases within its life cycle, a planktonic phase and a 
biofilm phase, however there are many clinically relevant phases in-between. The planktonic phase 
consists of individual bacteria with the ability to move in the mucosal fluid environment via the use 
of flagellae. These bacteria are much more susceptible to killing by the immune system or 
antibiotics as they are not living in a protective biofilm, however they have the ability to disperse 
and colonise other areas of the host. In the biofilm phase, the flagellum is lost and P. aeruginosa 
group together to form more stable colonies where, due to the protective alginate rich biofilm, they 
are less susceptible to antibiotic and host defences. In the lung, P. aeruginosa readily colonises the 
respiratory mucus [45], but has the ability to directly attach to the host epithelium via application of 
its pilus [46]. It is during the biofilm stage that quorum sensing is considered most active, where 
small diffusible molecules (quorum sensing molecules) are released into the extracellular milieu and 
diffuse into neighbouring bacteria causing up-regulation of quorum sensing controlled genes such as 
those responsible for forming biofilms [47, 48].  
 
This transition from planktonic to mature colonies is visualised in broth culture and measured by 
recording the optical density (OD), or turbidity of the broth over set time points. P. aeruginosa 
typically goes through 3 growth stages, a lag stage (with low cell numbers), a logarithmic stage 
(where the bacteria are multiplying at a rapid rate) and a stationary stage (Figure 2.1) where most of 
the readily available nutrients have been consumed and the bacteria begin establishing stable 
colonies, slowly turning over their numbers, without significantly increasing them. This is a 
somewhat stylistic concept however it highlights the different potential growth phases of P. 
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aeruginosa which will be discussed further. It is during the stationary stage, under controlled 
conditions, that quorum sensing is generally considered most active [49].  
 
 
Figure 2.1: Growth stages of P. aeruginosa. The early stage (the lag stage) is where there are low 
numbers of replicating bacteria. During the logarithmic stage there are a large number of bacteria 
present dividing at a high rate. During stationary phase, growth is slowed (usually due to 
diminishing nutrients) and the bacteria can enter into a biofilm phase if conditions permit. Dispersal 
at this point will start the process again. 
2.3.2 Pathogenesis and Virulence 
P. aeruginosa has a number of different pathogenic mechanisms to cause disease in the host. 
Secreted factors include elastase, which breaks down protein to allow host invasion and nutrient 
scavenging, phenazine [50], a redox active group of compounds, producing damaging reactive 
oxygen species, and rhamnolipids [51], lipid like structures which are inhibitory to leucocytes but 
also aid in the formation of an adhesion-resistant raft to allow swarming and dispersal. Other 
virulence factors produced by P. aeruginosa include alkaline protease, hydrogen cyanide and 
superoxide dismutases which all contribute to host cell destruction and bacterial persistence [11, 
52]; and this list is not exhaustive. All of the afore-mentioned molecules have been detected in the 
human host and have been associated with a faster decline in lung function and worse prognosis [53, 
54]. Notably, all of these factors have been shown to be under quorum sensing control. 
2.3.3 Antibiotic Resistance/Tolerance 
One of the main reasons why P. aeruginosa resists therapy is its antibiotic resistance profile. P. 
aeruginosa has many ways in which it develops antimicrobial resistance, including genomic 
antibiotic resistance genes such as DNA gyrase mutations, a beta lactamase and an acetylase. The 
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main mechanisms of antimicrobial, drug and host tolerance include biofilm, low cell membrane 
permeability and inducible efflux pumps (Section 2.4.6) [55]. 
2.4 QUORUM SENSING 
Quorum sensing is cell-to-cell communication via small diffusible molecules causing a density 
dependent alteration in phenotype. The production of quorum sensing molecules is tightly regulated 
and responsive to external, environmental stimuli [14, 48] allowing P. aeruginosa to adapt to its 
environment. Due to its intrinsic link with pathogenicity and persistence, quorum sensing has been 
postulated as an ideal target for new generation antimicrobials, which avoid induction of antibiotic 
resistance [15]. 
2.4.1 Acylhomoserine Lactone Based Quorum Sensing 
The most extensively studied quorum sensing signals in P. aeruginosa are the acylhomoserine 
lactones (AHL) that are found exclusively in Gram negative bacteria. They were originally 
discovered in the Vibrio species and considered to be critical to bioluminescence [56]. AHLs are 
lactone ring based substances which are acylated at the alpha position and possess a varying length 
carbon chain. There are several AHLs produced by P. aeruginosa but the two most abundant are N-
(3-oxododecanoyl)-L-homoserine lactone (3-oxo-C12-HSL) and N-butanoyl-L-homoserine lactone 
(C4-HSL). 
 
Synthesis of these two molecules is controlled by a LuxR/I homologous gene operon, with the I 
gene being the synthase gene and the R gene being the regulator gene. 3-oxo-C12-HSL is 
synthesised by the action of the LuxI homologue: LasI and C4-HSL by another LuxI homologue: 
RhlI (Figures 2.2 and 2.3). These two AHLs are synthesised from S-adenosyl-methionine (a 
ubiquitous molecule important in the synthesis of several mammalian and bacterial products) by the 
action of either LasI or RhlI. Stimulation of lasI or rhlI expression occurs when the relevant AHL 
molecule interacts with its LuxR homologue (LasR - for 3-oxo-C12-HSL or RhlR - for C4-HSL), 
causing it to activate the luxI promoter region, therefore auto-inducing its own synthesis (Figure 2.2) 
[47]. Both 3-oxo-C12-HSL and C4-HSL are able to diffuse freely out of the cell, however, due to 
the larger size of 3-oxo-C12-HSL, it is also actively pumped out of the cell via the AB and probably 
the EF efflux pump [57], which is a slower process, resulting in an intracellular concentration much 
higher than C4-HSL. 
 
The LuxR/AHL complex interacts with the quorum sensing regulon to effect changes in gene 
expression. The Las system typically controls transcription of the lasA and lasB elastase genes and 
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the Rhl system controls transcription of the rhlA/B genes, however, as will be reviewed shortly, 
there are many other genes activated or repressed in the presence of active quorum sensing. 
 
Figure 2.2: Synthesis and action of the acylhomoserine lactones. The luxI gene product converts S-
adenosyl-methionine to its specific acylhomoserine lactone. The luxR gene product LuxR associates 
with the product of the luxI gene which then goes on to direct gene expression. The LuxR/AHL 
complex then stimulates its own synthesis by interacting with luxI. 
 
Activation of quorum sensing can only occur when a particular cell density has been reached – i.e. a 
quorum. Typically quorum sensing gene activation occurs during the late logarithmic phase and 
stationary phase of colony growth, but is dependent upon certain environmental conditions (such as 
hypoxia or nutrient abundance or scarcity) and subject to significant transcriptional regulation.  
 
The AHL quorum sensing system is structured in a hierarchical manner, whereby the Las system 
controls activation of the Rhl system, via augmentation of RhlR by 3-oxo-C12-HSL (Figure 2.3). 
This means that there is a stepwise approach to the release of quorum sensing-controlled gene 
products [47, 48, 58]. 
2.4.2 Hepatydl–Alkyl-Quinolone Based Quorum Sensing 
There is one further quorum sensing system present in P. aeruginosa. This is the 4-hepatyl–alkyl-
quinolone system (HAQ), whose end product is 2-heptyl-3-hydroxy-4(1H)-quinolone, or the 
Pseudomonas Quinolone Signal (PQS), although there are four molecules present in P. aeruginosa 
belonging to this group. The HAQs, as the name suggests, are structurally based on a quinolone 
ring.  
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PQS is produced in late stationary phase of P. aeruginosa growth. PQS is synthesised from 
anthranillic acid via the activation of the pqsABCD operon by the regulator protein PqsR. PqsABCD 
converts anthranillic acid to 2-heptyl-4-quinolone (HHQ). HHQ is then converted to PQS via the 
action of PqsH. In a similar way to the AHLs, PQS is able to auto-induce its own production by 
enhancing the transcription of PqsA [59] (Figure 2.3). PQS is highly lipophilic and prefers to 
associate with the lipid rich cell membrane where it has been shown to bud away from the cell in 
small micelles [60]. However, in the presence of rhamnolipids (product of the rhlA/B gene) it is able 
to leave the cell surface and disperse [61].  
 
PQS enhances the transcription of rhlI and rhlR [62] leading to enhancement of Rhl phenotypes, 
suggesting a more complex link with the AHL hierarchy. In fact, LasR-3-oxo-C12-HSL controls 
transcription of psqR and pqsH, with RhlR-C4-HSL negatively feeding back on pqsR and pqsA [63].  
 
Figure 2.3: The Quorum Sensing Circuitry in P. aeruginosa. The quorum sensing circuitry 
involves a complex interaction between environmental stimuli, multiple gene repressors and 
activators and the central quorum sensing control genes based around the LuxR/I homologues – 
LasR/I and RhlR/I (shown at the top) and the Pseudomonas Quinolone Signal system (shown at the 
bottom of the pictogram). The red arrows demonstrate the ability of each molecule to auto-induce 
their own synthesis. The dashed blue arrows demonstrate the hierarchy, with the Las system having 
transcriptional control over both Rhl and PQS (adapted from Williams 2007 [12] and Diggle 2006 
[61]). 
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2.4.3 Regulation of Quorum Sensing in P. aeruginosa  
P. aeruginosa quorum sensing is a tightly regulated system, which enables it to respond to different 
environmental stimuli or nutritional needs. Several regulators exert transcriptional control over the 
Lux based systems. One of the first to be discovered was QscR (quorum sensing control regulator), 
which has a structure homologous to LuxR, without an associated synthase gene. QscR represses 
activation of lasI by forming a heterodimer with LasR until stationary growth phase, when it 
dissociates due to its interaction with 3-oxo-C12-HSL at high densities, therefore ensuring that a 
quorum has been reached [64]. VqsR (virulence and quorum sensing regulator) is another LuxR 
homologue which is activated by the LasR-3-oxo-C12-HSL complex and promotes the production 
of AHLs via up-regulation of lasI [65]. Vfr (virulence factor R) is another transcriptional regulator, 
but is not homologous to Lux. It exerts positive control over LasR by binding to its promoter region 
at high cell densities, enhancing its expression. Vfr mutants demonstrate low lasR transcription 
levels [66]. 
 
Two other genes exert negative control over the quorum sensing system, rsaL and mvaT. The rsaL 
gene is located in the intergenic region between lasR and lasI and is transcribed in the opposite 
direction to lasR. The product of this gene inhibits the transcription of lasI by competing for the 
same site as 3-oxo-C12-HSL on the lasI promoter region. Once a critical density of 3-oxo-C12-HSL 
is reached, this inhibition is overcome and transcription can occur [67]. The target of MvaT is not 
known, however mvaT mutants are able to overcome the growth phase dependency of quorum 
sensing, allowing expression of virulence genes earlier. This suggests that MvaT most likely inhibits 
transcription of target genes until stationary growth phase [68].  
 
Several post transcriptional regulatory circuits (including those by the global regulator RsmA) exist 
in P. aeruginosa and largely depend on specific environmental conditions for significant expression 
to occur [57].  
2.4.4 Genes Under Quorum Sensing Control 
Three microarray [69-71] analyses of PAO1 wild type and mutants have shown that over 300 P. 
aeruginosa genes are differentially controlled by the AHL quorum sensing system. Although there 
is some discrepancy between the three studies (likely due to the differing experimental conditions), 
at least 70 genes have been shown to be consistently under the control of the AHL quorum sensing 
system. Most of these code for secreted virulence factors including elastase, rhamnolipid and 
pyocyanin [72]. Microarray data from pqsR mutants (assessing the HAQ quorum sensing system) 
showed similar results, with a disproportionate number of virulence functions shown to be under 
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quorum sensing control [73]. Genes under quorum sensing control involved in P. aeruginosa 
virulence are shown in Table 2.1. 
 
Gene Name Function [Reference number] AHL/PQS 
palL PA-I galactophilic lectin [69] AHL 
phzCDE phenazine biosynthesis protein (pyocyanin) [73] AHL+PQS 
phzAB probable phenazine biosynthesis cluster [73] AHL+PQS 
aprI alkaline proteinase inhibitor AprI [69] AHL 
aprA alkaline metalloproteinase precursor [69] AHL 
aprDEF alkaline protease secretion proteins AprDEF [69] AHL 
lasA LasA protease precursor [74] AHL 
hcnABC HCN biosynthesis genes [69] AHL 
chiC Chitinase [74] AHL+PQS 
lasB elastase LasB [71] AHL 
rhlAB rhamnosyltransferase chain A, chain B [69] AHL 
mexGHI-opmD RND efflux transporter system [73] AHL+PQS 
rhlR regulatory protein RhlR [70] AHL 
katE catalase [70] AHL 
lecA galactose specific PA-I lectin – adhesin and cytotoxin [73] PQS 
lecB fructose binding lectin PA-IL – adhesin and cytotoxin [73] PQS 
phzM O-methyltransferase – phenazine biosynthesis [73] PQS 
pqsA-E PQS synthesis genes [73] PQS 
pqsR PQS regulator protein – regulates transcription of pqsA [73] AHL+PQS 
 
Table 2.1: Genes under quorum sensing control involved in P. aeruginosa virulence. Quorum 
sensing genes as defined by microarray studies demonstrating a >5 fold increase in expression 
during active quorum sensing [69-71, 74]. 
 
Only 7% of these genes had upstream DNA sequences homologous to known LasR/RhlR binding 
domains, suggesting that many quorum sensing controlled genes are activated via indirect 
mechanisms, or do not require binding of AHL to the regulator protein [13, 71]. 
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2.4.5 Phenotypes Under Quorum Sensing Control 
2.4.5.1 Elastase 
There are two elastases found in P. aeruginosa, LasA and LasB elastase. They are synthesised under 
the control of the lasA and lasB genes. They are both metalloproteinases, with LasB elastase having 
the greater elastolytic effect. LasA elastase has strong staphylolytic activity and is essential for 
competition in the environment with this organism [75, 76]. Both elastases are simplistically under 
the control of the Las quorum sensing system, although there is considerable crossover with Rhl and 
PQS. 
2.4.5.2 Pyocyanin 
Pyocyanin is a blue-pigmented phenazine compound. Phenazines are nitrogen containing 
heterocyclic ring structures. In P. aeruginosa the blue coloured pyocyanin gives infected sputum its 
dark blue/green colour [11]. Pyocyanin is synthesised from chorismic acid via the action of the 
products of PhzA, PhzM and finally PhzS [77]. The phenazines have significant redox ability leading 
to the creation of reactive oxygen species, which cause damage to surrounding cells. In CF, high 
levels of phenazine have been associated with an accentuated decline in lung function [50]. 
2.4.5.3 Rhamnolipids 
Rhamnolipids are glycolipid bio surfactants which have been shown to enhance swarming motility 
of P. aeruginosa [51], inhibit the activity of leucocytes [78], directly aid in the invasion of damaged 
epithelial cells and have haemolytic activity in vitro. Rhamnolipids have also been detected directly 
from the sputum of CF patients and have been associated with a more rapid decline in lung function 
[79]. Rhamnolipids are synthesised under the control of the rhlA/B genes, which are themselves 
controlled by the RhlR-C4-HSL complex. 
2.4.6 Quorum Sensing and the Genetic Diversity of P. aeruginosa within a Population 
Quorum sensing mutants (i.e. those unable to quorum sense) readily proliferate in an overnight broth 
culture of a single colony of P. aeruginosa, questioning its importance in chronic human infection. 
Quorum sensing is costly to the cell, requiring much more energy to occur. The ability to quorum 
sense, however, provides extracellular products such as elastase (which can break down proteins to 
provide a nutrient source), which are then exploited by the surrounding quorum sensing mutants (or 
“cheats”) [18]. The quorum sensing cheats therefore devote no energy to quorum sensing, yet 
benefit from the efforts of the quorum sensing active bacteria. Meaning that quorum sensing is 
likely relevant even in established infections. 
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This phenomenon has been confirmed in human studies. Investigation of isolates taken from CF 
patients demonstrated that LasR mutants had a growth advantage over wild type quorum sensing 
proficient P. aeruginosa when grown in an amino acid rich medium (similar to that of the CF 
airway) [44]. LasR mutants (as defined by colony morphology) also spontaneously appeared when 
CF sputum isolates were grown on Luria Bertani (LB) medium for an extended period of time. This 
suggests that nutrient availability is also an important reason as to why LasR mutants emerge. In 
support of this, a study in ventilator-associated pneumonia (VAP) also demonstrated that the 
proportion of LasR mutants isolated increased quickly with time [17]. Loss of LasR, by loss of 
function mutations in any part of the gene, seems to occur early in chronic P. aeruginosa infection 
and has been proposed as a hallmark of chronicity in CF [80]. However, the ability to quorum sense 
and produce quorum sensing molecules can still occur very late in the disease. Indeed, Rhl functions 
seem to last late into the disease and may be related to the ability of the rhamnolipids to protect the 
P. aeruginosa genome from free radical attack and subsequent DNA damage [80].  
 
Whether quorum sensing proficient strains remain in small numbers, as part of a wider colony of 
bacteria in the lung has not been investigated. However, in the chronically infected CF airway, P. 
aeruginosa exist with significant phenotypic variability, supportive of multicellular adaptation. This 
brings into question the validity of genotyping a single clinical isolate of P. aeruginosa and 
following it over time, because of this significant within patient diversity [42, 81, 82].  
2.4.7 Quorum Sensing and Antibiotic Resistance 
Quorum sensing-deficient isolates appear to have intrinsically higher antibiotic resistance rates. This 
suggests that strains that are unable to quorum sense may have a more resistant phenotype. A study 
using single isolates from intensive care patients demonstrated that loss of pyocyanin production, 
and thus one central quorum sensing controlled phenotype, was strongly associated with an increase 
in resistance to ciprofloxacin, ofloxacin, ceftazidime, tobramycin and amikacin [83] – all routinely 
used for the treatment of P. aeruginosa infections.  
2.4.7.1 Quorum Sensing and the Role of Efflux Pumps 
The role of efflux pumps in this resistance profile warrants further investigation. The efflux pumps 
export a broad range of substrates including antibiotics and other substances which may be toxic to 
the cell. Importantly, they are used by the quorum sensing system to export quorum sensing 
molecules out of the cell. There are several efflux pumps so far defined in P. aeruginosa, each with 
a relatively specific substrate.  
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The MexAB-OprM pump is constitutively expressed and is likely to confer intrinsic resistance to the 
beta lactams, however it can also export quinolones, tetracycline, chloramphenicol, trimethoprim, 
detergents, solvent molecules and 3-oxo-C12-HSL [84, 85]. It is repressed by the product of the 
gene mexR, which can be mutated, allowing expression of the full operon.  
 
The MexCD-OprJ pump exports fluroquinolones and macrolide. This pump is negatively regulated 
by NfxC [84]. Similarly, the MexEF-OprN has been shown to export HHQ [86] and 3-oxo-C12-
HSL. Overexpression of MexEF-OprN significantly decreases PQS/Rhl type exoproducts compared 
to wild type [87].  
 
The MexGHI-OpmD pump is down regulated in pqsR mutants [73] and has been shown to be 
essential for the functioning of the quorum sensing system, such that an inactive pump leads to 
decreased production of 3-oxo-C12-HSL, C4-HSL and PQS via probable post transcriptional 
modification. MexI mutants (therefore have an inactive pump) are much less virulent in rat lung 
infection models (wild type leading to 80% mortality and abscess formation in the lungs vs. 5% in 
the mutant) [88]. 
 
Finally, of relevance, the MexXY-OprM has been shown to export aminoglycosides, erythromycin 
and quinolones [87, 89], again making this an interesting pump to investigate with regards to the 
effect of macrolide on quorum sensing. 
2.4.8 Interaction with the Mammalian Host  
2.4.8.1 Detection of Quorum Sensing Molecules in Clinical Samples 
Quorum sensing activity in vitro has been extensively studied; however how this relates to in vivo 
effects warrants further investigation. The detection of quorum sensing molecules in the human host 
is therefore vital in order to understand the importance of it in chronic disease. 
 
Until recently, the detection of quorum sensing molecules in clinical specimens has relied on the use 
of biosensors [42, 80, 83, 90-95]. This technique has previously required collection of a clinical 
sample, culturing the P. aeruginosa on selective agar, selecting a colony, co-culturing with reporter 
strains then measuring turbidity and fluorescence. This ensures optimal conditions for the 
production of quorum sensing molecules ex vivo, however it is not clear whether this truly 
represents what is happening within the lung. Newer biosensor techniques have been able to detect 
quorum sensing signal molecules directly from sputum [91], bronchial alveolar lavage fluid [96], 
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tracheal aspirates [81] and tissue specimen culture medium [90], which is likely more representative 
of what is occurring at that point within the host. Other techniques include liquid chromatography 
[96], mass spectrometry [97, 98] and radiometric analysis [99] of quorum sensing molecules, 
directly in bodily fluids and lung tissue. This has improved both sensitivity and specificity for the 
detection of these molecules. 
 
Whilst biosensors are useful for the detection of quorum sensing molecules, mass spectrometry 
gives sensitive, specific, validated values for both the quantity and presence of specific quorum 
sensing molecules [97, 98]. The detection range of quorum sensing molecules in clinical samples 
with biosensors is in the nanomolar range for C4-HSL (2500 – 0.0025 nM) and in the picomolar 
range for 3-oxo-C12-HSL (20 nM–0.002 pM) [93]. In mass spectrometry, sensitivity (to date) is not 
as good, with clinical detection in the micromolar range (0.25 – 1.4 µM) dependent upon the culture 
conditions [98]. However, specificity is much better allowing simultaneous, quantitative profiling of 
all quorum sensing molecules in a sample. This makes mass spectrometry an attractive, rapid 
method of detecting quorum sensing molecules in respiratory secretions, assuming the abundance is 
reasonably high. 
 
Mass spectrometry has successfully been used to identify quorum sensing molecules in clinical 
samples [97, 100] including sputum and plasma from CF patients. To date, there is little else in 
published literature describing the detection of P. aeruginosa quorum sensing molecules directly 
from clinical samples, and there are no data using any method in non-CF bronchiectasis. 
2.4.8.2 Cell Culture  
As already described, active quorum sensing is associated with increased virulence of P. 
aeruginosa. In vitro and in animals, wild type P. aeruginosa has been show to induce a greater 
inflammatory response than P. aeruginosa with LasR mutations [69, 101], however a pro-
inflammatory phenotype is counter-intuitive to long term bacterial survival. This suggests a more 
complex host-pathogen interaction than first considered. 
 
In human cell culture 3-oxo-C12-HSL at concentrations ranging between 25-100 µM has been 
shown to stimulate the expression and release of functional IL-8 [102]. Further, 3-oxo-C12-HSL 
[103] has also been shown to induce Cox-2 and prostaglandin E2 production from human lung 
fibroblast cells at a concentration of 100 µM. Induction of NF-kB by 3-oxo-C12-HSL was central to 
this response supporting the significant pro-inflammatory character of 3-oxo-C12-HSL in these 
conditions. Clinical concentrations of AHL’s have been detected in the nano-molar range however 
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[93], and it is unlikely that such high concentrations of quorum sensing molecules will be 
encountered in vivo. 
 
3-oxo-C12-HSL is also a potent stimulator of MUC5AC gene and protein expression [104]. 
MUC5AC is one of the predominant secreted airway mucins, the other being MUC5B, and these 
mucins are the main components of normal mucus giving sputum its rheological properties. Mucins 
are cysteine rich, gel forming molecules expressed throughout the bronchial epithelium and are 
essential for the correct immunological functioning of the airway. They act as a trap for pathogenic 
bacteria and other inhaled material, allowing effective clearance via ciliary movement and 
expectoration. Many substrates can induce mucin secretion, including lipopolysaccharide, human 
neutrophil peptide [105], and P. aeruginosa supernatant [106], as well as human neutrophil elastase 
and a host of human inflammatory cytokines. However, if these mucins are inadequately cleared 
from the airway, as occurs in non-CF bronchiectasis, then the retained mucus becomes an 
environment in which pathogenic microbes reside. 
 
Interestingly, both 3-oxo-C12-HSL and PQS have been shown to, conversely, down regulate the 
host immune response to the above stimulation [107, 108]. In stimulated peripheral blood 
mononuclear cells (PBMCs), macrophages and neutrophils, inhibition of TNFα, IL-12 and IL-6 
release occurred with the addition of 3-oxo-C12-HSL and PQS [108, 109]. This seems to contradict 
the pro-inflammatory phenotype described in non-immune cells described above, and may represent 
a local survival response by the bacteria, preventing clearance by leukocytes. In mice, pulmonary 
infection with strains with full quorum sensing ability leads to increased cell damage, with reduced 
polymorphonuclear tissue infiltration [43, 78], suggesting that increasing tissue damage and immune 
suppression can occur concomitantly in the host infected with quorum sensing-capable strains. This 
is supported by work suggesting that 3-oxo-C12 modulates the immune responses of T and B cells 
both in vitro and in vivo [110]. 
 
The biochemical mechanisms underlying these differential host cell modulations is unclear. 3-oxo-
C12-HSL [108] and PQS [109] act on the NFκB pathway in a number of postulated ways, 
dependent upon the cell type and type of cellular stimulation. Interference with IκB, inhibition of 
peroxisome proliferator-activated receptor gamma (PPARγ) [111] and interference with host protein 
translation via induction of the unfolded protein response [112] are all mechanisms by which 3-oxo-
C12-HSL may modulate responses in mammalian cells. 
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2.4.8.3 Interaction with PPARγ  
PPARγ is a nuclear transcription regulator whose primary function is to bind to exogenous lipid-like 
ligands and then interact with specific PPAR response elements on nuclear DNA to modulate gene 
expression. Inhibition of PPARγ has been shown to produce a pro-inflammatory phenotype by 
interfering with its inhibitory action on the target genes of NFκB [113]. PPARγ production has been 
shown to be down-regulated in inflammatory airways diseases, including COPD [114] and CF 
[115], suggesting its suppression is involved in the underlying pathology. In vitro studies have 
demonstrated that the presence of P. aeruginosa AHLs suppress expression of PPARγ  [111, 115]. 
Somewhat tantalisingly, PPARγ gene expression can be agonised with commercially available 
medications such as rosiglitazone, which have been used successfully to treat type 2 diabetes, and 
could therefore be utilised as a possible treatment for non-CF bronchiectasis, should PPARγ be 
found to be relevant in this disease. 
 
The paroxinases (PON), particularly PON2 have been shown to lactolyse and clear fatty acid type 
molecules such as 3-oxo-C12-HSL [109] and are under-expressed in the CF lung, promoting 
quorum sensing and contributing to the persistence of P. aeruginosa [115]. 
2.4.8.4 Quorum Sensing in Clinical Studies 
In vitro studies have confirmed the importance of quorum sensing molecules on immune modulation 
and virulence of P. aeruginosa, but it is not clear what happens in the complex human host where 
multiple different microcolonies exist in a potentially hostile environment.  
 
There has only been one study to date looking directly at changes in quorum sensing gene 
expression in respiratory secretions taken from human subjects. This study followed the placebo arm 
of a larger randomised controlled trial, which aimed to assess the effect of azithromycin on the 
prevention of ventilator associated pneumonia (VAP) [54], (discussed further in section 2.4.9.2). 
Daily tracheal aspirates were taken from intubated patients and the samples assessed for their “in 
patient gene expression” directly from the aspirate. Bacterial load was assessed by quantification of 
total genomic DNA from the same sample. Although the numbers in this study were too small to 
undergo statistical analysis, they were able to detect induction of lasI and rhlA in two patients who 
developed VAP without a significant increase in bacterial load. The rhamnolipid activity noted in 
the isolates was most strongly associated with development of VAP, as suggested by the increase in 
rhlA. In both VAP patients and those without VAP, baseline quorum sensing gene expression was 
detectible and stable. This was confirmed with tests on simultaneously collected isolates, however 
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the isolates required specific culture to induce quorum sensing controlled genes. Interestingly, from 
genomic studies on the isolates, the majority of the initial colonising strains were quorum sensing 
deficient, but VAP was more likely to occur in patients initially colonised by quorum sensing 
proficient isolates. 
 
Although this study involved small numbers, it highlights that fact that quorum sensing is active (as 
shown by the detection of RNA transcripts) in the early stages of colonisation and infection in the 
human host, and may be associated with a clinically significant outcome.  
2.4.9 Quorum Sensing Inhibition – Overview 
Inhibition of quorum sensing has been an exciting new target for enhancing P. aeruginosa 
antimicrobial sensitivity [16]. Quorum sensing inhibitors have been found to naturally occur in the 
environment [116] and no doubt assist the organism in competing for space and nutrients in an 
ecological niche. Macrolide antibiotics, which have no intrinsic antimicrobial activity against P. 
aeruginosa, have been shown to inhibit quorum sensing in vitro, and this mechanism of action may 
be part of the reason as to why they are so effective in CF. 
2.4.9.1 Quorum Sensing Inhibition with Macrolide In Vitro 
The in vitro effects of sub MIC (minimum inhibitory concentration) macrolide antibiotics on P. 
aeruginosa are well described [117] with inhibitory effects on flagellin expression, exoenzyme 
production [118] and collagen adherence [119]. Multiple studies have demonstrated that macrolide 
antibiotics interfere with the quorum sensing circuitry of P. aeruginosa in vitro [20, 21, 43, 74, 117, 
119, 120] [17, 20, 120-123]. Macrolide antibiotics have been shown to inhibit the expression of 
rhlAB (rhamnolipid), lasR, rhlR, lasI and rhlI [21] as well as the production of elastase, pyocyanin 
[120]) and quorum sensing molecules [20, 21]. 
 
A microarray approach [74], investigating the effect of azithromycin on the transcriptome of the 
PAO1 strain of P. aeruginosa, demonstrated that azithromycin caused differential expression in 107 
genes, 10% of which were quorum sensing controlled. Another study suggested that macrolide had 
the biggest inhibitory effect on LasA (elastase) and AprA (alkaline metalloproteinase) [121], 
however elastase, rhamnolipid [123] and pyocyanin [124] were all relatively inhibited in other 
studies. The overall picture is of reduced expression of toxic quorum sensing controlled genes, 
particularly during stationary phase, where the effect of azithromycin on the ribosome most likely 
interferes with protein synthesis rather than P. aeruginosa growth [124].  
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In mammalian cell culture, azithromycin has been shown to attenuate 3-oxo-C12-HSL stimulation 
of MUC5AC in NCI-H292 cells [104], as well as secretion of CXCL8 by human 16HBE bronchial 
epithelial cells stimulated with bacterial culture supernatant [124]. However, azithromycin appears 
to have no effect on unstimulated, baseline cytokine secretion by bronchial epithelial cells [125]. 
2.4.9.2 Quorum Sensing Inhibition with Macrolide In Vivo 
Using a CF mouse, azithromycin, given at a dose of 500 mg/kg, inhibited P. aeruginosa quorum 
sensing activity, attenuated the production of alginate (biofilm) and quorum sensing-controlled 
virulence factors (such as elastase, pyocyanin and chitinase) and enhanced bacterial clearance in 
treated mice, compared with saline controls in an early infection model [43]. 
 
Human studies of quorum sensing in vivo after macrolide therapy have been limited. The only study 
looking specifically at the effect of macrolide on quorum sensing in the human host used tracheal 
aspirates to assess bacterial gene expression in order to determine quorum sensing activity following 
azithromycin therapy [17]. This study was part of a large multicentre randomized placebo controlled 
trial looking at the effect of azithromycin on the prevention of VAP in mechanically intubated 
intensive care patients. Patients were randomized to receive 300 mg per day of azithromycin 
(intravenously) or control when they became infected with P. aeruginosa (as determined by 
screening for P. aeruginosa via daily tracheal aspirate). Tracheal aspirates and one P. aeruginosa 
isolate were collected every 24 hours. Total bacterial DNA and RNA were extracted from the 
tracheal aspirate and the isolate. Overall there was a reduction in the total amount of P. aeruginosa 
(detected by RT-PCR of DNA) in the azithromycin treated group (p=0.06), consistent with some 
bactericidal or bacteriostatic effect. In the aspirates from infected patients, relative expression of lasI 
and rhlA were reduced in the patients treated with azithromycin. As expected, the proportion of lasR 
mutants (in the isolates) increased over time in the placebo group, suggesting a fitness advantage for 
the mutants in the presence of active quorum sensing. Those not treated with azithromycin had an 
increased incidence of VAP. These data would suggest that in the human host, quorum sensing is 
inhibited in the presence of azithromycin. There are many potential confounders to the results of this 
study however, including the effect of azithromycin on other microbes within the lung as well as its 
potential effect on bacterial adherence to the epithelium. This is certainly an area which needs 
further investigation, but lends support for the hypothesis that inhibition of quorum sensing will 
reduce the infectivity and virulence of P. aeruginosa.  
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2.5 SUMMARY AND EXPERIMENTAL DIRECTION 
There is evidence that macrolide antibiotics reduce the frequency of exacerbations in non-CF 
bronchiectasis [7-9]. The mechanisms of action are, however, unclear. Effects on local immunity are 
largely based on in vitro observations and have not been substantiated in clinical studies. The fact 
that infection with opportunistic pathogens such as P. aeruginosa portends a worse prognosis and 
that treatment with macrolide appears to benefit this group the most [10], suggests a possible link 
with macrolides and Pseudomonas-host interactions. Quorum sensing is an obvious target to 
investigate further. In vitro studies have confirmed that macrolides inhibit quorum sensing in 
bacterial cell culture, and human and mouse studies have suggested a negative effect on virulence 
and pathogenesis. What is not known, however, is whether quorum sensing is relevant during the 
later stages of P. aeruginosa infection in non-CF bronchiectasis, and what effect long-term 
macrolide therapy has on P. aeruginosa persistence within the human host. With the increasingly 
widespread use of these antibiotics, and the potential for side effects and resistance induction, it is 
essential that we further investigate the mechanisms of effect of macrolide within the human host. 
 
The research reported in this thesis will be the first study to look directly at the effect of a macrolide 
on P. aeruginosa in the respiratory secretions of non-CF bronchiectasis subjects in a randomised, 
controlled fashion. Induced sputum and bronchial alveolar lavage fluid (BAL) will be used to 
determine the effect of erythromycin on P. aeruginosa gene expression and exoproduct production 
with relevance to the quorum sensing circuitry over 12 months. Finally, the interaction of P. 
aeruginosa and quorum sensing molecules with PPARγ will be investigated in order to further 
understand the complex relationship this pathogen has with the human host in non-CF 
bronchiectasis. 
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CHAPTER 3: HYPOTHESES AND AIMS 
3.1 HYPOTHESES: 
This project will comprise three distinct parts with the following hypotheses: 
 
Hypothesis 1: 
Erythromycin will reduce production of quorum sensing controlled exoproducts and quorum sensing 
specific gene expression in vitro. 
 
Hypothesis 2: 
Erythromycin will inhibit quorum sensing gene expression in the airways of P. aeruginosa infected 
non-CF bronchiectasis subjects. 
 
Hypothesis 3: 
Non-CF bronchiectasis subjects will have a lower airway level of PPARγ and PON2 gene expression 
compared with healthy controls and the presence of P. aeruginosa will be associated with a lower 
level of PPARγ gene expression. 
 
Hypothesis 3a:  
Erythromycin will have no effect on airway levels of PPARγ gene expression. 
3.2 AIMS 
AIM 1: To determine the effect of erythromycin on quorum sensing in P. aeruginosa laboratory and 
clinical isolates. 
To culture P. aeruginosa laboratory strains and clinical isolates in varying culture media and growth 
conditions and assess the baseline phenotypic variability pertinent to quorum sensing, including 
pyocyanin, elastase, quorum sensing molecules and quorum sensing specific gene expression.  
 
To culture P. aeruginosa laboratory strains and clinical isolates in varying culture media and growth 
conditions in the presence of sub-inhibitory concentrations of erythromycin and measure changes in 
quorum sensing, virulence and efflux pump gene expression, secreted elastase and pyocyanin (using 
the Elastin Congo Red assay and established methods for pyocyanin), and measure quorum sensing 
molecules using mass spectrometry. 
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AIM 2: To determine the in vivo effect of erythromycin on quorum sensing by P. aeruginosa within 	
the respiratory tract of patients with non-CF bronchiectasis. 
To measure gene expression using assessment of RNA transcripts for quorum sensing controlled 
genes and efflux pumps in the airway secretions of non-CF bronchiectasis subjects and evaluate 
changes in these levels following treatment with erythromycin or placebo for 12 months.  
 
To measure the levels of P. aeruginosa-derived quorum sensing molecules in the airway secretions 
of non-CF bronchiectasis subjects using mass spectrometry and evaluate changes in these levels 
following treatment with erythromycin or placebo for 12 months. 
 
To correlate presence of P. aeruginosa quorum sensing gene expression and quorum sensing 
molecule levels with important clinical outcomes in non-CF bronchiectasis subjects. 
 
AIM 3: To determine whether PPARγ is inhibited by P. aeruginosa in the airways of non-CF 	
bronchiectasis subjects. 
To measure PPARγ gene expression in the airway secretions of non-CF bronchiectasis subjects and 
compare these with PPARγ gene expression in the airways of healthy control subjects. 
 
To correlate levels of PPARγ gene expression with important clinical outcomes in non-CF 
bronchiectasis subjects. 
 
To determine whether airway levels of PPARγ gene expression are affected by the presence of 
erythromycin. 	 	
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CHAPTER 4: METHODS 
This project utilises several methodologies, some of which are standard protocols and others that 
required specific development. This chapter outlines both the standard protocols that needed little 
modification for application here, along with methods that required substantial development. These 
methods will be described in more detail within each section. 
4.1  SUBJECTS 
This research was approved by the Mater Health Service Human Research and Ethics Committee 
under the approval for project numbers 1244A, 1534A, 1847A and the Low and Negligible Risk 
Number 2012 35 LNR. All study samples were de-identified immediately after collection and all 
laboratory determinations were made blind to the diagnosis and treatment. 
 
The samples analysed in this study were taken from subjects participating in the BLESS trial [7]. 
Eligible non cystic fibrosis bronchiectasis patients were aged between 20 and 85 years and had 
received at least two courses of antibiotic therapy in the preceding twelve months for pulmonary 
exacerbations. Subjects required a confirmed diagnosis of bronchiectasis by HRCT within the 
previous three years, airway obstruction on spirometry (but with an FEV1 >25% predicted), and 
chronic productive cough (with at least 5 mL sputum production per day). Patients with active 
tuberculosis or non-tuberculous mycobacterial infection, who smoked cigarettes within the 
preceding 6 months, who had a history of malignant arrhythmia or QTc prolongation on baseline 
ECG, and patients who were receiving macrolide antibiotics at time of recruitment, were excluded.  
 
A total of 679 subjects were screened, with 117 subjects recruited. Subjects recruited into the trial 
were randomised to treatment with low dose erythromycin (erythromycin succinate 400 mg twice 
per day) or placebo. Figure 4.1 demonstrates the patient flow through the study. Subjects were 
matched at baseline (Table 4.1). 
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Figure 4.1: Flow of subjects through the BLESS trial [7]  
 
A subset of 40 subjects (20 each from the erythromycin and placebo groups) were randomly 
selected for bronchoalveolar lavage fluid (BAL) collection. These subjects were selected based on 
the absence of co-existing pulmonary disease and the ability to safely undergo bronchoscopy. 
Subjects with asthma, bleeding diathesis, current anticoagulation users, and those who had suffered 
a recent acute myocardial infarction or uncontrolled cardiac arrhythmia, were excluded from this 
subgroup. Twenty normal controls (non-smokers, with no known respiratory disease) were also 
recruited for bronchial biopsy, BAL, brushings and induced sputum sample collection.  
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 Placebo (n=58) Erythromycin (n=59) 
Age, mean (SD), y 63.5 (9.5) 61.1 (10.5) 
Female sex, No. (%) 33 (56.9) 38 (64.4) 
FEV1, mean (SD) 
Post bronchodilator, L 
Post bronchodilator, % predicted 
  
1.93 (0.79) 1.93 (0.69) 
73.6 (20.6) 70.2 (17.2) 
P. aeruginosa at baseline, no. (%) 18 (31.0) 23 (39.0) 
> 5 Exacerbations in prior year, No. (%) 20 (34.5) 22 (37.3) 
Ex-smokers, No. (%) 15 (25.9) 10 (16.9) 
Comorbidities, No. 
Hypertension 
Asthma 
Ischaemic heart disease 
Cerebrovascular disease 
Diabetes Mellitus 
  
20 17 
10 12 
6 5 
4 2 
2 1 
 
Table 4.1: Baseline demographics of BLESS subjects [7]. No. = number, SD = standard deviation. 
FEV1 = forced expiratory volume in one second. 
 
 
Patients were recruited from South East Queesnland (Australia). All eligible subjects were assessed 
solely at the Mater Adults Hospital Respiratory Department prior to participation in the study. All 
samples were collected by A/Prof. David Serisier, Dr. Simon Bowler (Respiratory Physicians Mater 
Health Services, Brisbane Australia) and Ms. Megan Martin (Respiratory Research Nurse, Mater 
Health Services, Brisbane Australia). Figure 4.2 summarises the visit number and the samples 
collected at each visit. Subjects attended nine visits throughout the trial. 
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x = Induced Sputum 
x = Bronchoscopy and lavage 
x = Serum 
Figure 4.2: Summary of visits and samples collected during BLESS. Trial drug was taken between 
weeks 0 and 48, with a 4-week wash out period prior to visit 9. 
 
4.2  PROCEDURES 
During BLESS subjects underwent a number of procedures aimed at assessing both respiratory and 
general health.  
4.2.1  Physical Examination 
A general and respiratory physical examination was carried out at visits 1, 2 5 and 8. Vital signs 
including heart rate, blood pressure, temperature and arterial oxygen saturation were also recorded 
to objectively assess for clinical stability whilst on the trial. 
4.2.2 Clinical Investigations 
Lung function was assessed at each visit by spirometric testing. Forced expiratory volume in one 
second (FEV1) and forced vital capacity (FVC), FEV1/FVC ratio, forced expiratory flow between 
25%-75% (FEF25-75), and peak expiratory flow (PEF) were measured as per standard procedure 
[126].  
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4.2.3  Quality Of Life Questionnaires 
Two validated quality of life (QoL) questionnaires were completed at each visit: The St. George's 
Respiratory Questionnaire (SGRQ) is a disease-specific measure used to assess patients with 
respiratory airway disease [127] measuring overall health, daily life, and perceived well-being. The 
measure consists of 50 (76 responses) items that produce three domain scores. The Leicester Cough 
Questionnaire (LCQ) [128] consists of 19 questions on a 7 point Likert scale and more specifically 
targets cough as a symptom impacting QoL. 
4.2.4  Lower Airway Sampling 
Subjects underwent sputum induction at visits 1, 2, 5, 8 and 9. Sputum induction was performed 
according to the standardised protocol recommended by the European Respiratory Society Task 
Force [129]. 
The following procedure for sputum induction was followed: 
1. Using an ultrasonic nebuliser, the pre-bronchodilator FEV1 was measured and 200 µg of 
inhaled salbutamol was administered.  
2. Using sterile 4.5% saline solution, induction was performed in 5 min blocks for up to 20 
min total. 
3. At the end of each 5 min block, the subject rinsed their mouth with water, FEV1 was 
measured, the subject was instructed to expectorate, and samples collected in a sterile 
container. 
4. The sputum samples were immediately aliquoted into 2 mL collecting tubes and stored at -
80oC 
The bronchoscopy subgroup underwent bronchoscopic airway sampling at visits 1, 2 and 8. BAL 
was collected after wedging the bronchoscope in a sub segmental bronchus with known 
bronchiectasis (on HRCT). 140 mL of warmed sterile saline was instilled, followed by aspiration 
through the bronchoscope suction channel.  
4.3  SAMPLE PROCESSING 
4.3.1  Induced Sputum 
Stored induced sputum samples were further processed as follows. One aliquot was diluted 1:3 in 
phosphate buffered saline and homogenised by vortexing. Three 10 µL aliquots were stored and 
frozen in LB Broth (Invitrogen, California, USA) and 30% Glycerol for further assessment if 
required. Those known to be P. aeruginosa positive at screening were plated onto MacConkey agar 
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(Oxoid, Adelaide, Australia) and incubated for 48 h at 37oC. Three representative isolates were 
taken from each plate and stored in LB glycerol stock at -80oC. Two 1 mL aliquots of the 1:4 
dilution was centrifuged at 16,000 x g for 10 min at 4oC and the supernatant removed for 
inflammatory cytokine assessment in another project. The remaining pellet was resuspended in 
RNA protect (Qiagen, Germantown, USA). 100 µL from each of the two pellets was removed for 
DNA extraction and stored at -80oC. The remainder was stored at -80oC for exoproduct assessment. 
4.3.2  Bronchoalveolar Lavage Fluid 
BAL samples were delivered to the laboratory on ice immediately following collection. Two 1mL 
aliquots of the crude suspension were immediately stored at -80°C. The remainder of the BAL were 
processed to maximise mammalian RNA extraction for assessments of PPARγ gene expression, 
detailed in Chapter 7. BAL samples were centrifuged at 500 x g for 5 min at 4°C and the cell pellets 
were stored at -80°C prior to mammalian RNA extraction.  
4.4  ISOLATION AND IDENTIFICATION OF P. AERUGINOSA ISOLATES  
There are many approaches that can be used to identify bacterial isolates. Conventional diagnostic 
bacterial identification is generally performed using morphological assessment of isolates grown on 
selective media. However, presumptive identification can only be made on morphological 
assessment. Other techniques have therefore been developed to improve identification. Three 
techniques were used in this study to confirm identification of P. aeruginosa in BLESS isolates 
prior to gene expression and exoproduct analysis. 
4.4.1  Morphological Assessment 
Morphological assessment of bacterial isolates grown on selective media provides an initial 
identification of bacterial species. Here, growth on MacConkey agar was used to suppress the 
growth of gram positive organisms thereby increasing the likelihood of P. aeruginosa isolation. On 
MacConkey agar P. aeruginosa should be non-lactose fermenting, look mucoid, green and or clear 
and round and have a serrated edge [130].  
 
To isolate P. aeruginosa, frozen sputum was homogenised 1:3 with phosphate buffered saline 
(PBS) and a 1 µL loop was streaked into MacConkey agar. Plates were incubated at 37oC and 
reviewed after 48 h of growth. Colonies which appeared round and clear in colour with serrated 
edges (non-lactose-fermenting) were presumptively identified as P. aeruginosa (Figure 4.3).  
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Figure 4.3: A typical P. aeruginosa colony morphotype cultured on MacConkey agar 
demonstrating the round shape, clear colour and serrated edged characteristically seen on this 
media. 
 
Indeterminate colonies were further sub-cultured onto clear LB agar. Here, the formation of mucoid 
colonies and the production of blue/green pigmentation (indicative of pyocyanin production) were 
confirmatory of P. aeruginosa identification. Three representative P. aeruginosa colonies were 
stored in 30% glycerol/LB broth at -80oC for further analysis. 
4.4.2  P. aeruginosa Specific PCR 
PCR assays have been developed for the direct detection and quantification of P. aeruginosa in 
both clinical and environmental samples. These assays rely on the amplification of P. aeruginosa 
specific DNA sequences, and can be applied directly to clinical samples (culture-independent) or to 
isolates grown in culture.  
 
One such PCR assay is based on amplification of a region of the oprL gene. OprL is a 
peptidoglycan associated lipoprotein precursor that forms part of the bacterial outer membrane. 
Feizebaldi [131] have shown previously that a TaqMan assay designed to amplify a 117 base pair 
region of this gene is specific to P. aeruginosa.  
 
PCR was performed using reagents and conditions different to those published previously. A 
process of optimisation was therefore carried out to identify appropriate reaction conditions.  
4.4.2.1  Annealing Temperature 
To identify the annealing temperature at which the brightest oprL amplicon occurred, end point 
PCR was performed across a temperature gradient of 55 – 62oC. The Taq polymerase used in this 
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reaction is optimised for 60oC, therefore a range spanning this temperature was selected to 
determine the annealing temperature at which the reaction was the most efficient. 
Mastermix components (per 25 µL reaction): Sensimix 12.5 µL, Primer (Forward and Reverse) 400 
nM, H2O 5.5 µL, Template (PAO1 67.6 ng/ µL DNA 1:10 dilution) 2 µL 
 
PCR conditions were as follows: Hold 95oC 2min, Cycle (x40): 95oC 15 s, Gradient 55 - 62oC 30 s, 
72oC 30 s, Hold 72oC 2 min 
 
The Bio-Rad C100 Thermal cycler (California, USA) was used for end point PCR assessment. 
 
Amplicons were visualised by agarose gel electrophoresis (1.5% agarose tris acetate EDTA gel), 
Figure 4.4. 
 
Figure 4.4: Agarose gel electrophoresis of the oprL amplicon across a temperature gradient 
demonstrating the 117 base pair amplicon across temperatures ranging from 62oC to 55.6oC. There 
is a visible reduction in efficiency at 62oC.  
 
All temperatures tested below 62oC produced a bright amplicon, although efficiency appeared to 
drop off at temperatures above 61.6oC as demonstrated by the reduction in intensity of the 
amplicons visualised on agarose gel electrophoresis. An annealing temperature of 60oC was 
therefore selected as this is a highest temperature visualised on the gel before loss of efficiency was 
noted. This is also the optimal working temperature for the polymerase used. 
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4.4.2.2  Amplification and Efficiency 
End point PCR is useful to assess whether a gene is being expressed. However relative gene 
expression is more easily determined using real time PCR (RT-PCR). RT-PCR uses different 
reagents which will have different, albeit similar properties, to those used in the previous section. 
RT-PCR is a significantly more expensive modality and it is not possible to perform a temperature 
gradient on these machines. Therefore the annealing temperature optimised in the previous section 
was selected for further assessments using a dilution series in RT-PCR.  
 
DNA was extracted from 1 mL of P. aeruginosa PAO1 (OD600 1.0) and quantified by using a 
spectrophotometer (Section 4.11.6.1) as 67.6 ng/ µL. A three-fold 1:10 dilution series was 
generated and used as a template for PCR amplification using the conditions described below. DNA 
extracted from P. aeruginosa infected CF sputum was also extracted in a similar manner. CF 
sputum was used for these optimisation experiments due to the ready availability of discarded, 
expectorated sputum at this centre. Total bacterial DNA from this extraction was not quantified as 
the relative contribution of human to bacterial DNA cannot be differentiated prior to PCR. 
 
For RT-PCR TaKaRa Sybr Green reagents (Takara Bio Inc. Japan) were used with ROX as the 
passive reference dye. 
 
The total reaction volume was 7.5 µL with the following components: Sybr 3.75 µL, Primer (F+R) 
200 nM, 0.75 µL, ROX 0.15 µL, H2O 0.35 µL, Template 2.5 µL. 
 
Thermal cycling conditions were as follows: Hold 95oC 2 min, Cycle (x40): 95oC 15 s, 60oC 30 s, 
72oC 30 s, Hold 72oC 2 min. 
 
Melt curve analysis was used to determine the specificity of the RT-PCR reaction. Each PCR 
product has a unique melting temperature. It is the temperature at which the double stranded DNA 
melts into single strands, leading to a reduction in fluorescence which is detected by the PCR 
machine. The melt curve for oprL demonstrated a single peak at all dilutions assessed (Figure 4.5). 
 
Efficiency was assessed by plotting the Ct values against Log10 concentration and performing linear 
regression analysis. oprL had an efficiency of 98.1% (r2=0.989). 
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Figure 4.5: Example of the amplification plot (left panel) and melt curve (right panel) for oprL 
PCR demonstrating the increase in fluorescence seen as the product is amplified. A three-fold, 1:10 
dilution series is shown in the left panel. A single peak seen on the melt curve is specific to oprL 
and is indicative that a single product is being amplified 
 
4.4.2.3  Specificity 
Specificity of the P. aeruginosa specific PCR assay was determined by assessing its ability to 
amplify DNA extracted from other respiratory pathogens commonly isolated from the airways of 
non-CF bronchiectasis subjects. Clinical isolates of respiratory pathogens were kindly provided by 
Dr Sanmarie Schlebusch (Director of Microbiology, Mater Health Services, Brisbane Australia). 
These included Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus and 
Moraxella catarrhalis. These isolates were subjected to end point PCR as has been described in 
section 4.4.2.1. There was no amplification when H. influenzae and human templates were used, 
however low amplification was observed with S. aureus, M. catarrhalis and K. pneumoniae (Figure 
4.6). These findings suggest that this assay, using this primer with Sybr Green reagents, is not 
specific to P. aeruginosa. However, when used as a confirmatory technique in isolates with a 
presumptive identification of P. aeruginosa, it is supportive of correct identification. A final 
confirmatory modality was therefore employed to correctly identify BLESS isolates as P. 
aeruginosa and will be described in section 4.4.3. End point PCR was applied to the BLESS 
isolates pending this final assessment.  
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Figure 4.6: Agarose gel electrophoresis of the oprL amplicon using DNA extracted from P. 
aeruginosa as a positive control. There was no amplification when H. influenzae (H.infl) and 
human templates were used, however there was low amplification with M. catarrhalis (M. cat) and 
K. pneumoniae (K. pneumo). NTC = no template control. 
4.4.2.4  Application of PCR Identification to BLESS Isolates 
Six clinical isolates from BLESS patients (collected at baseline) presumptively identified as P. 
aeruginosa based on morphological assessment, were selected. Total DNA was extracted from a 
single colony. P. aeruginosa specific PCR was performed as descried above. S. pneumoniae was 
used as a negative control and P. aeruginosa strain PAO1 was used as a positive control. All 
isolates were presumptively consistent with P. aeruginosa as determined by amplification of the 
oprL gene (Figure 4.7). 
 
 
Figure 4.7: Identification of P. aeruginosa by amplification of the oprL gene in 6 isolates from the 
BLESS cohort. neg = negative control (S. pneumoniae). Isol = isolate number. 
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4.4.3  MALDI -TOF 
Matrix assisted laser desorption/ionisation – time of flight mass spectrometry (MALDI-TOF) is 
used in the diagnostic setting as routine assessment of bacterial species in microbiological 
laboratories. The principle involves the use of a laser to ionise particles across a sample (bacterial 
colony) embedded in a matrix. The ionised particles then pass along a tube. The time of flight for 
each particle is monitored and is related to its mass/charge ratio. Each species of bacteria have a 
specific MALDI-TOF motif, therefore each sample can be compared with known standards. On the 
Bruker Microflex MS each sample is scored on a log scale from 0-3 for similarity to a standard. A 
score of >2.0 is consistent with species identification, scores between 1.7-<2.0 are acceptable to the 
genus level. All six BLESS isolates were assessed on the Bruker Microflex MS system and scored 
>2.0. 
4.5  MEASUREMENT OF BACTERIAL GROWTH BY OPTICAL DENSITY  
Measurement of absorbance is a standard way to determine bacterial growth. It is a measure of the 
increasing density of a liquid culture and is expressed as the absorbance at a particular wavelength. 
An optical density (OD) recorded at 600 nm is used conventionally to determine the density of 
bacterial suspensions. Here, POLARstar Omega, and the PHEARstar FS, (BMG Labtech 
Ortonberg, Germany) plate readers were used for optical density measurements. 
 
To determine bacterial growth, isolates were cultured overnight in LB broth and standardised to an 
OD600 of 1.0 by dilution in fresh media. Overnight cultures were further diluted 1:100 in either LB 
or the media being investigated. 1 mL of this suspension was added to one well of a 48 well plate. 
The plate was covered with clear plastic (to limit evaporation) and a small puncture was made at the 
12 o’clock position with a 27G needle (to reduce condensation). Plates were incubated at 37oC with 
continuous shaking at 200 rpm in the POLARstar Omega plate reader (BMG Labtech, Ortonberg, 
Germany) for 24 h. OD600 readings were taken at 30 min intervals and bacterial growth curves 
plotted. 
4.6  ASSESSMENT OF BACTERIAL LOAD BY PLATE COUNT 
The number of colony forming units (cfu) per unit volume was determined by inoculating LB agar 
spread plates with 100 µL of serial dilutions of bacteria. Colony numbers were counted at an 
appropriate dilution (between 30 and 300 colonies per plate) and the original bacterial load 
calculated based on the dilution factor. When performed on bacterial suspensions that have 
undergone OD600 measurement, this process can be used to calibrate OD600 to cfu/mL values.  
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4.8  SYNTHETIC GROWTH MEDIA  
Synthetic Sputum Media (SSM) is useful in in vitro experiments with respiratory bacteria to mimic 
the nutrient availability, viscosity and pH commonly found in the lung making in vitro experiments 
as closely representative of the in vivo condition as possible. SSM has been defined by analysis of 
the amino acid constituents of CF sputum [132] with a number of subsequent modifications based 
on assessments of mucin and DNA concentrations in CF sputum [133, 134]. In addition to SSM, a 
variant that included porcine mucin (MSSM) was used in this study. Whilst high mucin content 
resulted in more representative rheological properties, it hampered optical density measurement. 
SSM was therefore used for bacterial growth measurement. 
4.8.1  Formulation Of Synthetic Media  
MSSM was formulated as follows. SSM was formulated in the same way, but with the omission of 
mucin (Step 1) 
1. 10 g of porcine gastric mucin was steeped in 70% ethanol [135] and exposed to ultraviolet 
light for 20 min for sterilisation, followed by centrifugation at 3000 x g for 10 min at room 
temperature. Excess ethanol was discarded. Mucin was heated at 67oC overnight to vent the 
remaining ethanol, before resuspension in sterile water. Mucin sterility was confirmed by 
the inoculation of 100 µL of this suspension onto an LB agar plate and incubation at 37oC 
for 5 days. All chemicals were purchased from Sigma-Aldrich (St. Louis, USA) unless 
otherwise stated. 
2. In a separate sterile flask, the following components were added to 250 mL sterile water: 59 
mg diethylenetriaminepentaacetic acid, 6.5 mL 0.2 M NaH2PO4, 6.25 mL 0.2 M Na2HPO4, 
0. 348 mL 1 M KNO3, 0. 122 g NH4Cl, 1. 114 g KCl, 3.03 g NaCl, 2.312 g MOPS, 1.4 g 
herring sperm DNA. 
The suspension was autoclaved at 120oC for 15 min. 
3. The following sterile components were added 
5 mL egg yolk emulsion (phosphatidylcholine) (Oxoid, Adelaide, Australia) 
10 g bovine serum albumin       
1.754 mL 1 M CaCl2   
0.606 mL 1 M MgCl2   
1 mL 3.6mM FeSO4 _7H2O  
3 mL 1M D-Glucose 
9.3 mL L-Lactate - Lactate stocks were adjusted to a pH of 7.0 with NaOH 
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4. Amino acids were filter sterilised through a 0.22 µm filter and added from 10 mM stocks. 
Amino acids were maintained as 100mM stocks in deionised water and stored in the dark at 
4°C. Tyrosine, aspartate, and tryptophan were resuspended in 1.0 M, 1.0 M, and 0.2 M 
NaOH, respectively.  
8.27 mL L-aspartate    
10.72 mL L-threonine    
14.46 mL L-serine    
15.49 mL L-glutamate_HCl   
16.61 mL L-proline    
12.03 mL L-glycine    
17.8 mL Lalanine    
1.6 mL L-cysteine_HCl 
11.17 mL L-valine   
6.33 mL L-methionine 
11.2 mL L-isoleucine  
16.09 mL L-leucine 
8.02 mL L-tyrosine  
5.3 mL L-phenylalanine 
6.76 mL L-ornithine_HCl 
21.28 mL L-lysine_HCl 
5.19 mL L-histidine_HCl   
0.13 mL L-tryptophan   
3.06 mL L-arginine_HCl   
5. Media was made up to 1000 mL with sterile water allowing for pH adjustment and addition 
of mucin in the final step. Media was adjusted to pH 6.8. 
6. Media was again filtered through a 0.22 µm filter. 
7. Re-dried, sterile mucin from step 1 was added and allowed to hydrate. 
4.8.2 Validation Of SSM 
To demonstrate the ability of pseudomonads to grow in SSM, P. aeruginosa was inoculated into an 
aliquot of SSM and incubated overnight at 37oC with continuous shaking at 250 rpm in the Pherstar 
FS plate reader (BMG Labtech, Ortonberg, Germany). OD600 measurements were taken every 30 
min. Growth in LB, Kings A media and MacConkey broth were also measured as comparators 
(Figure 4.8). 
	 80 
 
 
 
Figure 4.8: Growth curves of PAO1 in synthetic sputum media (SSM), Luria broth, Kings A media 
and MacConkey broth. OD600 measurements were taken every 30 min for 24 h. The was no growth 
in all of the blank samples except in LB after 14 hours indicating potential contamination in the 
blank for that sample. 
 
4.9 PRIMER OPTIMISATION 
PCR amplification of specific genes were used to determine the activity of P. aeruginosa quorum 
sensing both in vitro and in vivo. In order to do this primer pairs targeting unique sequences on 
genes of interest were designed. Optimised primers are listed in Table 4.2. Primers were optimised 
from published sequences or designed de novo using the Primer3 (http://bioinfo.ut.ee/primer3-
0.4.0/primer3/) software against the PAO1 P. aeruginosa genome as published on the website: 
pseudomonas.com (http://pseudomonas.com/ December 2012). Specificity was determined using 
the National Center for Biotechnology Information (NCBI) Basic Local Alignment Tool (BLAST) 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) for highly similar sequences and via RT-PCR amplification 
against cDNA from H. influenzae and Homo sapiens. All primers were optimised in the same way; 
initially using P. aeruginosa DNA as a template (later cDNA) as described in section 4.9.1-3.  
 
The housekeeping genes rpoD and rpsL were also optimised. Housekeeping genes are constitutively 
expressed genes that can be used as controls for differential gene expression studies. rpoD has been 
previously studied and validated as a stable housekeeper [136] in a variety of strains of P. 
aeruginosa and was therefore optimised for use in this project. rpsL is also a well described P. 
aeruginosa housekeeping gene [17] and demonstrated excellent correlation with rpoD in this study. 
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Table 4.2: Primer sequences for those used in this project with reference where appropriate. Non 
referenced primers were developed de novo. 
Name Primers Base 
Pairs 
Reference 
16S rRNA F 5'-TCCTACGGGAGGCAGCAGT-3' 
R 5'-GGACTACCAGGGTATCTAATCCTGTT-3'  
466 [137] 
rpoD F 5'-GGGCGAAGAAGGAAATGGTC-3' 
R 5'-CAGGTGGCGTAGGTGGAGAA-3' 
178 [136] 
oprL F 5'-CGAGTACAACATGGCTCTGG-3' 
R 5'-ACCGGACGCTCTTTACCATA-3' 
Probe: CCTGCAGCACCAGGTAGCGC  
117 [131] 
rpsl F 5'-GCAAGCGCATGGTCGACAAGA-3'  
R 5'-CGCTGTGCTCTTGCAGGTTGTGA-3' 
~200 [17] 
lasR F 5'-ACGCTCAAGTGGAAAATTGG-3'  
R 5'-GTAGATGGACGGTTCCCAGA-3'  
247 [77] 
lasI F 5'-CTACAGCCTGCAGAACGACA-3'  
R 5'-ATCTGGGTCTTGGCATTGAG-3'  
168 [77] 
rhlR F 5'-AGGAATGACGGAGGCTTTTT-3'  
R 5'-CCCGTAGTTCTGCATCTGGT-3' 
231 [77] 
rhlI F 5'-CTCTCTGAATCGCTGGAAGG-3'  
R 5'-GACGTCCTTGAGCAGGTAGG-3'  
240 [77] 
pqsR F 5'-AACCTGGAAATCGACCTGTG-3' 
R 5'-TGAAATCGTCGAGCAGTACG-3' 
238  
rhlA F 5'-CGAGGTCAATCACCTGGTCT-3' 
R 5'-GACGGTCTCGTTGAGCAGAT-3' 
208  
rhlB F 5'-GAGCGACGAACTGACCTACC-3' 
R 5'-GGGAATCCCGTACTTCTCGT-3' 
208  
lasB F 5'-ATCGGCAAGTACACCTACGG-3' 
R 5'-ACCAGTCCCGGTACAGTTTG-3' 
238  
pqsA F 5'-CAATACACCTCGGGTTCCAC-3' 
R 5'-TGAACCAGGGAAAGAACAGG-3' 
184  
pqsH F 5'-ATGTCTACGCGACCCTGAAG-3' 
R 5'-AACTCCTCGAGGTCGTTGTG-3' 
169  
phzA F 5'-AACCACTTCTGGGTCGAGTG-3'  
R 5'-GTGGGAATACCGTCACGTTT-3'  
202  
qscR F 5'-TCCTTCCTGCTCTGGATCAC-3' 
R 5'-TGTTGCTGGAGTTGAGCTTG-3' 
229 [77] 
vqsR F 5'-GGTGACGGACGAAGTTCAAT-3' 
R 5'-GCGATATCAACCCTCTCCAG-3' 
236  
vfR F 5'-TACCCACACACCCAAACTCA-3' 
R 5'-ATCACCGCTGTTGAGGTAGC-3' 
199  
mexA F 5'-GCAGACGGTGACCCTGAATA-3' 
R 5'-GGGTCGATCTGGTAGAGCTG-3' 
153  
mexB F 5'-ATGACCATCACCGTGACCTT-3' 
R 5'-AGAGTGGGTCCTGGATGTTG-3' 
238  
oprM F 5'-AGCCAGCAGGACTTCGATAC-3' 
R 5'-GGTGAAATCCGCATAGATCG-3' 
213  
mexY F 5'-CCAAGGACCATTACCAGGAA-3' 
R 5'-AACAGCGGTACCAGGAACAC-3' 
226  
mexX F 5'- AGCTGCTGTTCTCCGACCT-3' 
R 5'- TTTGGGTTGACCACCTTGAC-3' 
208  
dksA F 5'-TCCACCAAAGCAAAACAACA -3' 
R 5'-TACGGTCGACCTCTTCCATC-3' 
160  
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4.9.1  Annealing Temperature 
The optimal annealing temperature was determined by performing PCR with a temperature gradient 
(Bio-Rad C100 Thermal cycler, California USA) as described in section 4.4.2.1. An annealing 
temperature of 61oC was determined to provide efficient amplification and high specificity for 
rpoD. 
4.9.2  Amplification and Melt Curve Analysis 
Serial 1:10 dilutions (five-fold) of DNA extracted from 1 mL of P. aeruginosa strain PAO1 OD600 
1.0 (starting concentration 67.7 ng/ µL) and DNA extracted from CF sputum (starting concentration 
total DNA 368.9 ng/ µL) was used in RT-PCR (Viia 7 Real time PCR system, Applied Biosystems, 
USA) to assess amplification and melt temperature (Figure 4.9). All dilutions amplified 
appropriately and had the same melt temperature (87.7oC) regardless of whether DNA was 
extracted from sputum or cultured P. aeruginosa.  
 
Figure 4.9: Amplification (left) and melt curve plot (top right) for the rpoD gene. There was no 
amplification in the NTC as shown by the absence of a discernible peak in the melt curve in the 
bottom right panel. DNA extracted from P. aeruginosa is shown. 
4.9.3  Amplification Efficiency 
To assess amplification efficiency RNA was extracted from an overnight culture of P. aeruginosa 
PAO1 (OD600 1.0) and reverse transcribed cDNA using random hexamer primers. RT-PCR of 
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fivefold serial 1:10 dilutions of cDNA was performed (starting concentration 2.3 ng/mL). 100% 
efficiency is achieved where there is a doubling in signal with each cycle during the exponential 
phase. Cycle threshold (Ct) values plotted against known Log10cfu/mL has a slope of -3.32 for 
reactions of 100% efficiency. Efficiency between 90-110%, with slopes between -3.58 and -3.10, 
were deemed acceptable, in line with convention. All primers optimised for this study had 
efficiencies between 90-110% and are listed in Table 4.3. 
 
Name Efficiency% r2 slope Annealing 
Temp oC 
rpoD 95.3 0.989 -3.44 61 
rpsL 104.3 0.998 -3.22 61 
oprL 98.1 0.989 -3.369 60 
lasR 101.9 0.943 -3.277 60 
lasI 89.4 0.994 -3.606 60 
rhlR 92.2 0.978 -3.524 60 
rhlI 105.4 0.995 -3.199 60 
rhlB 103.5 0.979 -3.242 60 
lasA 106.3 0.966 -3.178 61 
pqsA 102.4 0.99 -3.266 60 
phzA 95.3 0.995 -3.441 60 
qscR 108.5 0.983 -3.134 60 
vqsR 103.0 0.945 -3.251 60 
vfR 99.9 0.991 -3.323 61 
mexA 94.3 0.997 -3.465 60 
mexB 108.8 0.979 -3.127 60 
oprM 108.3 0.965 -3.139 60 
mexX 103.9 0.966 -3.232 60 
dskA 93.3 0.995 -3.492 60 
 
Table 4.3: Table showing the amplification efficiencies, r2 value and slope calculated from linear 
regression analysis of serially diluted cDNA. The annealing temperature for each primer is also 
shown. 
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4.9.4  TaqMan Optimisation 
The use of TaqMan probes in addition to specific primers provides a greater level of confidence in 
the specificity of an assay due to their sequence-specific binding to the target region. The probe also 
contains a fluorescent reporter that is cleaved off as the forward and reverse primers are 
polymerised. The fluorescent reporter used in this project was FAM. TaqMan primers [131] 
directed at the oprL gene were used in this study to detect and quantify P. aeruginosa in sputum. 
4.9.4.1  Reaction Volume 
The standard protocol for the TaqMan master mix recommends a 20 mL reaction consisting of the 
primer/probe mix and the universal master mix (plus template). However, due to the expense of the 
reagents, it was decided to reduce the reaction volume. In order to do this serial 1:10 x 5 fold 
dilutions of DNA extracted from 1 mL of cultured P. aeruginosa (OD600 1.0) were prepared as a 
template (2 µL per reaction). The standard mastermix was prepared in 20, 15, 10 and 5 µL final 
volumes. The standard TaqMan PCR protocol was then followed using the 7900HT fast PCR cycler 
(Applied Biosystems, USA). Cycling conditions were as follows: 50oC for 2 min, 95oC for 10 min, 
followed by 40 cycles of 95oC for 15 s and 60oC for 60 s. 
 
Linear regression analyses were used to demonstrate that all reaction volumes tested had 
efficiencies between 90-110% (Figure 4.10) and were therefore acceptable. A reaction volume of 10 
µL was chosen as it was less likely to be subject to fluid handling errors, while being more cost 
effective than 20 µL reaction volumes (10 µL volume r2=0.998, slope=-3.514). 
 
Figure 4.10: Plot of Ct vs. Log10 concentration of P. aeruginosa using different concentrations of 
oprL master mix. Circles = 20 µL, squares = 15 µL, triangles = 10 µL and upside down triangles = 
5 µL. Points represent mean values of duplicate reactions and error bars represent standard 
deviation. 
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4.9.4.2  Amplification of BLESS Samples 
To determine whether oprL could be amplified in sputum samples, eight randomly selected spare 
BLESS samples were amplified using the protocol described in section 9.4.1. Six of the eight 
samples had detectable P. aeruginosa (Figure 4.11). 
 
Figure 4.11: Ct values following amplification of the oprL gene from 8 BLESS sputum samples, 
demonstrating the ability to amplify this gene in DNA extracted from sputum. Each closed circle 
represents the duplicate Ct value for that sputum number. The horizontal bar represents the mean. 
 
4.10  DNA EXTRACTION 
DNA was extracted from both sputum, BAL and cultured P. aeruginosa using the QIAamp DNA 
mini kit (Qiagen, Germantown, USA), following the manufacturers protocol (Appendix 1) with 
minor modifications which included an initial 3 h lysis step and elution of total DNA in 100 µL 
elution buffer.  
4.10.1  Validation of DNA Extraction and PCR Efficiency from Sputum 
The efficiency of bacterial DNA extraction from sputum using the commercially available kit was 
assessed. DNA extraction was performed on 1 mL of P. aeruginosa infected CF sputum and 1 mL 
of P. aeruginosa overnight culture. The resultant DNA was serially diluted (1:10) and 16S 
ribosomal RNA gene PCR amplification performed. Linear regression analysis revealed equivalent 
slopes and y-intercepts demonstrating that the extraction efficiency from CF sputum (r2=0.997) was 
comparable to that of P. aeruginosa (r2=0.998) broth culture (Figure 4.12). 
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Figure 4.12: Cycle threshold (ct) values of Serial dilutions of P. aeruginosa DNA (circles) and P. 
aeruginosa infected cystic fibrosis sputum DNA (squares) vs. cfu/mL equivalents. 
  
4.10.2  PCR Reproducibility 
To determine PCR reproducibility, 12 DNA extracts from BLESS samples were amplified with 
using the 16S rRNA gene PCR assay described in section 10.5 in two independent reactions. 
Separate DNA dilutions were performed and different master mix generated for each of these 
duplicate reactions. The results of these two reactions were compared to assess PCR reproducibility. 
Duplicate reactions had a Spearman’s r of 0.909 (Figure 4.13).  
 
 
Figure 4.13: Comparison of twelve consecutive extracted DNA samples from visit one BLESS 
sputum samples. Samples were extracted at the same time but subjected to 16S PCR on separate 
days. Each point represents the mean value calculated from duplicate reactions.  
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4.10.3  Extraction Reproducibility 
To demonstrate extraction reproducibility, thirteen randomly selected BLESS samples (six from 
visit 1 and 7 from visit 8) were subjected to two, independent, repeat extractions. Amplification of 
the 16S amplicon showed excellent correlation (Spearman’s r=0.901) between the two extractions 
(Figure 4.14). 
 
Figure 4.14: Correlation between thirteen BLESS sputum samples (6 from visit one and 7 from 
visit 8) extracted on separate occasions and then amplified in the same PCR run. The 16S amplicon 
was amplified. Each point represents the mean value calculated from duplicate reactions. 
4.10.4  PCR Inhibition 
To determine if there was any significant inhibition of PCR amplification by factors co-extracted 
with DNA from sputum, RT-PCR was performed 1000 ng/µL mouse cDNA spiked 50/50 with 
extracted BLESS sputum DNA. Mouse cDNA was used as the aim was to amplify a housekeeping 
gene from a different species to determine whether there was any inhibition from the mixed 
human/bacterial BLESS sputum DNA extract. Serial 1:10 dilutions x six fold of both P. aeruginosa 
positive (BLESS #562 = 98.8 ng/µL) and P. aeruginosa negative (BLESS #BB10 = 5.6 ng/µL) 
samples were added to the same concentration of mouse cDNA. Samples were amplified with the 
mouse housekeeper gene Gadph. 
 
Amplification efficiency was determined by comparison of the amplification slope, time to reach 
plateau and the cycle threshold values for the different samples. In the absence of inhibition, the 
efficiency of the reactions should be the same (as determined by the amplification slope), the cycle 
threshold value should be the same, and the time to reach plateau should also be the same. 
Assessment of the amplification plots did not show any significant differences in these factors 
(Figure 4.15) 
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Figure 4.15: Amplification plot of mouse cDNA alone, mouse cDNA spiked with P. aeruginosa 
positive and negative sputum DNA. There is no discernible difference between the slopes. 
 
There was no significant difference (Kruskal-Wallis p=0.79) in the amplification slope at the 
highest concentration used (Figure 4.16).  
 
 
 
Figure 4.16: Amplification slope during the exponential RT-PCR phase. Mouse cDNA was spiked 
50/50 with DNA extracted from P. aeruginosa positive (squares) and P. aeruginosa negative 
(triangles) sputum. Unspiked mouse cDNA is shown as a control (circles). There was no difference 
in amplification slope at the same cycle threshold (Ct) values. Each point represents the mean of 
duplicate reactions. 
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4.10.5 Standard Curve Generation for the Calculation of cfu/mL Equivalents in Extracted 
DNA 
To determine the number of bacterial colony forming units per mL (cfu/mL) in the DNA extracts, a 
standard curve was generated. To do this, P. aeruginosa strain PAO1 was cultured in LB to an 
OD600 of 1.0. 100 µL of a 1:10 dilution series across 10 dilutions were spread onto LB agar plates. 
Plates with between 30-300 colonies were counted to determine the number of cfu/mL in 1mL of P. 
aeruginosa. Total DNA was then extracted. In this case, 1 mL of P. aeruginosa strain PAO1 
cultured in LB contained 1 x 108 cfu. 
 
Extracted DNA from a known quantity of P. aeruginosa (as determined by prior plate counts) was 
serially diluted 1:10 x 6 fold and used as template for RT PCR amplification of 16S in a Sybr Green 
reaction with the following components per 7.5 µL: 
 
Sybr 3.75 µL 
Primer (F+R) 200 nM 
ROX 0.15 µL 
H2O 0.35 µL 
Template 2.5 µL 
Thermal cycling conditions were as follows: 
Hold 95oC 2 min 
Cycle (x40) 
95oC 15 s 
60oC 30 s 
72oC 30 s 
Hold 72oC 2 min 
 
Resulting Ct values were plotted against the known Log10 cfu/mL, and linear regression analysis 
performed to determine the y intercept and slope. The following calculation was then used to 
determine the number of cfu/mL equivalents in the sample: 
 
To enumerate the total bacterial load per mL in BLESS sputum samples, the number generated 
above was multiplied by 20 to account for the dilution during initial processing of the samples. 
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4.10.6  Comments and Conclusions 
The use of a commercially available DNA extraction kit is an appropriate method for extraction of 
bacterial DNA from sputum samples as has been demonstrated in this section. Extraction 
reproducibility was excellent as was PCR reproducibility using sputum DNA extracts. No PCR 
inhibition was demonstrated suggesting that co-extracted inhibitors were also minimal using this 
technique. 
4.11  RNA EXTRACTION 
Direct extraction of bacterial mRNA from clinical samples is hampered by a number of factors. 
These include the rapid degradation of mRNA by RNase, human derived inhibitors, and the high 
ratio of human to bacterial cells. Published techniques [54] have struggled to obtain sufficiently 
high yields of high integrity bacterial RNA, whilst ensuring extracts are free of DNA 
contamination. As such, it was necessary to develop an effective and efficient methodology for 
extraction of bacterial RNA from sputum.  
 
RNA extraction involves several steps, each of which had to be optimised to provide sufficient 
amounts of high integrity bacterial RNA.  
 
The initial step involves lysis of bacterial cells in order to release the RNA from the intracellular 
compartment. Several approaches can be used to achieve cell lysis, including the use of physical, 
chemical, or enzymatic disruption of cellular integrity. Bacterial species differ in structure, and 
therefore require different levels of lysis stringency for effective RNA extraction. To ensure lysis of 
all species present, more than one approach to cellular disruption can be employed.  
 
The second step involves the isolation of RNA from cellular components and other constituents of 
sputum. This can be achieved either using an acidic buffered column membrane or acidic phenol 
chloroform followed by lithium chloride precipitation 
  
Following elution (where a column is used) or re-suspension (where phenol chloroform extraction 
is used), co-extracted DNA must be removed. DNase treatment is essential in RNA extraction, 
regardless of the method used, as DNA carryover is virtually impossible to prevent, and antisense 
DNA strands can act as template for subsequent reverse transcription reactions. 
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4.11.1  Extraction Method 
The High Pure RNA isolation kit (Roche, Indianapolis, USA) was used for RNA extraction 
according to the manufacturer's instructions (Appendix 2 and Figure 4.17). However a number of 
modifications were necessary to optimise the kit for extraction of RNA from sputum and will be 
outlined in the following sections. 
4.11.2 Cell Lysis 
Cell lysis in the RNA isolation kit is achieved by mixing the sample with a guanidium-based lysis 
buffer prior to adding the mixture to a column. Sputum, however, contains a variable amount of 
mucin and DNA which may mechanically interfere with the column membrane. P. aeruginosa itself 
is relatively easy to lyse. However, if it is adherent to mucin or within a biofilm, uniform cell lysis 
is less likely. A physical disruption technique was therefore employed to aid lysis of the bacterial 
cells within the sputum.  
 
A single tungsten carbide bead (3mm) (Qiagen, Germantown, USA) was added to a matrix lysing 
tube along with approximately 10 x 0.5 mm ceramic beads, 400 µL of lysis buffer, and 200 mL 
PBS. The sample was then homogenised using a MP-bio FastPrep-24 (California, USA) instrument 
for 40 s at 6.5 m/s. The sample was then centrifuged at >10,000 x g for 5 min at 4oC, and the 
supernatant added directly to the column.  
4.11.3  Precipitation And Washes  
The manufacturer's protocol for addition to the membrane and washes was followed. Briefly, the 
sample was added to the column after lysis and centrifuged at 10,000 x g for 30 s at room 
temperature. The eluent was discarded. 500 µL wash buffer 1 was added to the column and 
centrifuged as previously. This was repeated with wash buffer 2. Finally 200 µL of wash buffer 2 
was added and the column centrifuged at maximum speed for 1 min to ensure that there was no 
ethanol carry over. 
4.11.4  Elution 
RNA was eluted in 20 µL elution buffer which was heated to 65oC. The elution buffer was left on 
the column for 1 min to ensure maximal elution of the RNA from the column matrix, prior to 
centrifugation at 8,000 x g for 1 min.  
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Figure 4.17: Protocol for RNA extraction using the High Pure RNA isolation kit (Roche) taken 
from the manufacturer’s protocol (http://www.roche-applied-science.com/shop/products/high-pure-
rna-isolation-kit#tab-3). 
 
4.11.5 DNase Treatment 
The exclusion of DNA from RNA extracts is particularly important when assessing bacterial gene 
expression as bacterial DNA does not contain introns or exons around which to design primers. 
There are several DNase treatments commercially available and these can be divided into two 
categories: on column DNase treatment and DNase treatment of the eluent. 
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4.11.5.1  DNase Treatment Validation 
On column DNase treatment is useful when extracting RNA from a non-complex matrix. The 
standard on column DNase treatment supplied with the Roche columns was used. RNA was 
extracted on column and treated with DNase for the recommended 15 min. PCR amplification 
occurred in control reactions where no reverse transcription reaction had been performed, indicating 
the presence of DNA contamination (Figure 4.18). 
 
 
Figure 4.18: Amplification plot after 1 x 15 min on column DNase treatment. The ribosomal gene 
rpsL was amplified. There is amplification seen in the reverse transcription negative (RT-ve) 
samples. The melt curve for the RT-ve samples is the same as that for cDNA indicating the same 
product is being amplified. The NTC amplification represents primer-dimer formation as indicated 
by the earlier melt temperature. 
 
DNA free RNA was obtained only following four 30 min on column DNase treatments, Figure 
4.19.  
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Figure 4.19: Amplification plot after 4 x 30min DNase treatments. There is non-specific 
amplification in the RT-ve samples. There was no amplification in the NTC. The oprL gene was 
amplified. 
 
The Invitrogen TURBO DNA free kit was also assessed. The TURBO DNase is superior to 
conventional DNase I treatment as it is less sensitive to inhibition by salt carry over and is 
therefore, according to the manufacturer, fifty times more efficient. 
 
The protocol for TURBO DNase treatment is as follows: Add 0.1 x volume incubation buffer to the 
eluted RNA plus 1 µL TURBO DNase. Incubate at 37oC for 20 min with gentle shaking. Add 0.1 x 
volume of the DNase stop buffer and incubate at 25oC for 5 min. Centrifuge for 1.5 min and remove 
the clarified RNA sample to a separate tube in preparation for cDNA synthesis. 
 
DNase treatment time was optimised as follows: 
Three conditions were tested: 
1. P. aeruginosa 108 cfu/mL 
2. P. aeruginosa infected CF sputum 
3. P. aeruginosa infected CF sputum spiked with 108 cfu/mL P. aeruginosa 
DNA was extracted from 1 mL of each of the above using the QIAamp mini kit as described in 
section 10. The eluent was then DNase treated for 20, 30, 40, 50 or 60 min. One aliquot was used as 
a non-treated control. Samples were then amplified by PCR of the lasI gene. Twenty min of DNase 
treatment was adequate to remove all DNA in all samples treated (Figure 4.20). For this project, 30 
min of DNase treatment was selected as is was one time point longer than the minimum time 
required to remove all DNA. 
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Figure 4.20: Agarose gel demonstrating absence of amplified lasI DNA following 20 min of 
DNase treatment.  
 
The manufacturer’s protocol suggests that if there is a high level of potential DNA contamination 
present, a more rigorous protocol of DNase treatment should be carried out. The manufacturer 
suggests adding half of the DNase and buffer for the first 30 min, and then adding the second half 
for a final 30 min. However, this approach means that the sample will be incubated for 60 min at 
37oC, providing a greater period of time for potential degradation of RNA by RNases.  
 
Given that the level of DNA contamination is likely to vary between samples, it is still reasonable 
to consider a more rigorous protocol. The addition of more DNase after 15 min was considered 
preferable to a longer incubation. TURBO DNase treatment was therefore completed as per the 
manufacturer’s protocol with the exception of a 30 min incubation time and an additional 1 µL 
DNase added after 15 min of incubation. Reverse transcription negative samples (RT-ve) were run 
after this treatment protocol and demonstrated absence of contaminating DNA. 
 
To determine which of the two techniques were optimal for use in this project, a series of PCR 
amplifications were carried out, firstly to determine whether there was any contaminating DNA 
carry over, and secondly to assess yield of RNA recovery, and thus stability through the extraction 
process. Whilst both techniques were optimal in ensuring there was no DNA carry over (as per 
absence of amplification of RT-ve samples (Figures 4.19 and 4.22), the “on-column” method 
proved superior in RNA recovery and was thus favoured for the extraction process.  
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4.11.5.2  Reverse Transcriptase Negative PCR 
To confirm that there was no DNA carryover into the extracted RNA using the optimised on-
column DNAse treatment, 8 random RT-ve samples from extracted BLESS sputa were subjected to 
PCR amplification of the rpoD gene. No amplification was seen in the RT-ve samples (Figure 
4.21). 
 
Figure 4.21: Twenty random P. aeruginosa positive extracted BLESS induced sputum samples 
were amplified after on column extraction and TURBO DNase treatment. There was inconsistent 
and poor amplification of the samples, suggestive of poor extraction reproducibility and potentially 
RNA degradation prior to cDNA synthesis.  
 
 
 
Figure 4.22: Amplification plot rpoD gene from RT-ve samples generated from extracted P. 
aeruginosa infected BLESS induced sputum samples and treated with an on column DNase. There 
was no amplification in the RT-ve samples. 
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4.11.6  RNA Quality 
The concentration and purity of extracted RNA can be determined using a spectrophotometer. This 
method gives an accurate quantification of the concentration of nucleic acid in a sample as well as 
giving an indication of the purity. 
4.11.6.1 Spectrophotometric Assessment of RNA Concentration and Purity 
The NanoDrop 1000 spectrophotometer (Thermo Scientific, USA) was used in this project to 
determine both the quantity and quality of RNA. RNA absorbs at 260 nm. A single peak at this 
wavelength is an indication of the quantity of RNA. Quality is assessed by looking at the ratio of 
the absorbance of the solution at 260 nm and 280 nm as well as at 230nm. A 260/280, and a 
260/230 ratio of 2 is considered ideal for RNA. Co-extracted protein, phenol and ethanol carry over 
can all lower the 260/280 ratio as they absorb at or near 280. Proteins can also absorb at 230, 
lowering the 260/230 ratio (Figure 4.23). 
 
 
Figure 4.23: NanoDrop spectrum showing a Roche column extracted RNA sample. There is an 
ideal 260/230 ratio but a slight decrease in the 260/280 suggesting contamination. In this case 
protein or ethanol carry over was suspected as phenol was not used in this extraction.  
 
4.11.6.2 Assessment of Extracted RNA Integrity by Gel Electrophoresis 
Good quality RNA extraction from sputum is notoriously difficult. The yield is often very low and 
high levels of RNase are present leading to rapid degradation. Indicative of this loss of integrity, 
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ribosomal bands are not typically visualised on a standard 1.5% agarose gel. As expected, agarose 
gel electrophoresis demonstrated no ribosomal bands in RNA extracted from sputum, either using 
on column or acid phenol chloroform methodologies, suggesting that substantial RNA-degradation 
had occurred (Figure 4.24). 
 
 
Figure 4.24: Agarose gel electrophoresis demonstrating degradation of RNA from sputum samples 
extracted both on-column or with phenol. Ribosomal bands are visible in RNA extracted from 
cultured P. aeruginosa. 
 
Due to the presence of inhibitors in the sputum and the presence of vastly more human RNA 
compared with bacterial RNA, it is difficult to ascertain on a gel whether the degraded RNA seen is 
human or bacterial RNA. The initial fast centrifugation step (16,000 x g Section 4.3.1) to pellet the 
sputum will rupture delicate mammalian cells, releasing both RNase and mammalian RNA, whilst 
pelleting the much smaller bacteria. The most reliable method, therefore, of assessing RNA quality 
from sputum is to assess the reproducibility of PCR amplification from repeated extractions. 
4.11.7  Extraction Reproducibility 
To assess extraction reproducibility of P. aeruginosa RNA from sputum, a CF sputum sample was 
extracted in quadruplicate as described above. RT-PCR amplification of the ribosomal rpsL gene as 
well as the mRNA gene rpoD was performed in duplicate. There was no statistically significant 
difference in Ct value for either primer used (ANOVA p=0.140 and ANOVA p=0.327 respectively) 
Figure 4.25. 
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Figure 4.25: Cycle threshold (Ct) value vs. replicate number for four separate RNA extractions 
from the same sputum sample amplified with rpsL (A) and rpoD (B). Circles represent duplicate 
values. The horizontal bar and error bars represent the mean and standard deviation. 
 
4.11.8  NTC Amplification 
To assess whether there was any environmental contamination by DNA (or PCR product) during 
the extraction process, 2 x 1 mL aliquots of saline were extracted at the same time as the sputum 
extractions described in section 4.8.3. RT-PCR amplification of rpsL did not produce any 
amplification after 50 cycles, Figure 4.26. 
4.11.9  cDNA Synthesis 
cDNA synthesis for the non-amplified RNA samples was performed using the iScript cDNA 
synthesis kit (Bio-Rad, California USA) as per the manufacturer’s instructions. 1 µg RNA from 
each sample was used as template in each cDNA synthesis reaction. 
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Figure 4.26: Amplification and melt curve plot of 2 saline samples which were put through the 
RNA extraction protocol optimised in section 8. RT-PCR was performed in duplicate. Both the 
cDNA and RT-ve samples are shown. There is no amplification after 50 cycles and no peak seen on 
the melt curve. 
4.11.10 Comments And Conclusions 
Acid phenol chloroform extraction was trialled, however, RNA quality and yield was not superior. 
The more rapid on column technique was therefore favoured and employed as above. DNase 
treatment using an extended on-column DNase digestion step proved the best way to remove DNA 
from the samples. Using these methods RNA extraction from sputum samples was reproducible and 
DNA free, however integrity, as demonstrated by agarose gel electrophoresis, could not be 
improved regardless of the method used. It was therefore decided to proceed with the described 
method as all other quality measures had been satisfied. 
 
4.12  EXOPRODUCT DETECTION AND QUANTIFICATION: QUORUM SENSING 
MOLECULES 
4.12.1  Extraction of Quorum Sensing Molecules 
For this study samples were extracted using an adaptation of a method kindly provided by Prof. 
Miguel Cámara (Department of Molecular Microbiology, University of Nottingham, UK). The 
extraction protocol was as follows: 
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1. Samples were homogenised in 3 volumes of PBS by vortexing. 
2. Samples were aliquoted as necessary into 1.5 mL Eppendorf tubes. 
3. 500 µL of acidified ethyl acetate (0.01% acetic acid v/v) was added to the sample and mixed 
by vigorous vortex for 30 s. 
4. The samples were centrifuged at maximum speed (>16,000 x g) for 5 min. 
5. The ethyl acetate layer was removed to a separate 1.5 mL tube. 
6. Parts 3-5 were repeated twice more, pooling subsequent extracts. 
7. The pooled extracts were centrifuged once more and the top 1 mL was removed into a 
separate 1.5 mL tube. 
8. The extracts were dried in a centrifugal evaporator for 1-3 h. 
9. Samples were then resuspended in 50-100 µL 100% methanol prior to loading onto the mass 
spectrometer. 
4.12.2  Mass Spectrometry 
All mass spectrometry analyses were carried out in collaboration with Dr Brett Hamilton (Mater 
Health Services OMICS laboratory, Brisbane, Australia).  
 
Mass spectrometry, which measures the mass / charge (m/z) of molecules, has successfully been 
used to identify quorum sensing molecules in clinical samples [97, 100] including sputum and 
plasma of CF patients. However, sensitivity is reportedly an issue with detection limited to the low 
nanomolar range.  
 
In this project, a Bruker Microtof Q II mass spectrometer, which is a hybrid quadrupole time-of-
flight or QqTOF instrument, was used with an electrospray source. This QqTOF mass spectrometer 
differentiates ions based upon the time taken to travel the distance of the time-of-flight (TOF) tube. 
Electrospray ionisation provides the mechanism of converting the flow of eluent from a High Pure 
Liquid Chromatographer (HPLC) into ions suitable for the high vacuum conditions of a mass 
spectrometer. Electrospray ionisation is a concentration dependant ionisation process, making it 
very suitable for the quantitation of molecules in a variety of samples. Once ionised, the ions are 
drawn into a heated capillary and travel through the first mass resolving quadrupole and then either 
transmitted or fragmented in the second quadrupole before being exposed to a high voltage which 
pulses packets of ions into the time-of-flight (TOF) mass analyser. The time of flight is dependent 
upon the mass of the molecule, with heavier molecules taking longer to reach the TOF detector 
(Figure 4.27). 
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Figure 4.27: Electrospray ionisation machine - MicrOTOF-Q-II 
 
Whilst much of the published literature for quorum sensing molecules has been performed using 
triple quadrupole (QqQ) mass spectrometers, there are some advantages in using a QqTOF. QqQ 
mass spectrometers have been present in clinical biochemistry departments for some time, which in 
part explains their more common usage, additionally QqQ mass spectrometers are extremely 
sensitive when operated in multiple reaction monitoring (MRM) mode, whereby the QqQ can scan 
large lists of precursor/product pairs very quickly. The disadvantage of QqQ mass spectrometers is 
that each MRM needs individual optimisation, and the overall method can only report back on the 
specific MRMs included in the method. A QqTOF mass spectrometer is a little less sensitive than a 
QqQ, however, it will record spectra for the entire mass range during the analysis. This means that a 
single QqTOF analysis can allow the observation of large numbers of analytes.  
 
The analysis of the quorum sensing molecules was optimised using purified standards, and included 
several steps to eliminate the carry-over of quorum sensing molecules, particularly PQS, from one 
analysis to the next. The problem has been well known, albeit absent from published manuscripts. 
We solved the issue of carry over using a programmed injection which included washing the sample 
loop and injection needle with 8 µL methanol, and then 8 µL of Buffer A (0.2% formic acid) before 
drawing up the 2 µL of sample for each analysis. These efforts were found to mitigate the carry-
over issue.  
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4.12.2.1  Mass Spectrometry Validation  
Extracts and standards were resuspended in 50 µL methanol. Retention times, m/z ratio, peak 
intensity and area under the peak were measured for each molecule of interest (C4-HSL, 3-oxo-
C12-HSL, HHQ and PQS) see Figure 4.28. The retention time is specific to each molecule and is 
dependent upon the polarity of the molecule, with highly polar molecules (such as C4-HSL) 
appearing sooner than the non-polar molecules. The m/z ratio is again specific to the molecule of 
interest and is used to identify the molecule. The extraction ranges for the extracted ion 
chromatograms of the quorum sensing molecules were typically less than 0.02 Da, making the peak 
determination quite specific. Quantitation is determined by measurement of the area under the peak 
against a calibration curve.  
 
 
Figure 4.28: Retention times and peaks for each molecule of interest (C4-HSL, 3-oxo-C12-HSL, 
HHQ and PQS). The peaks of interest are highlighted in blue and are derived from interrogation of 
the total ion chromatogram seen in the first row. 
4.12.2.2  Sensitivity  
Sensitivity was initially assessed by using pure standards. PQS was detectable to 7.5 pM (r2=0.99), 
Figure 4.29. Detection of C4-HSL was not as sensitive as PQS (0.125 µM–250 µM). 
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Figure 4.29: Calibration curve of PQS standards diluted 1:2 x 8 fold in methanol. PQS was 
detectable to 7.5 pM (range 225 pM–7.5 pM) 
 
To assess both extraction reproducibility and sensitivity in sputum, serial (1:2 x 8 fold) dilutions of 
quorum sensing molecules were added separately to MSSM (as a surrogate for sputum) and 
extracted in ethyl acetate as described. PQS was detectable in extracts to 78 nM, Figure 4.30. C4-
HSL-HSL was detectable to 10 nM in extracts. Linear regression analysis revealed straight lines 
with r2 values of 0.994 (PQS and C4), confirming that the extractions were reproducible.  
 
 
Figure 4.30: Serial (1:2) dilutions x 6 fold of PQS extracted from MSSM demonstrating linearity to 
78 nM. 
4.12.3  Biosensors 
The principle of biosensor assays is based upon the induction of luminescence in the presence of the 
desired molecule. Most biosensors utilise a plasmid encoding a luciferase (LuxAB) gene coupled to 
a promoter which is only transcribed in the presence of the molecule of interest. Variations on this 
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include constructing a knock out mutant of the gene of interest and inserting the promoter coupled 
to a Lux gene into the chromosome. 
 
Biosensors are very sensitive for the detection of quorum sensing molecules both in vitro [21] and 
in vivo [93]. Specificity is an issue however with most biosensors only able to differentiate between 
short and long chain AHLs. Differentiation of AHQs is only achievable with the addition of thin 
layer chromatography or mass spectrometry. 
The biosensors used in this study have been kindly supplied by Prof. Miguel Cámara (University of 
Nottingham, UK). Two biosensors are plasmid based (pSB1142 and pSB536) which luminesce in 
the presence of 3-oxo-C12-HSL (based on LasR and the promoter for LasI) and C4-HSL 
respectively (based on RhlR and the promoter for RhlI). The third biosensor is a PAO1 PqsA 
mutant transfected with a luxCDABE based pqsA promoter (PAO1 ΔPqsA CTX-P pqsA-lux). This 
is used for the detection of AHQ quorum sensing molecules (PQS and HHQ). 
4.12.3.1  Extraction And Detection 
Samples were extracted in acidified ethyl acetate as described in section 4.12.1. The protocol for 
detection of quorum sensing molecules using a microplate was developed by the University of 
Nottingham [138], and is as follows: 
1. A single colony of the biosensor is inoculated into fresh LB broth and cultured overnight. 
2. Overnight cultures are diluted to an OD600 of 1.0 with LB.  
3. Further dilution is performed to give 1:100 and 1:50 dilutions. 
4. 5uL of the methanol extract is added to 100 µL of LB media and added to one well of a 96 
well plate. 
5. 100 µL of the 1:50 dilution biosensor is added to the above mixture, giving a final volume 
of 200 µL 
6. Incubate at 37oC for 24 h with shaking at 200 rpm in a plate reader (Pherastar Omega), with 
luminescence and absorbance (at OD600) measured at 30 min intervals. 
7. The peak luminescence is determined and divided by the absorbance at the same time point 
(RLU/OD600) 
4.12.3.2  Influence From Vehicle 
When following this protocol it was noticed that the vehicle control (5 µL methanol per 200 µL 
broth) inhibited both the luminescence and absorbance of the biosensor (unpaired t test p=0.017). 
This was particularly noticeable in the PAO1 ΔPqsA CTX-P pqsA-lux strain, Figure 4.31. 
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Figure 4.31: Graphical demonstration of the significant inhibition of both luminescence and growth 
measured by absorbance of the PAO1 ΔPqsA biosensor in the presence of 2.5% methanol (vehicle) 
or LB broth (negative control). Four negative controls in duplicate were placed on the same plate. 
The vehicle control was performed in triplicate. Each circle represents the relative light units / 
absorbance (RLU/OD600) for each well. Horizontal bars represent the mean and standard error of 
the mean.  
 
The protocol was therefore amended to remove this inhibition as follows. Methanol was added 
directly to the 96 well plate and allowed to evaporate for 5 min at room temperature in a laminar 
flow hood, prior to the addition of 200 µL of the 1:100 dilution of the biosensor. This significantly 
reduced the inhibition of the vehicle control (p=0.543, unpaired t test), Figure 4.32. 
 
 
 
Figure 4.32: Graphical demonstration of the reduction of inhibition compared with Figure 4.31 of 
both luminescence and growth measured by absorbance of the PAO1 ΔPqsA biosensor when the 
methanol extract is allowed to evaporate prior to the addition of the biosensor. Each circle 
represents the mean of the relative light units / absorbance (RLU/OD600) for triplicate reactions. 
Horizontal bars represent the mean. 
 
Addition of methanol directly to wells allowed the re-suspension of the pellet in a larger volume of 
methanol, thus reducing fluid handling errors and increasing quorum sensing molecule solubility. 
To test whether the addition of a larger volume of vehicle to the plate had a detectable effect on 
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luminescence and absorbance, 10 µL methanol was added to the well and allowed to evaporate. 
This was compared with the negative control as described previously, Figure 4.33. No significant 
difference between the two treatments was observed (p=0.259, unpaired t-test). 
 
 
 
Figure 4.33: Graphical demonstration of the reduction of inhibition compared with Figure 4.32 of 
both luminescence and growth measured by absorbance of the PAO1 ΔPqsA biosensor when 10 µL 
of the methanol extract is allowed to evaporate prior to the addition of the biosensor. Each circle 
represents the relative light units / absorbance (RLU/OD600) for each well. The horizontal bars 
represent the mean and standard deviation. 
 
The final optimised protocol used in sample analysis was as follows: 
1. Inoculate a single colony of the biosensor into fresh LB media and culture overnight. 
2. Dilute with LB to an OD600 of 1.0.  
3. Further dilute the culture to give a 1:100 dilution. 
4. Add 10 µL of the methanol extract directly to the empty well of a clear bottom, white side 
96 well plate (Grenier Bio-One, California, USA). 
5. Add 200uL of the 1:100 dilution biosensor after evaporation has occurred.  
6. Incubate at 37oC for 24 h with shaking at 200 rpm in a plate reader (Pherastar FS), taking 
both luminescence and absorbance (at OD600) readings every 30 min. 
7. Record the peak luminescence and divide this by the absorbance at the same time point 
(RLU/OD600). 
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4.12.3.3  Sensitivity 
To assess sensitivity, serial (1:2 x 8 fold) dilutions of quorum sensing molecules were added 
separately to MSSM and extracted in ethyl acetate as described. PQS was detectable in extracts 
down to 7.8 nM and 4.8 nM in standards, Figure 4.34 A. C4 HSL was detectable to 18 nM in 
extracts and 9 nM in standards, Figure 4.34 B. 3-oxo-C12 had a narrow range over which the 
standard curves were linear. In extracts and in standards the linear detection range was 9-75 nM. 
 
Figure 4.34: Left Panel: Bioluminescence data of serial 1:2 dilutions of PQS extracts (circles) and 
PQS standards (triangles) r2 extracts=0.965, r2 standards=0.939. Right Panel: Bioluminescence data 
of serial 1:2 dilutions of C4-HSL extracts (circles) and C4-HSL standards (triangles). 
r2extracts=0.863, r2 standards=0.824. Each point represents the mean value. The error bars represent 
the standard deviation. 
4.12.3.4  Extraction Efficiency 
To assess extraction efficiency, PQS and C4-HSL were spiked in triplicate into MSSM to give a 
final (in biosensor) concentration of 0.625 µM prior to extraction. Quorum sensing molecules were 
also spiked into MSSM post extraction, to the same concentration. These extracts were compared 
with the standard on the same biosensor. There was a significant difference between the pre-spiked 
and the standard for PQS (p=0.027, Kruskal-Wallis). However, there was no significant difference 
between the pre and post-spiked samples. There was no statistically significant difference between 
the three conditions for C4-HSL (p=0.066, Kruskal-Wallis). There was a trend, however for 
decreased extraction efficiency, Figure 4.35. 
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Figure 4.35: Comparison of extraction efficiency for PQS (Left) and C4-HSL (Right). Samples 
were either pre or post spiked with the same final concentration of QS molecule (0.625 µL). A non-
extracted standard has been added for comparison. Each point represents the relative light units / 
absorbance (RLU/OD600) for each well. The horizontal bars represent the mean and standard 
deviation. 
4.12.3.5  Processing/Storage Time 
The reduction in extraction efficiency is likely to result from small losses at each stage of the 
extraction process. However, it was observed that when samples were extracted and stored at -20oC 
overnight either dry or in methanol, there was a further reduction in detection. C4 HSL is shown as 
an example, Figure 4.36. 
 
Figure 4.36: Graphical demonstration of the reduction in detection when extracts are stored in 
methanol (MeOH) overnight compared with addition of a standard alone or when extracted and 
processed immediately (0.625 µM C4HSL final concentration). 
 
4.12.3.6  Reproducibility 
To assess reproducibility of extraction and detection, four MSSM samples were spiked with 1.25 
mM PQS or C4 HSL and extracted as described above. All four samples were run on the same plate 
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in duplicate. No significant difference was observed between the four samples for PQS (p=0.231, 
ANOVA) or C4-HSL (p=0.242, ANOVA), Figure 4.37. 
 
 
Figure 4.37: Graphical demonstration of the Relative light units/ absorbance at 600 nm for repeated 
extracts of PQS (left panel) and C4-HSL (right panel) on their respective biosensors. Each circle 
represents the relative light units/absorbance (RLU/OD600) for each well. Horizontal bars represent 
the mean and standard deviation. 
 
4.12.4   Comments and Conclusions 
The data described in the preceding sections confirmed that biosensors were sensitive to the low 
nanomolar range and gave reproducible assessments of the levels of quorum sensing molecules in 
spiked extracts when the samples were extracted immediately prior to assessment. There was a 
reduction in extraction efficiency, but extracted curves were still linear, suggesting that this is a 
consistent phenomenon across all extractions. Storage in methanol overnight appears to reduce the 
detection threshold and is therefore not recommended. For this project, the aim is to determine 
whether quorum sensing molecules are detectable in the non-CF bronchiectatic lung and whether 
there was a change with erythromycin. Therefore, absolute determination of concentration using 
biosensors was not necessary to answer this question, rather presence or absence, or relative change 
to each other. Combining the data obtained by these biosensors and that obtained by mass 
spectrometry will give a strong indication of the level of quorum sensing molecule production in the 
non-CF bronchiectatic lung. 
4.13  EXOPRODUCT DETECTION AND QUANTIFICATION: LASB ELASTASE 
To assess for LasB elastase, the Elastin Congo Red (ECR) assay was used. ECR is an insoluble 
elastase substrate (elastin) which releases its red colour into the reaction buffer (Tris 100 mM + 1 
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mN CaCl2) when it is cleaved by elastase. The red colour is then read on a spectrophotometer at 492 
nm. Relative and absolute changes in absorbance can be measured against a calibration curve. 
4.13.1  Preparation of Elastase from P. aeruginosa and Sputum. 
The source of elastase for optimisation was an overnight culture of P. aeruginosa PAO1 or CF 
sputum. 1 mL of an overnight culture of PAO1 was centrifuged at room temperature for 10 min at 
13,000 x g. The supernatant was removed and filtered through a 0.22 µm syringe filter. 1 mL of 
sputum was centrifuged at room temperature for 10 min at 13,000 x g. The supernatant was 
removed and filtered through a 0.22 µm syringe filter.  
4.13.2  Elastin Congo Red Protocol 
10-20 mg ECR Sigma Aldrich, St Louis, USA (see section 10.3.1.3) was added to 900 mL 100 mM 
Tris base (pH 8) with 1 mM CaCl2. 100 µL filtered supernatant was added and the suspension 
incubated at 37oC with shaking at 250 rpm. for 12 h. The insoluble ECR was then pelleted by 
centrifugation and the clarified supernatant was read on a spectrophotometer (Synergy Mx, Bio 
Tek, Vermont, USA) at 492 nm. 
4.13.2.1 Optimisation of ECR Concentration 
Published work on the ECR assay uses variable amounts of ECR. Masses between 10-30 mg per 
reaction are cited [139, 140]. Intuitively the substrate should be in excess in order to maximise the 
sensitivity of the reaction by increasing the availability of the substrate. 
To determine the optimal amount of ECR in a reaction with cultured P. aeruginosa, 100 µL filter 
sterilised overnight culture of PAO1 was added to 900 µL Tris/CaCl2 with 0, 1, 5, 10, 15 or 20 mg 
of ECR. There was a linear increase in absorbance until 15mg ECR was reached (Figure 4.38), 
demonstrating that a minimum of 15 mg ECR per reaction is required to optimally assess the 
amount of elastase activity in cultured P. aeruginosa. 
4.13.3  ECR in Sputum Supernatant 
To assess whether this assay would be appropriate for assessing bacterial elastase activity in 
sputum, CF sputum supernatant was prepared as described in section 4.10.3.1.1 and added to 15 mg 
ECR in 900 µL buffer. Elastase was strongly detectable in this sample, however absorbance 
readings were recorded above the detection limit of the spectrophotometer (>4.0). This is because 
the ECR assay is a non-specific elastase assay and will be responding (most likely) to neutrophil 
elastase activity as well as the minor contribution of bacterial elastase.  
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This assay is therefore useful in bacterial culture but cannot be translated to in vivo assessments of 
bacterial activity without the prior removal or inactivation of any neutrophil elastase. For these 
reasons, in this project, ECR was reserved for in vitro assessment of elastase activity alone. 
 
Figure 4.38: Graphical demonstration of the increase in absorbance readings with increasing ECR 
substrate. ECR = Elastin Congo Red. 
4.14  EXOPRODUCT DETECTION AND QUANTIFICATION: PYOCYANIN 
Pyocyanin is a blue pigment produced by P. aeruginosa. It is non-fluorescent and only appears as 
blue in the oxidised state. Pyocyanin has been measured in respiratory secretions using mass 
spectrometry and high performance liquid chromatography [50]. It can, however, be measured more 
simply by reading its absorbance at 695 nm in a neutral [53] solution or at 520 nm [141] in an 
acidic solution.  
4.14.1 Extraction 
Two methods have been published previously for the extraction of pyocyanin from respiratory 
samples [50, 142]. To assess for the blue (neutral) form of pyocyanin (neutral pH, oxidised), 
sputum is centrifuged at high speed and the resultant supernatant filter sterilised through a 0.22 mm 
filter. For the pink (acidic) form, sputum is extracted in chloroform and then re-extracted into 0.2M 
HCl as follows: 
1. Whole sputum was centrifuged at 10,000 x g for 10 min 
2. 1 mL of sputum supernatant was added to 0.6 mL chloroform and vortexed vigorously for 
20 s each. 
3. The sample was centrifuged at >10,000 x g for 10 min 
4. The aqueous phase was removed completely (the interphase can be left) and 200 µL of 0.2M 
HCl was added and vortexed vigorously for 20 s 
5. The sample was centrifuged again at >10,000 x g for 10 min. 
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6. 50 µL of the pink aqueous phase was removed for analysis in a monochromator (Synergy 
Mx, Bio Tek, Vermont, USA) in a 384 well black side, clear bottom plate (Corning, NY, 
USA). 
4.14.2  Absorption Spectrum 
The absorption spectrum generated by 50 µM blue pyocyanin and 50 µM pink (chloroform 
extracted) pyocyanin demonstrated maxima at 695nm and 520nm respectively, consistent with 
published work, Figure 4.39. 
 
Figure 4.39: The absorption spectra for 50 µM blue (neutral) and 50 µM pink (chloroform 
extracted) pyocyanin. The pink pyocyanin was extracted into chloroform and back extracted into 
0.2 M HCL. 
 
Both the blue and the pink pyocyanin were excited at wavelengths ranging from 300-600 nm but no 
emission spectrum was detected. 
 
Assay detection sensitivity was determined by performing 1:2 x 12 dilutions of known 
concentrations of pyocyanin to generate a standard curve. For assessment in acidic conditions, 
pyocyanin was first spiked into P. aeruginosa negative sputum (pooled BLESS samples #BB10 and 
#BB16) and extracted in chloroform as described above. Chloroform extracted pyocyanin was 
detectable down to 1.5 µM. Blue pyocyanin was spiked into MSSM after serial 1:2 x 12 dilutions in 
PBS, the sample was centrifuged and the supernatant read at 695 nm. Using this method, pyocyanin 
was also detectable to 1.5 µM, Figure 4.40.  
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Figure 4.40: Left panel: Standard curve of serial dilutions of known concentrations of chloroform 
extracted pyocyanin. It is linear to 1.5 µM r2=0.992. Right Panel: Standard curve of serial dilutions 
of known concentrations of un-extracted pyocyanin. It is linear to 1.5 M. 
 
4.14.3  Reproducibility  
To determine reproducibility, three 1 mL MSSM aliquots were spiked with 25 µM final 
concentration of pyocyanin, serially diluted 1:2 x 4, extracted as described, and absorption spectra 
generated. Out of 12 samples analysed, 10 could be read accurately on the monochromator. These 
samples gave reproducible results (Table 4.4).  
 
  25 µM 12.5 µM 6.25 µM 3.125 µM Saline 
1 0.089 0.069 0.059 * 0.053 
2 0.085 0.067 0.058 0.052 0.049 
3 0.086 0.069 0.060 *   
            
Average 0.087 0.068 0.059 0.052 0.051  
Std. dev. 0.002 0.001 0.001     
 
Table 4.4: Table showing OD520 absorbance measurements for pyocyanin extracted from MSSM 
which had been spiked with varying concentrations of pyocyanin, demonstrating reproducibility 
where readings were able to be taken. *beyond measureable range 
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4.14.4  Detection in Sputum 
To determine whether pyocyanin can be detected in sputum using this method, CF sputum was 
assessed. OD520 readings marginally above the saline control were noted. To increase sensitivity, 1 
mL CF sputum was concentrated by freeze-drying and re-suspension in 0.5 mL PBS before 
extraction. An increase in the measured OD520 reading was observed, however there was no 
discernible maxima at OD520 seen on the spectrum (Figure 4.41). This brings into question the 
validity of readings recorded where there is no discernible peak at the expected wavelength. 
Sensitivity using this technique is likely to be suboptimal given the low levels detectable in 
concentrated CF sputum. 
 
Figure 4.41: Graphical demonstration of the absorbance spectra obtained from extracted, 
concentrated CF sputum shown with the absorbance spectra for saline. There is no discernible peak 
seen at 520 nm. 
 
4.14.5  Mass Spectrometry to Detect Pyocyanin in Clinical Samples 
To increase sensitivity, mass spectrometric techniques were used for the detection of pyocyanin in 
clinical samples. Pyocyanin was serially diluted 2:1 x 12 in PBS and then spiked into MSSM. Three 
aliquots were extracted in chloroform and HCl and another 3 aliquots were simply centrifuged and 
the supernatant assessed. Pyocyanin was detectable by mass spectrometry with a retention time of 
7.9 min. Both extracted and supernatant samples gave similar, linear readings. Sensitivity was 
determined from the calibration curve, Figure 4.42. Pyocyanin was detectable to 195 nM 
(r2=0.998). 
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Figure 4.42: Standard curve of serial dilutions of known concentrations of pyocyanin spiked into 
MSSM. The supernatant was assessed by mass spectrometry. It was linear to 195 nM, r2=0.998. 
 
4.15  CELL CULTURE 
4.15.1  Cell Culture 
16HBE is a transformed normal human bronchial epithelial cell line that retains similar 
characteristics to primary epithelial cells. 16HBE is therefore an ideal cell line for the preliminary 
investigation of epithelial responses to stimuli. 
 
16HBE cells were kindly donated to us by Prof. John Upham (Department of Respiratory Medicine, 
Diamantina Institute, University of Queensland). They were expanded from frozen aliquots by 
washing with 10 mL media (Dulbecco’s Modified Eagle Media (DMEM) 4.5 g/L glucose, Gibco, 
Life Technologies, USA) then pelleting at 500 x g for 5 min at 4oC. The pelleted cells were 
resuspended in fresh media and dispersed into a T-25 flask for expansion. When the cells were 80% 
confluent they were passaged with trypsin and further expanded in T-75 flasks. Once 80% confluent 
they were seeded into a 24 well plate (1.7 x 105 cells per well) and allowed to expand. Once 
confluent, quorum sensing molecules were added to the media for 15-24 h along with a vehicle 
control, dimethyl sulfoxide (DMSO). At the end of the experiment the media was removed and 
stored at -80oC for inflammatory cytokine assessment by Dr Alice Chen. Roche lysis buffer was 
added to the cell layer and stored at -80oC to await RNA extraction. 
4.15.2  Peripheral Blood Mononuclear Cell Extraction and Treatment 
Peripheral blood mononuclear cells (PBMCs) were isolated from fresh blood of 5 healthy control 
subjects. 20 mL of whole blood was collected into anti-coagulant (EDTA or heparin) collecting 
tubes, and then diluted to 35 mL with 1 x DPBS in a 50 mL tube. 15 mL Ficoll-Hypaque was 
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underlayed into each tube. Tubes were centrifuged at 550 x g for 20 min at room temperature with 
no brake. The PBMC layer was collected from the interface using a 10 mL pipette, without 
touching or disturbing the red blood cell layer. Cells were then washed with PBS x 2, and pelleted 
by centrifugation at 1600 rpm. (550 x g), 5 min, 4 oC. Cells were resuspended in DMEM (low 
glucose, +pyruvate, +glutamine) + 10% foetal calf serum, + 1% penicillin streptomycin and seeded 
at 1x105 cells per well of a 24 well plate (at 2x105 cells/mL).  
 
PBMCs were activated with the addition of 25 ng phorbol 12-myristate 13-acetate (PMA) and 250 
ng ionomycin per well (Sigma, St. Louis), 10 µM 3-oxo-C12-HSL or 10 µM PQS (kindly supplied 
by Prof. Miguel Cámara, University of Nottingham, UK) diluted in DMSO (1:10,000 final 
concentration). PBMCs were incubated overnight (15 h) before harvesting into lysis buffer (Roche) 
prior to RNA extraction using the High Pure RNA extraction kit (Roche) in accordance with the 
manufacturer’s protocol. 
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CHAPTER 5: THE IN VITRO EFFECT OF SUB MIC ERYTHROMYCIN ON P. 
AERUGINOSA QUORUM SENSING 
5.1 INTRODUCTION 
Macrolide antibiotics, predominantly azithromycin, have been shown to inhibit P. aeruginosa 
quorum sensing in vitro. This effect may be common to all macrolides through their interaction 
with the bacterial 50S ribosomal subunit. However,	 whether	 this	 effect	 also	 occurs	 with	 the	short-acting	macrolide	 erythromycin,	 has	not	been	demonstrated.	Further, where an effect is 
evident, the extent to which it is conserved across pseudomonal isolates, both within and between 
patients, is unclear. In this chapter, the effect of erythromycin on P. aeruginosa quorum sensing on 
both typed strains and clinical isolates taken from subjects participating in the BLESS randomised 
controlled trial is described [7].  
 
Along with assessment of quorum sensing specific gene expression and quorum sensing molecule 
determination, two main phenotypic characteristics will also be assessed as part of these 
experiments, pyocyanin and elastase. Pyocyanin is a blue-green pigment produced by P. 
aeruginosa. It has been implicated in lung function decline in CF and is nominally under quorum 
sensing control, particularly in relation to the Pseudomonas Quinolone Signal (PQS), activity of 
which enhances the production of pyocyanin. Elastase is a metalloprotease produced by P. 
aeruginosa predominantly to enable break down of proteins for nutrient acquisition. Elastase also 
provides P. aeruginosa with a competitive advantage over S. aureus, being directly toxic to this 
commonly co-existing bacterium. Clinically, elastase production has been associated with 
accelerated lung damage and is an important predictor of lung function decline. Importantly, 
elastase is generally under quorum sensing control, with the LasR/I system being most 
predominantly implicated in controlling elastase production.  
 
In the first part of this chapter, the phenotypic diversity at baseline across different clinical isolates, 
when compared with the well-described typed strain PAO1, will be reported.	In the second part, the 
impact of erythromycin exposure on the expression of these phenotypic traits will be investigated.  
5.2 METHODS 
5.2.1 Selection Of Isolates 
The following experiments used both a P. aeruginosa type strain (PAO1) and clinical isolates. The 
P. aeruginosa clinical isolates were obtained from individual sputum samples collected as part of 
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the BLESS randomised controlled trial. Isolates were selected and cultured as follows: A 10 µL 
loop, scraped across frozen stored sputum, was used to streak inoculate MacConkey agar. The 
isolates were then incubated at 37oC for 24-48 hours. P. aeruginosa colonies were identified based 
on morphological features. A sterile 1 µL loop was used to re-streak individual colonies onto LB 
agar, which were incubated at 37oC for 24-48 hours to obtain pure populations for further analysis. 
The isolates were confirmed as P. aeruginosa by both MALDI-TOF and species-specific PCR 
(described in section 4.4). Isolates were stored at -80oC in LB supplemented with 30% glycerol 
prior to subsequent analysis. In addition to clinical isolates, the fully quorum sensing competent 
type strain, PAO1, was used as a positive control in all in vitro experiments.  
5.2.2 Growth Media 
Three different media were used in the following experiments. LB was used to allow comparison to 
data generated in previous studies using this media. Kings A media was used for the pyocyanin 
experiments. Kings A media contains peptone and potassium and is supplemented with magnesium 
to promote the production of pyocyanin by P. aeruginosa. Synthetic sputum media (SSM) 
(described in Chapter 4.8) was used in order to replicate, as closely as possible, the available 
nutrients found within the lung environment. 
5.2.3 Culture Conditions 
Three different culture conditions were used in the following experiments: (A) aerobic, with 
shaking at 250 rpm in a shaking incubator, (S) aerobic, but placed in a non-shaking, stationary 
incubator, and (M) microaerophilic, placed in a microaerophilic chamber in a stationary incubator. 
All were incubated at 37oC. 
5.2.4 In Vitro Growth Experiments 
For growth experiments, isolates were processed initially as follows: Overnight broth cultures of a 
single colony of PAO1 and the six P. aeruginosa clinical isolates were diluted to an OD600 of 0.5. 
100 µL of this solution was added to 900 µL LB. This was performed in triplicate for each isolate. 
This procedure was repeated with SSM. Isolates were cultured in 48-well clear, flat-bottomed plates 
for 24 hours at 37oC in a shaking plate reader at 250 rpm. Absorbance at 600nm was measured 
every 30 min for 24 hours.  
5.2.5 In Vitro Phenotype Experimental Conditions 
Isolates were cultured in 1 mL LB broth in 48-well flat-bottomed plates for 24 hours at 37oC with 
shaking, (as described above). After 24 hours, cells were pelleted by centrifugation at 16,000 x g for 
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10 min. The supernatant was removed and the pellet resuspended in fresh liquid media 
(supplemented with or without 5 µL erythromycin) and incubated for a further 24 hours in one of 
the three conditions outlined above: A (aerobic with shaking); S (aerobic without shaking) and M 
(microaerophilic). Experiments were performed in triplicate (Figure 5.1). Analysis was performed 
in this way to control for any effect of differences in growth rate and bacterial load between the 
different media/conditions. 
 
Figure 5.1: Experimental conditions. An overnight culture of P. aeruginosa was pelleted and 
resuspended in either LB or SSM alone or supplemented with 5 µg/ml erythromycin. Three 
different culture conditions were assessed: aerobic with shaking (A), aerobic without shaking (S), 
and microaerophilic without shaking (M). 
5.2.6  Statistical Methodology 
Several methodologies were used to determine the significance of the difference between measured 
outcomes. The difference in growth rate was determined by linear regression analysis of the 
exponential growth phase of the respective isolate using the F test. Two-way ANOVA (with time 
and erythromycin being the two factors) with Sidak’s multiple comparison post test was used to 
assess the difference in growth between control and erythromycin. To test the difference between 
variables as assessed in one of three different growth conditions, one-way ANOVA was used with 
Holm-Sidak’s multiple comparison post test for parametric data, whereas the Kruskal-Wallis with 
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Dunn’s multiple comparison post test was used for non-parametric data. When testing the effect of 
erythromycin on each variable, unpaired t-test was used for parametric data and Mann-Whitney for 
non-parametric data (where normality of distribution could not be confirmed). In all cases the 
confidence interval was set at 95%, defining statistical significance as a p value <0.05. Normality of 
data distribution was assessed with both the D’Agostino & Pearson normality test and the Shapiro-
Wilk normality test. 
5.3 RESULTS 
5.3.1 Baseline Phenotypic Differences Between P. aeruginosa Isolates 
5.3.1.1 Growth Rate of P. aeruginosa Clinical Isolates in Standard Culture Media 
P. aeruginosa PAO1 and the 6 clinical isolates were cultured in triplicate in LB, as described in 
section 5.2.4 above. Figure 5.2 demonstrates the significantly	different	growth	patterns between 
isolates (F = 40.73, p<0.001). PAO1 growth was more rapid than that exhibited by any of the 
respiratory isolates and was used as the control for statistical analysis. Each growth curve was 
significantly different to PAO1. 
 
 
Figure 5.2: Growth curves of PAO1 and six clinical isolates cultured in LB in a shaking plate 
reader at 37oC. Absorbance at OD600 was recorded every 30 mins until stationary phase was 
reached. Points represent mean values of three independent cultures taken from the same overnight 
broth culture of a single colony. Error bars represent the standard deviation. 
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5.3.1.2 P. aeruginosa Isolate Pigmentation  
At the end of the 24 hour growth period above, pigmentation of the isolates were assessed visually. 
Figure 5.3 shows the variability in baseline pigments produced by the isolates following growth in 
standard media.  
 
 
 
Figure 5.3: Significant variability in pigment phenotypes noted in different clinical isolates of P. 
aeruginosa following 24 hours of culture in LB at 37oC. Isolates are arranged in columns, each with 
three replicates, labelled #3 - #181. The penultimate column is PAO1 and the top right well is the 
media blank.  
 
Repetition of the experiment resulted in replication of the observed pigmentation patterns. However 
when the experiment was repeated under microaerophilic conditions, there was a substantial 
difference in the pigmentation observed. Figure 5.4 shows the difference in pigmentation in isolates 
#8 and #168 (yellow pigment in aerobic and green in microaerophilic) and the change from brown 
pigmentation to green in isolate #109. Isolate #115 had a green pigment in aerobic (A) conditions 
and a yellow pigment in microaerophilic (M) conditions. It must be noted that the starting bacterial 
load and pigmentation was consistent within isolates, prior to incubation under these conditions. 
 
 
 
#3 Blank #8 #109 #115 #168 #181 PAO1 
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Figure 5.4: Substantial differences in pigment phenotypes between aerobic and microaerophilic 
conditions in six different clinical isolates of P. aeruginosa observed under white light trans-
illumination. Rows represent individual clinical isolates. The first three columns represent 
individual cultures of a specific isolate cultured aerobically in LB. The last three columns represent 
individual cultures of the isolates cultured in LB, in a microaerophilic environment.  
 
Further, the pigmentation phenotype also differed between clinical isolates when cultured under 
aerobic conditions in SSM versus LB (Figure 5.5). For example, isolate #3 produced a dark green 
pigment in LB (Figure 5.4 above), but was pale green/yellow when cultured in SSM (Figure 5.5). 
Again, the starting bacterial load was consistent within isolate at the start of this experiment. 
 
 
Figure 5.5: Substantial variability in pigment phenotypes noted between different clinical isolates 
of P. aeruginosa when cultured in SSM under aerobic conditions. Columns represent individual 
clinical isolates. The penultimate column is PAO1 and the top right well is the media blank. For 
comparison, Figure 5.3 shows pigmentation when these isolates are cultured in LB. 
#3 Blank #8 #109 #115 #168 #181 PAO1 
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5.3.1.3 Pyocyanin 
In order to determine whether the pigment variability noted in the isolates in different growth media 
above was due to variability in pyocyanin production, pyocyanin levels were determined by 
assessment of the filtered supernatant of bacterial cultures, treated as described in Figure 5.1. The 
blue-green pigment of pyocyanin absorbs light at 695 nm. Absorbance at 695 nm was therefore 
determined to assess for the presence of pyocyanin in the supernatant. Pyocyanin concentration was 
then determined via comparison to a simultaneously generated standard curve.  
 
There was a significant difference in pyocyanin levels between isolates when cultured in LB under 
aerobic (A) conditions, with mean pyocyanin concentrations varying between 0-60 µM, p<0.001 
(one-way ANOVA) (Figure 5.6). 
 
Figure 5.6: Baseline pyocyanin levels (as determined by absorbance at 695 nm versus a standard) 
of 6 respiratory isolates of P. aeruginosa and PAO1 cultured in LB, aerobically at 37oC with 
shaking at 250 rpm. Significance determined by one-way ANOVA with individual differences 
determined by the Holm-Sidak post test. Points represent individual values (n=3), columns 
represent the mean value. Error bars represent the standard deviation. Significant differences 
denoted by an asterisk (*). 
 
In order to reinforce the results determined above, isolate #181 and PAO1 were taken forward for 
more detailed assessments across the different culture conditions and different media. Isolate #181 
was used as it grew rapidly, produced pyocyanin reliably and did not overproduce biofilm, making 
continuous spectrophotometric analysis more reliable.  
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When PAO1 was cultured in LB in the different culture conditions (A, S and M), there was no 
significant difference in pyocyanin content between groups when assessed by Kruskal-Wallis 
(p=0.125), with no significant differences using the Dunn’s post hoc test (Figure 5.7). Conversely, 
when PAO1 was cultured in SSM, there were significant differences in pyocyanin production 
between each culture condition as determined by the Kruskal-Wallis test (p<0.001, Kruskal-Wallis). 
Specifically, pyocyanin production was greatest in condition S (* Dunn’s post test), produced at 
low levels in microaerophilic conditions, and not produced in aerobic conditions with shaking 
(Figure 5.8).  
 
Figure 5.7: Pyocyanin concentrations (as determined by absorbance at 695 nm versus a standard) in 
filtered supernatant of a 24 hour culture of PAO1 cultured in LB in differing oxygen tensions (A 
(aerobic with shaking n=7); S (aerobic without shaking n=8) and M (microaerophilic n=8)). 
Horizontal lines represent median values, boxes represent the interquartile range. Significance 
determined Kruskal-Wallis with individual differences determined by the Dunn’s post-test; ns = not 
significant.  
 
Figure 5.8: Pyocyanin concentrations (as determined by absorbance at 695 nm versus a standard) in 
filtered supernatant of a 24 hour culture of PAO1 cultured in SSM in differing oxygen tensions (A 
(aerobic with shaking n=5); S (aerobic without shaking n=5) and M (microaerophilic n=5)). 
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Horizontal lines represent median values, boxes represent the interquartile range. Significance 
determined Kruskal-Wallis with individual differences determined by the Dunn’s post-test. 
Significant values denoted by an asterisk (*). 
 
Isolate #181 reflected the findings of PAO1 in SSM, with a significantly higher pyocyanin 
production in condition S (p<0.001 Kruskal-Wallis, *Dunn’s post test). In LB however, pyocyanin 
production was greatest in condition A, with substantially lower pyocyanin production in conditions 
S and M (p<0.001 Kruskal-Wallis, * Dunn’s post test) Figure 5.9. 
 
Figure 5.9: Pyocyanin concentrations (as determined by absorbance at 695 nm vs. a standard) in 
filtered supernatant of a 24 hour culture of isolate #181 cultured in LB (left panel) or SSM (right 
panel) in differing oxygen tensions (A (aerobic with shaking n=6); S (aerobic without shaking n=6) 
and M (microaerophilic n=8)). Significance determined Kruskal-Wallis with individual differences 
determined by the Dunn’s post-test. Significant values denoted by an asterisk (*). 
5.3.1.4 Elastase 
Elastase activity was determined from assessment of filter sterilised supernatant from cultures of 
isolates treated as in Figure 5.1 using an Elastin Congo Red method as described in Chapter 4.13 
(Methods). The presence of elastase in the supernatant leads to cleavage of the red pigment from the 
elastin, leading to red pigmentation of the sample, which can be measured by absorbance at 495 nm. 
In keeping with the assessment of pyocyanin production, there was significant variability in elastase 
production at baseline between the different respiratory isolates compared with PAO1. Specifically, 
there was much lower elastase produced by all respiratory isolates compared with PAO1, with 
ongoing variability between isolates (p<0.001, ordinary one-way ANOVA, *Holm-Sidak post test), 
Figure 5.10. 
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Figure 5.10: Elastase production in 6 respiratory isolates (n=3), and PAO1 (n=6) as measured by 
absorbance at 495 nm after overnight incubation with ECR. Significance determined by one-way 
ANOVA with individual differences determined by the Holm-Sidak post test. Significant 
differences denoted by an asterisk (*). 
 
PAO1 and #181 were assessed in further detail. Significant culture condition specific intra-isolate 
variability in elastase production was observed. Specifically, PAO1 had the greatest production of 
elastase when cultured in LB under condition A (PAO1 LB p=0.008, Kruskal-Wallis test, *Dunn’s 
post test), with significantly less produced under microaerophilic conditions. Substantially less 
elastase was produced overall in SSM, with the most being produced under condition S (PAO1 
SSM p<0.001 (Kruskal-Wallis test, *Holm-Sidak post test), Figure 5.11). 
 
Figure 5.11: Elastase concentrations as determined by absorbance at 495 nm in the ECR cleavage 
assay in filtered supernatants of 24 hour cultures of PAO1 cultured in LB (left panel) or in SSM 
(right panel), in differing oxygen tensions (A (aerobic with shaking n=8); S (aerobic without 
shaking Left n=8, Right n=4) and M (microaerophilic n=8)). Significance determined Kruskal-
Wallis with individual differences determined by the Dunn’s post test. Significant differences 
denoted by an asterisk (*). 
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Isolate #181, similar to the other respiratory isolates, produced less elastase overall, with no 
difference in production in any culture condition when LB was used (#181 LB, p=0.259 (Kruskal-
Wallis test)). When cultured in SSM, however, there was more elastase produced under condition S 
than either of the other two conditions, with the significant difference across the group driven by the 
increase in condition S, Figure 5.12 (#181 SSM, p<0.001 (Kruskal-Wallis test, Dunn’s post test)). 
 
Figure 5.12: Elastase concentrations as determined by absorbance at 495 nm in the ECR cleavage 
assay in filtered supernatants of 24 hour cultures of isolate #181 cultured in LB (left) or in SSM 
(right), in differing oxygen tensions A (n=6), S (n=6) and M (n=6). Significance determined 
Kruskal-Wallis with individual differences determined by the Dunn’s post test. Significant 
differences denoted by an asterisk (*). 
5.3.1.5 The Pseudomonas Quinolone Signal 
In order to determine whether quorum sensing molecule levels also varied across the isolates, the 
quorum sensing molecule PQS was assessed. PQS is a quorum sensing molecule implicated in the 
production of pyocyanin and was therefore chosen to enable correlation with pyocyanin production.  
 
Concentrations of PQS molecules were determined in ethyl acetate extractions of 1 ml of cultured 
PAO1 or isolate #181 broth under the aforementioned experimental conditions (Figure 5.1). The 
level of PQS was determined by mass spectrometry and quantified against a standard curve 
generated simultaneously (Figure 5.13).  
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Figure 5.13: Standard curve generated for the quantification of PQS by MS in ethyl acetate 
extracted samples of culture medium. Each point represents the mean of three replicates. R2 = 
0.993, Slope = 4.08 x 106, Y intercept = 0.15 x 106. 
 
As with pyocyanin, PQS production showed significant intra-strain variability between culture 
conditions. Specifically, PAO1 produced the most PQS in conditions A and M, (PAO1 LB, p=0.008 
(Kruskal-Wallis test, *Dunn’s post test)), with substantially lower PQS production in SSM overall, 
with the most being in condition S (Figure 5.14, PAO1 SSM, p<0.001 (Kruskal-Wallis test, 
*Dunn’s post test)).  
 
Figure 5.14. PQS concentrations as determined by mass spectrometry of an ethyl acetate extract of 
a 24 hour broth culture of PAO1 cultured in LB (left panel) or SSM (right panel) in differing 
oxygen tensions (A (aerobic with shaking n=6); S (aerobic without shaking n=5) and M 
(microaerophilic n=5)). Horizontal lines represent median values, boxes represent the interquartile 
range. Significance determined Kruskal-Wallis with individual differences determined by the 
Dunn’s post test. Significant values denoted by an asterisk (*). 
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Conversely, isolate #181 produced similar amounts of PQS in all culture conditions when cultured 
in LB (#181 LB p=0.259, Kruskal-Wallis test), however the isolate produced significantly more 
PQS in condition S when cultured in SSM. Again, the amount of PQS produced was substantially 
lower overall in SSM than in LB (Figure 5.15 (#181 SSM, p<0.001, Kruskal-Wallis test, *Dunn’s 
post test)). Importantly, there did not appear to be a significant correlation between PQS and 
pyocyanin production in this analysis (r=-0.389, p=0.067, Spearman r) suggesting a more complex 
relationship. 
 
 
Figure 5.15: PQS concentrations as determined by mass spectrometry of an ethyl acetate extract of 
a 24 hour broth culture of isolate #181 cultured in LB (left panel) or SSM (right panel) in differing 
oxygen tensions (A (aerobic with shaking n=6); S (aerobic without shaking n=6) and M 
(microaerophilic n=6)). Horizontal lines represent median values, boxes represent the interquartile 
range. Significance determined Kruskal-Wallis with individual differences determined by the 
Dunn’s post-test; ns = not significant. Significant values denoted by an asterisk (*). 
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5.3.2 Effect of Erythromycin on P. aeruginosa Quorum Sensing Phenotypes 
5.3.2.1 Effect of Erythromycin on P. aeruginosa Growth Rate and Cell Density 
In order to determine whether erythromycin inhibits growth rate in P. aeruginosa, PAO1 was 
cultured as described in section 5.2.4 in LB broth supplemented with increasing concentrations of 
erythromycin varying from 2.5 to 160 µg/mL. Growth was detected in all concentrations tested with 
no difference between the slopes up to a concentration of 20 µL/mL (F = 0.754, p=0.56); however 
at concentrations greater than 40 µg/mL, there was a discernible slowing of the growth rate 
compared with control (Figure 5.16). 
 
 
Figure 5.16: Growth curves of PAO1 cultured in LB broth with increasing concentrations of 
erythromycin. Growth rate is matched in all groups during logarithmic phase until a concentration 
of 40 µg/mL. Growth curves were generated from triplicate cultures. The symbol represents the 
mean value. Error bars represent the standard deviation. 
 
Growth in the presence of erythromycin at a concentration of 5 µg/mL was further assessed for the 
six P. aeruginosa clinical isolates. This concentration of erythromycin was selected due to it having 
no impact on logarithmic growth of PAO1 in the preceding experiment, and is in keeping with the 
highest expected achievable maximum concentration (Cmax) recorded in healthy humans when 
dosed orally with 250 mg erythromycin, four times per day [143].  
 
As expected, there was minimal discernible difference in growth with addition of erythromycin in 
the cultures of P. aeruginosa isolates (Figure 5.17), however when assessed with a two-way 
ANOVA, erythromycin contributed to the variation between the curves in isolates #3 (p=0.050), #8 
(p=0.050) and #168 (p=0.020). However, when the growth rate was assessed during exponential 
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growth by linear regression, only growth in isolate #168 remained significantly different with 
erythromycin (F = 61.98, p<0.001). Assessing growth rate during the exponential phase is most 
appropriate as OD measurements outside this range can become unreliable due to the presence of 
aggregates of biofilm, falsely elevating the OD600 (best observed in isolate #3). 
 
 
Figure 5.17: Growth curves of clinical isolates of P. aeruginosa cultured in LB broth with 5 µg/mL 
erythromycin. Growth curves were generated from triplicate cultures. Black circles represent the 
mean absorbance for the untreated isolates. Grey squares represent the mean absorbance for the 
erythromycin treated isolates. All were not statistically different apart from isolate #3 and #168 as 
assessed by two-way ANOVA. Only #168 remained significantly different when growth rates were 
assessed by linear regression analysis. Asterisks (*) represent significantly different mean values as 
assessed by Sidak’s multiple comparison analysis. Error bars represent the standard deviation. 
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5.3.2.2 P. aeruginosa Isolate Pigmentation in the Presence of Erythromycin 
PAO1 was cultured as described above in LB broth supplemented with increasing concentrations of 
erythromycin varying from 2.5 to 160 µg/mL. Pigmentation was observed at the end of the growth 
period. There was a visible reduction in pigment production (Figure 5.18) with increasing 
concentrations of erythromycin, without a demonstrable alteration in logarithmic growth before 40 
µg/mL (as demonstrated spectrophotometrically in section 5.3.2.1 above). 
 
 
Figure 5.18: P. aeruginosa strain PAO1 was cultured in a single well of a 48 well flat bottomed 
plate and incubated at 37oC, with shaking at 250 rpm in LB broth supplemented with increasing 
concentrations of erythromycin varying from 0 to 160 µg/mL. There was a discernible change in 
colour with increasing concentrations of erythromycin. Columns represent triplicate cultures at the 
given concentration. Numbers represent µg/mL erythromycin. 
 
 
Variable results were seen across the 6 different respiratory isolates tested. Isolates were cultured in 
LB in aerobic (A) conditions, with and without 5 µg/mL erythromycin, as described in Figure 5.1 
above. Figure 5.19 shows the difference in pigmentation between the isolates cultured in LB with 
and without erythromycin. In those producing a blue/green pigment at baseline (isolate #3 and 
#181), there is a discernible reduction in pigmentation seen in the presence of erythromycin. 
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Figure 5.19: P. aeruginosa isolates were cultured in condition A, in LB broth supplemented with 
and without 5 µg/mL erythromycin. There was a discernible change in colour with erythromycin in 
those isolates producing a blue/green pigment in the control wells. The first three rows represent 
triplicate cultures without erythromycin; the last three rows represent triplicate cultures with 5 
µg/mL erythromycin. 
 
 
5.3.2.3 Pyocyanin Production in the Presence of Erythromycin 
In order to determine whether erythromycin inhibits pyocyanin production, pyocyanin levels were 
determined in the supernatant of bacterial cultures treated as described in Figure 5.1.  
 
Erythromycin inhibited the production of pyocyanin by PAO1 LB broth culture when cultured 
under aerobic conditions (A) (control: 28.4 +/- 2.1 µM (SD); erythromycin 5.1 +/- 0.97 µM 
p<0.001, unpaired t-test) and aerobic without shaking conditions (S) (21.9 +/- 3.9 µM vs. 7.2 +/- 3.7 
µM p<0.001, unpaired t-test) and trended towards inhibition when cultured under microaerophilic 
(M) conditions (23.1 +/-13.3 µM vs. 12.9 +/- 6.0 µM, p=0.056, Mann-Whitney U test). When 
cultured in SSM, no pyocyanin production was detected in condition A, there was a significant 
reduction in pyocyanin production in condition S (control: 110.0 +/- 12.0 µM (SD); erythromycin 
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76.4 +/- 20.5 µM p<0.001, unpaired t-test), and no difference in condition M (control: 27.1 +/- 11.9 
µM (SD); erythromycin 30.9 +/- 11.0 µM p=0.309, Mann-Whitney U test) (Figure 5.20). 
 
 
 
Figure 5.20: Comparison of the inhibitory effect of erythromycin on the production of pyocyanin 
by PAO1 under three different growth conditions, aerobic with shaking (A), aerobic without 
shaking (S) and microaerophilic (M). Measurements were by absorbance at 690 nm with 
comparison to a standard curve to determine concentration. Cultures were in LB broth or SSM 
supplemented with 5 µg/mL erythromycin (LBE, SSME). Horizontal bars represent mean values of 
8 replicates. Significant values denoted by an asterisk (*). Significance determined by unpaired t-
test (A and S) or Mann-Whitney U test (M). 
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In order to determine whether erythromycin inhibits pyocyanin in a media favouring pyocyanin 
production. PAO1 was cultured in Kings A media with and without 5 µL erythromycin. While 
erythromycin significantly inhibited the production of pyocyanin when cultured under aerobic 
conditions in Kings A media, the relative magnitude of the change was lower than when cultured in 
LB (control: 174.4 +/- 4.59 µM (SD); erythromycin 131.9 +/- 1.31 µM p <0.001 (unpaired t-test 
test)), Figure 5.21. 
 
Figure 5.21: Comparison of the inhibitory effect of erythromycin on the production of pyocyanin 
as measured by absorbance under aerobic growth conditions in Kings A media. Columns represent 
mean values of 3 replicates. Error bars represent the standard deviation. Significant values denoted 
by an asterisk (*). Significance determined by unpaired t-test. 
 
 
Figure 5.22: Correlation between pyocyanin levels detected by mass spectrometry (n=21) versus 
absorbance (n=21). Points represent individual measurements of pyocyanin in cultured PAO1. 
Black circles represent control; grey squares represent erythromycin treated isolates. Straight lines 
represent lines of best fit. 
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The pyocyanin concentrations measured in the absorbance assay above were compared with 
measurements obtained by mass spectrometry. Mass spectrometric measurement provides greater 
specificity for the compound in question as, unlike absorbance-based measures, it is not affected by 
the presence of other compounds with similar absorbance profiles. When pooled data was assessed, 
strong correlation was observed between mass spectrometry and absorbance assay measurements, 
regardless of whether the isolates had been treated with erythromycin or not (control R2 = 0.633, 
p<0.001, Pearson r; erythromycin R2 = 0.842, p<0.001, Pearson r). There was no difference 
between the two slopes (F = 3.02, p=0.090), Figure 5.22. 
 
 
However, growth condition did appear to impact the correlation with the strongest correlation 
between mass spectrometry and absorbance being in condition S (control: R2 0.851, p=0.004, 
Pearson r; erythromycin: R2 0.929, p<0.001, Pearson r) and the control group of condition A (R2 
0.998, p<0.001). There was no correlation between mass spectrometry and absorbance in the 
microaerophilic group (Figure 5.23). The microaerophilic group phenotypically had a denser 
biofilm, which most likely impacted the absorbance measurements at 690 nm. 
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Figure 5.23: Correlation between pyocyanin levels detected by mass spectrometry versus 
absorbance in condition A (top), condition S (middle) and condition M (bottom). Points represent 
individual measurements of pyocyanin in cultured PAO1. Black circles represent control; grey 
squares represent erythromycin treated isolates. Straight lines represent lines of best fit. 
 
A similar reduction in pyocyanin production in the presence of erythromycin, as determined by the 
more specific mass spectrometry technique, was seen when PAO1 was cultured aerobically (A) 
both in LB (control: 22.1 +/- 3.0 µM vs. erythromycin: 0.89 +/- 1.36 µM, p<0.001, unpaired t-test) 
and Kings A media (control: 45.5 +/- 4.1 µM vs. erythromycin: 26.4 +/- 1.96 µM p<0.001, unpaired 
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t-test). Similarly a significant reduction in pyocyanin production, in the presence of erythromycin 
was also seen in condition S (control: 4.40+/- 1.30 µM vs. erythromycin: 0.00+/-0.00 µM p=0.008, 
unpaired t-test), Figure 5.24). Interestingly, no pyocyanin was detectable with mass spectrometry in 
the microaerophilic group when PAO1 was cultured in LB, in conflict with the absorbance data 
(Figures 5.7 and 5.8).  
 
 
Figure 5.24: Comparison of the inhibitory effect of erythromycin on the production of pyocyanin 
by PAO1 under four different growth conditions, aerobic with shaking (A), aerobic with shaking 
using Kings A media (A, Kings A), aerobic without shaking (S) and microaerophilic (M). 
Measurements were by mass spectrometry with comparison to a standard curve to determine 
concentration. Cultures were in LB broth or Kings A (Con) supplemented with 5µg/mL 
erythromycin (Ery). Columns represent mean values of 3 replicates. Error bars represent the 
standard deviation. Significant values denoted by an asterisk (*). Significance determined by 
unpaired t-test. 
 
Isolate #181 was also extensively tested using absorbance at 690 nm, for the presence of pyocyanin, 
with and without erythromycin. Similar to PAO1 there was inhibition of pyocyanin by 
erythromycin when cultured in LB in conditions A (control: 92.6 +/- 12.0 µM (SD); erythromycin 
10.7 +/- 5.7 µM p<0.001, unpaired t-test) and S (control: 16.6 +/- 5.3 µM (SD); erythromycin 10.4 
+/- 1.3 µM p=0.019, unpaired t-test). However, there was no inhibition of pyocyanin production by 
erythromycin when cultured under microaerophilic (M) conditions (control: 27.3 +/- 2.6 µM (SD); 
erythromycin 26.1 +/- 10.5 µM, p=0.875, Mann-Whitney U test).  
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Similar to PAO1 there was no pyocyanin production when cultured in SSM in condition A. There 
was no difference in pyocyanin production in SSM when cultured in condition S (control: 85.5 +/- 
11.1 µM (SD); erythromycin 76.9 +/- 3.3 µM p=0.099, unpaired t-test) and, interestingly, there was 
an increase in pyocyanin production in microaerophilic (M) conditions (control: 16.8 +/- 4.9 µM 
(SD); erythromycin 38.4 +/- 10.0 µM, p=0.002; Mann-Whitney U test), Figure 5.25. 
 
Figure 5.25: Comparison of the inhibitory effect of erythromycin on the production of pyocyanin 
by isolate #181 under three different growth conditions, aerobic with shaking (A), aerobic without 
shaking (S) and microaerophilic (M). Measurements were by absorbance at 690nm with comparison 
to a standard curve to determine concentration. Cultures were in LB broth or SSM supplemented 
with 5 µg/mL erythromycin (LBE, SSME). Horizontal bars represent median values of 6 replicates. 
Significant values denoted by an asterisk (*). Significance determined by unpaired t-test (A and S) 
or Mann-Whitney U test (M). 
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When the effect of erythromycin on pyocyanin production was assessed in the respiratory isolates 
in LB broth in condition A, only 4 of the 6 tested produced pyocyanin at baseline. Three of the 4 
pyocyanin producing isolates demonstrated significant inhibition with erythromycin (#181 (control: 
27.9 +/- 8.5 µM (SD); erythromycin 6.7 +/- 3.2 µM p=0.016 (unpaired t-test)) or trended down: #3 
control: 54.0 +/- 3.85 µM (SD); erythromycin 38.3+/- 9.54 µM p=0.058 (unpaired t-test), #109 
control: 61.5 +/- 11.27 µM (SD); erythromycin 38.1 +/- 6.99 µM p=0.052 (Mann Whitney U test)). 
Erythromycin convincingly had no effect on one isolate: #115 control: 16.2 +/- 0.35 µM (SD); 
erythromycin 13.9 +/- 13.14 µM p=0.783 (Mann Whitney U test, Figure 5.26). 
 
 
Figure 5.26: Comparison of the inhibitory effect of erythromycin on the production of pyocyanin 
by 6 respiratory P. aeruginosa isolates incubated at 37oC, with shaking at 250 rpm in LB broth 
supplemented with and without 5 µg/mL erythromycin. Con = control, Ery = erythromycin. 
Columns represent mean values of 3 replicates. Error bars represent the standard deviation. 
Significant values denoted by an asterisk (*). Significance determined by unpaired t-test (#3, #109, 
#181) or Mann-Whitney U test (#115). Statistical test determined by prior assessment of data 
normality. 
 
5.3.2.4 The Effect of Erythromycin on the Production of Elastase 
Elastase was determined by assessment of the supernatant in a similar fashion to that described in 
section 5.3.1.4 (elastase) above, under the same experimental conditions, with and without 5 µg/mL 
erythromycin.  
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Erythromycin inhibited the production of elastase by PAO1 in LB broth culture when cultured 
under condition A (control: 0.644 +/- 0.150 nm (SD); erythromycin: 0.355 +/- 0.067 nm; p<0.001 
(unpaired t-test)), condition S (control: 0.425 +/- 0.059 nm (SD); erythromycin: 0.291 +/- 0.057 nm 
p<0.001 (unpaired t-test)) and trended down when cultured under microaerophilic (M) conditions 
(control: 0.358 +/- 0.139 nm (SD); erythromycin: 0.251 +/- 0.082 nm p=0.074 (Mann Whitney U 
test)); Figure 5.27.  
 
Figure 5.27: Comparison of the inhibitory effect of 5 µg/mL erythromycin on elastase production, 
as measured by the Elastin Congo Red assay, by PAO1 under three different growth conditions, 
aerobic with shaking (A), aerobic without shaking (S) and microaerophilic (M). Measurements 
were by absorbance at 495nm. Cultures were in LB broth (Con) or LB supplemented with 5 µg/mL 
erythromycin (Ery). Horizontal bars represent median values of 8 replicates.  Significant values 
denoted by an asterisk (*). Significance determined by unpaired t-test (A and S) or Mann-Whitney 
U test (M). Statistical test determined by prior assessment of data normality. 
 
There was no effect of erythromycin on elastase production by PAO1 when cultured in SSM under 
both condition A and S. However there was an increase in elastase production when cultured under 
microaerophilic (M) conditions (control: 0.128 +/- 0.019 nm (SD); erythromycin: 0.166 +/- 0.017 
nm p<0.001 (unpaired t-test)) (Figure 5.28). It must be noted that there was a lower amount of 
elastase detected in SSM in any of the culture conditions, compared with LB, which is probably 
reflective of the abundance in SSM of base amino acids readily available as a nutrient source.  
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Figure 5.28: Comparison of the inhibitory effect of 5 µg/mL erythromycin on elastase production, 
as measured by the Elastin Congo Red assay, by PAO1 under three different growth conditions, 
aerobic with shaking (A), aerobic without shaking (S) and microaerophilic (M). Measurements 
were by absorbance at 495nm. Cultures were in SSM (Con) or SSM supplemented with 5 µg/mL 
erythromycin (Ery). Horizontal bars represent median values of 8 replicates. Significant values 
denoted by an asterisk (*). Significance determined by unpaired t-test. 
 
Different results to PAO1 were seen when isolate #181 was tested. Erythromycin inhibited the 
production of elastase by isolate #181 in LB broth culture when cultured in condition S (control: 
0.256 +/- 0.027 nm (SD); erythromycin: 0.190 +/- 0.016 nm, p<0.001 (Unpaired t-test)), but did not 
change under condition A (p=0.722 (unpaired t-test)) or condition M (p=0.305, Mann Whitney U 
test); Figure 5.29. There was no significant difference in elastase production between control and 
erythromycin treated cultures of isolate #181 in SSM, in any of the conditions tested (A, p=0.052; 
S, p=0.099; M, p=0.507 (Mann-Whitney U test); Figure 5.30. 
 
When the six respiratory isolates were tested under the same conditions, variable results were seen. 
There was a significant reduction in elastase production in the presence of erythromycin in isolate 
#115 (p=0.032, unpaired t-test) and #181 (p=0.030, unpaired t-test) in condition A, and in isolates 
#109 (p=0.026, unpaired t-test), #168 (p=0.034, unpaired t-test) and #181 (p=0.037, unpaired t-test) 
in condition S. Notably, there was an increase in elastase production in isolate #168 in condition M 
(p=0.002, unpaired t-test, Figure 5.30). However, there was no change in elastase production in the 
presence of erythromycin in any of the other isolates in any of the other conditions. The amount of 
elastase measured was very low in these isolates in comparison to PAO1 and may not represent 
biologically and clinically significant changes in elastase production. 
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Figure 5.29: Comparison of the inhibitory effect of 5 µg/mL erythromycin on elastase production, 
as measured by the Elastin Congo Red assay, by isolate #181 under three different growth 
conditions, aerobic with shaking (A), aerobic without shaking (S) and microaerophilic (M). 
Measurements were by absorbance at 495nm. Cultures were in LB broth (Con) or LB supplemented 
with 5 µg/mL erythromycin (Ery). Horizontal bars represent median values of 8 replicates.  
Significant values denoted by an asterisk (*). Significance determined by unpaired t-test (A and S) 
or Mann-Whitney U test (M). Statistical test determined by prior assessment of data normality. 
 
 
Figure 5.30: Comparison of the inhibitory effect of 5 µg/mL erythromycin on elastase production, 
as measured by the Elastin Congo Red assay, by isolate #181 under three different growth 
conditions, aerobic with shaking (A), aerobic without shaking (S) and microaerophilic (M). 
Measurements were by absorbance at 495nm. Cultures were in SSM (Con) or SSM supplemented 
with 5 µg/mL erythromycin (Ery). Horizontal bars represent median values of 8 replicates.  
Significance determined by Mann-Whitney U test. 
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Figure 5.31: Comparison of the inhibitory effect of 5 µg/mL erythromycin on the production of 
elastase by 6 respiratory P. aeruginosa isolates cultured in LB in three different oxygen tensions; A: 
aerobic with shaking, S: aerobic without shaking and M: microaerophilic, as measured by the 
Elastin Congo Red assay. Black columns represent LB broth alone. Grey columns represent LB 
supplemented with 5 µg/mL erythromycin. Columns represent mean values of 3 replicates. Error 
bars represent the standard deviation. Significant values denoted by an asterisk (*). Significance 
determined by unpaired t-test. 
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5.3.2.5 The Effect of Erythromycin on the Quorum Sensing Molecule PQS 
The quorum sensing molecule PQS was measured in an ethyl acetate extract of cultured PAO1 and 
isolate #181, cultured in the experimental conditions outlined in Figure 5.1, with and without 5 
µg/mL erythromycin. 
 
Erythromycin inhibited the production of the quorum sensing molecule PQS by PAO1 in LB broth 
culture when cultured in condition A (61.8 +/- 10.0 pmol vs. 39.1 +/- 8.17 pmol, p=0.003, unpaired 
t-test). PQS levels trended up in condition S (35.3 +/- 10.22 pmol vs. 47.9 +/- 4.68 pmol, p=0.082 
(Mann-Whitney U test)) but trended down in condition M (126.8 +/- 104.8 pmol vs. 86.5+/- 30.7 
pmol, p=0.388, unpaired t-test). When cultured in SSM PAO1 demonstrated small but significant 
increases in PQS in the presence of erythromycin under condition A (p<0.001, Mann-Whitney U 
test) and condition M (p=0.030, Mann-Whitney U test). However, there was minimal overall PQS 
production, questioning the biological and clinical significance of these findings (Figure 5.32). 
 
This trend was repeated with isolate #181 when cultured in LB. There was a significant reduction in 
PQS production in the presence of erythromycin when cultured under condition A (28.9 +/- 3.91 
pmol vs. 20.7 +/- 3.75 pmol, p=0.040, Unpaired t-test). Similarly there was a significant increase in 
PQS in the presence of erythromycin, in condition S (43.5 +/- 20.3 pmol vs. 85.5 +/- 10.2 pmol, 
p=0.001, unpaired t-test)), whereas there was no difference in PQS production when cultured under 
microaerophilic (M) conditions (28.4 +/- 9.50 pmol vs. 45.5 +/- 19.6 pmol, p=0.085, unpaired t-
test). When cultured in SSM isolate #181 demonstrated significant increases in PQS in the presence 
of erythromycin under condition S (p=0.002, Mann-Whitney U test) and a trend to increase in 
condition M (p=0.178, Mann-Whitney U test). However, as with the PAO1 cultures, there was a 
low level of PQS production (Figure 5.33). 
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Figure 5.32: Comparison of the inhibitory effect of erythromycin on the production of PQS by 
PAO1 under three different growth conditions, aerobic with shaking (A), aerobic without shaking 
(S) and microaerophilic (M). Measurements were by mass spectrometry with comparison to a 
standard curve to determine concentration. Cultures were in LB broth or SSM supplemented with 5 
µg/mL erythromycin (LBE, SSME). Horizontal bars represent median values of 6 replicates.  
Significant values denoted by an asterisk (*). Significance determined by unpaired t-test (LB A and 
M) or Mann-Whitney U test (LB S and all SSM). Statistical test determined by prior assessment of 
data normality.  
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Figure 5.33: Comparison of the inhibitory effect of erythromycin on the production of PQS by 
isolate #181 under three different growth conditions, aerobic with shaking (A), aerobic without 
shaking (S) and microaerophilic (M). Measurements were by mass spectrometry with comparison to 
a standard curve to determine concentration. Cultures were in LB broth or SSM supplemented with 
5µg/mL erythromycin (LBE, SSME). Horizontal bars represent median values of 6 replicates.  
Significant values denoted by an asterisk (*); ns = not significant. Significance determined by 
unpaired t-test or Mann-Whitney U test (SSM condition S and M only). Statistical test determined 
by prior assessment of data normality. 
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5.3.2.6 Effect of Erythromycin on P. aeruginosa Gene Expression 
In order to determine whether the above changes in pyocyanin, elastase and PQS were related to 
changes in specific, known quorum sensing genes (lasI, lasR, rhlI, rhlR and the efflux pump mexX), 
RNA was extracted from the cell pellet, collected at the end of the experiment outlined in Figure 
5.1, using the “on column” RNA extraction protocol described in detail in section 4.11. Relative 
gene expression was assessed by comparison with the expression of two housekeeping genes, rpsL 
and rpoD and normalised to the median of the control group. 
 
Extensive assessments of quorum sensing gene expression of PAO1 cultured in LB were carried out 
(condition A). Despite there being no significant difference in growth rate in the presence of 
erythromycin, significant changes in gene expression levels were observed. Expression of lasI, the 
gene encoding the quorum sensing autoinducer protein LasI, and associated with the production of 
elastase, was substantially lower in the presence of erythromycin (5 µg/mL) compared to control 
(erythromycin: fold change 0.545 (IQR, 0.37-0.69), n=5; control: fold change 1.000 (IQR, 0.80-
1.09), n=6; p=0.004, Mann-Whitney U test) (Figure 5.34).  
 
 
 
Figure 5.34: LasI expression in P. aeruginosa (PAO1) cultured for 24 h in the presence of 
erythromycin (5µg/mL) compared to control. Points represent mean fold change of duplicate 
measures, normalised to expression levels of two housekeeping genes (rpoD and rpsL) and 
expressed as the fold change relative to the median of the control group. Horizontal bars represent 
median values of 6 replicates. Significant values denoted by an asterisk (*). Significance 
determined by Mann-Whitney U test. 
 
Expression of pqsA, the gene encoding the quorum sensing auto inducer PQS, and associated with 
the production of pyocyanin, was not altered by erythromycin despite there being a significant 
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inhibition of both pyocyanin and PQS (erythromycin: fold change 1.80 (IQR, 1.3-2.1), n=5; control: 
fold change 1.00 (IQR, 0.36-2.03), n=6; p=0.247, Mann-Whitney test), Figure 5.35. 
 
Figure 5.35: PqsA expression in P. aeruginosa (PAO1) cultured for 24 h in the presence of 
erythromycin (5 µg/mL) compared to control. Points represent mean fold change of duplicate 
measures, normalised to expression levels of two housekeeping genes (rpoD and rpsL) and 
expressed as the fold change relative to the median of the control group. Horizontal bars represent 
median values of 6 replicates. Significance determined by Mann-Whitney U test; ns = not 
significant. 
 
Conversely, expression of mexX, the gene encoding the efflux pump responsible for eliminating 
erythromycin from the cell, and not quorum sensing controlled, was significantly up-regulated in 
the presence of erythromycin (erythromycin: fold change 3.050 (IQR, 2.53-6.46), n=5; control: fold 
change 1.000 (IQR, 0.71-1.24), n=6; p=0.022, unpaired t-test, Figure 5.36).  
 
Figure 5.36: MexX expression in P. aeruginosa (PAO1) cultured for 24 h in the presence of 
erythromycin (5 µg/mL) compared to control. Points represent mean fold change of duplicate 
measures, normalised to expression levels of two housekeeping genes (rpoD and rpsL) and 
expressed as the fold change relative to the median of the control group. Horizontal bars represent 
median values of 6 replicates. Significant values denoted by an asterisk (*). Significance 
determined by unpaired t-test. 
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Providing important validation of the experiment, there was no significant change in the expression 
of mexB, the gene encoding an efflux pump for which erythromycin is not a substrate 
(erythromycin: fold change 0.739 (IQR, 0.70-1.32), n=5; control 1.00 (IQR, 0.60-1.29), n=6; 
p=0.813), Figure 5.37.  
 
 
 
Figure 5.37: MexB expression in P. aeruginosa (PAO1) cultured for 24 h in the presence of 
erythromycin (5 µg/mL) compared to control. Points represent mean fold change of duplicate 
measures, normalised to expression levels of two housekeeping genes (rpoD and rpsL) and 
expressed as the fold change relative to the median of the control group. Horizontal bars represent 
median values of 6 replicates. Significance determined by Mann-Whitney U test; ns = not 
significant. 
 
 
When tested in condition S, there was a significant increase in pqsA expression (p=0.002, Mann 
Whitney U test) in the presence of erythromycin (5 µg/mL), consistent with the increase in both 
PQS and pyocyanin seen in the previous experiments. There was a non-significant trend down in 
lasI expression (p=0.132, Mann Whitney U test) and an expected, and significant increase in mexX, 
but not mexB, expression (p=0.004, Mann Whitney U test), Figure 5.38. 
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Figure 5.38: Quorum sensing gene expression in P. aeruginosa (PAO1) cultured for 24 h in the 
presence of erythromycin (5 µg/mL) compared to control in condition S. Points represent mean fold 
change of duplicate measures, normalised to expression levels of two housekeeping genes (rpoD 
and rpsL) and expressed as the fold change relative to the median of the control group. Horizontal 
bars represent median values of 6 replicates. Significant values denoted by an asterisk (*); ns = not 
significant. Significance determined by Mann-Whitney U test. 
 
In microaerophilic conditions, there was, again, an expected, significant, increase in mexX 
expression (p=0.002, Mann Whitney U test) in the presence of erythromycin (5 µg/mL), an increase 
in pqsA expression (p=0.004, Mann-Whitney U test) and no change in lasI expression (p=0.792, 
Mann-Whitney U test), Figure 5.39. There was no difference in the expression of mexB (p=0.813, 
unpaired t-test), an efflux pump which is constitutively expressed and is not under the control of the 
quorum sensing system, nor is erythromycin a specific substrate for it. 
 
The other central quorum sensing genes tested (lasR, rhlR, rhlI, pqsR) did not show significant 
differences between culture conditions (A, S or M), or within culture conditions between control 
and erythromycin. Indeed, when the expression profile was expanded to include direct virulence 
genes such as lasA, and regulator genes such as qscR, no consistent differences were observed.  
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Figure 5.39: Quorum sensing gene expression in P. aeruginosa (PAO1) cultured for 24 h in the 
presence of erythromycin (5 µg/mL) compared to control in condition M (microaerophilic). Points 
represent mean fold change of duplicate measures, normalised to expression levels of two 
housekeeping genes (rpoD and rpsL) and expressed as the fold change relative to the median of the 
control group. Horizontal bars represent median values of 6 replicates. Significant values denoted 
by an asterisk (*); ns = not significant. Significance determined by Mann-Whitney U test. 
 
Testing these genes in respiratory isolates, demonstrated variable effects of erythromycin on gene 
expression, despite an obvious and significant impact on quorum sensing controlled protein 
production. The only significant change in the presence of erythromycin observed in the isolates, 
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was with isolate #8, where a significant down regulation of lasI gene expression was noted in the 
presence of erythromycin. Somewhat interestingly, mexX was also down-regulated in the presence 
of erythromycin in this isolate, contrary to the up-regulation observed in PAO1 (Figure 5.40). 
 
 
Figure 5.40: Quorum sensing gene expression in P. aeruginosa clinical isolates cultured for 24 h in 
the presence of erythromycin (5 µg/mL) compared to control in condition S. Points represent mean 
fold change of duplicate measures, normalised to expression levels of two housekeeping genes 
(rpoD and rpsL) and expressed as the fold change relative to the median of the control group. 
Columns represent mean values of three replicates; error bars represent the standard deviation. 
Significant values denoted by an asterisk (*), ns = not significant. Significance determined by 
Mann-Whitney U test. 
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5.4  DISCUSSION 
This chapter described an investigation into the effect of erythromycin on P. aeruginosa quorum 
sensing in typed strains and clinical isolates of P. aeruginosa. Previous studies by other researchers 
have demonstrated that the macrolide, azithromycin, inhibits quorum sensing at multiple levels, 
including gene expression [21, 121], however only one previous study has demonstrated that the 14 
ring macrolide, erythromycin also inhibits the production of the quorum sensing molecule C4-HSL 
[20]. It is therefore unclear as to whether erythromycin inhibits quorum sensing phenotypes more 
globally and whether this is true in both typed and clinical (respiratory) isolates of P. aeruginosa. 
This chapter therefore aimed to investigate whether the 14 ring macrolide, erythromycin, inhibits 
quorum sensing in P. aeruginosa in both typed strains and clinical isolates. Data from this chapter 
would then be used to guide experiments to investigate the potential in vivo mechanism of action of 
this drug in non-CF bronchiectasis patients colonised with P. aeruginosa  
 
There were a number of unanswered questions which needed addressing prior to assessing the 
impact of erythromycin on cultured bacteria. Firstly, as this chapter forms part of a wider thesis 
examining the effect of erythromycin on P. aeruginosa quorum sensing in a clinical context, it was 
important to assess the quorum sensing phenotypes and the effect of erythromycin on both typed 
strains (as have been reported previously) as well as clinical isolates. Secondly, whilst macrolide 
has been shown to clearly inhibit quorum sensing when cultured in standard laboratory media (LB) 
under aerobic culture conditions [20, 21], it is not clear that this inhibition holds true in conditions 
which may be encountered in the diseased human lung, where bacterial colonies exist in a 
microaerophilic state [144] and the surrounding environment is sputum rather than in vitro culture 
media like LB [133]. In order to control for these variables a series of experiments were conducted 
in standard and non-standard media (Section 5.2.2) and culture conditions (Section 5.2.3) using 
both typed strains and clinical isolates taken directly from the induced sputum of BLESS [7] 
subjects, aiming to look for a consistent response that may be predicted in vivo.  
 
There are multiple different strains of P. aeruginosa, all with different quorum sensing ability 
(likely to due to inactivating mutations in the central quorum sensing genes) and the ability to alter 
phenotype dependent on environmental stimulus [18]. In order to stress the importance of assessing 
in vivo effects globally, this chapter highlights the differences both between and within isolates, 
contributing more evidence of inter-strain variance in quorum sensing. 
 
The baseline (and therefore non quorum sensing dependent) inter-strain difference is exemplified 
by assessing growth in standard media. Clinical isolates are highly adapted to their environment, 
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and therefore are likely to show a slower growth rate when cultured in a different setting, as has 
been reported previously [18, 145]. This was confirmed with the respiratory isolates tested as part 
of this investigation, with all six of the clinical isolates displaying slower growth both in the lag 
phase (which may simply represent a different starting number of bacteria despite starting at the 
same optical density), but also a different rate of growth during the exponential phase, when 
compared with PAO1. Conversely, the typed strain, PAO1 grows well in LB under aerobic 
conditions (in a shaking incubator at 250 rpm at 37oC), achieving stationary phase after 9 hours of 
growth.  
 
Partly due to, and also independent of, any differences in growth potential under laboratory 
conditions, there was also a significant difference between isolates in observable phenotypes such 
as pigmentation. In LB, cultured aerobically, there were clear, observable differences between the 
isolates when compared with PAO1. The distinctive blue-green pigmentation generally seen in P. 
aeruginosa is thought to be due to the presence of pyocyanin, and is therefore likely to be present in 
PAO1 as well as isolates #3, #115 and #181. Isolate #109 appeared to be a red-brown colour which 
may be due to the presence of pyorubin [146]. Isolate #8 did not appear to produce any 
pigmentation.  
 
Pigmentation itself is not necessarily under quorum sensing control (pyorubin is not known to be 
associated with quorum sensing for example). However, detailed analysis of quorum sensing 
controlled traits supported these phenotypic differences between strains. In this study, production of 
pyocyanin, elastase and PQS were assessed across the P. aeruginosa isolates during stationary 
growth phase. There were significant differences in pyocyanin, elastase and PQS production 
between PAO1 and the clinical isolates. Isolate #181 had the most similar phenotype to PAO1 at 
baseline and was assessed in a more detailed fashion, generating reproducible results.  
 
Further to this, this chapter confirms the crucial impact that growth media and conditions have on 
the expression of important P. aeruginosa phenotypes and also provide more evidence that growth 
conditions contribute to intra-strain differences in quorum sensing. 
 
Importantly, pyocyanin production in PAO1 demonstrated the least variability across different 
culture conditions but was significantly impacted by culture media. When isolate #181, an isolate 
which produced the same amount of pyocyanin as PAO1 when cultured aerobically in LB, was 
cultured in stationary and microaerophilic conditions, there was significantly less pyocyanin 
production, suggesting that pyocyanin production in isolate #181 favours an aerobic environment. 
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Pyocyanin production in SSM was significantly different both between and within isolates, with the 
most pyocyanin production noted under conditions of oxygen deprivation. SSM is a media where 
amino acids are freely available [133] and perhaps a degree of oxygen deprivation is therefore 
required in order to stimulate pyocyanin synthesis in these isolates.  
 
Similar differences were also observed when assessing another quorum sensing controlled 
phenotype, elastase. Elastase was produced minimally in all clinical isolates compared with PAO1 
which may reflect loss-of-function LasR mutations which are frequently seen in chronically 
infected CF sputum isolates [80, 147]. Detailed experiments on PAO1 and isolate #181 confirmed 
that culture condition and media significantly impacted the amount of elastase activity detected. 
Similarly, culture condition and media also impacted PQS production, with the least PQS produced 
in SSM cultured aerobically, consistent with the minimal pyocyanin detected in this condition, 
confirming the intrinsic link between PQS and pyocyanin production [148]. This is supported by 
previous work which has demonstrated the significant within patient variability of P. aeruginosa 
phenotypes [42] and the speed at which P. aeruginosa can adapt to its environment [18, 149], 
dependent upon culture conditions. This also supports the fact that P. aeruginosa clinical isolates 
are highly adapted to their environment and are therefore likely to demonstrate different phenotypes 
under laboratory conditions than they do within the lung [150]. 
 
Having established that strain specific and environmental factors both contributed substantially to 
the expression of quorum sensing controlled traits it was clear that assessment of the impact of 
erythromycin must be performed across multiple isolates with strict attention to exacting culture 
conditions and media. All experiments comparing erythromycin to control were therefore 
performed simultaneously to ensure all confounders were controlled for.  
 
Although phenotypic experiments were carried out at stationary growth phase, following a period of 
growth in the absence of erythromycin, it was important that this analysis was performed at a 
concentration of erythromycin beneath that capable of significantly inhibiting growth, as small 
changes in bacterial density may account for changes in measurable phenotype. It was also 
important to select a dose range which may be encountered in vivo in order to assess these 
experiments in the wider context of the BLESS clinical trial samples and low dose macrolide 
therapy in general. In PAO1, exponential growth was not inhibited by erythromycin up to a 
concentration of 40 µg/mL. This is consistent with previously reported data demonstrating a lack of 
inhibition of P. aeruginosa bacterial growth with azithromycin in PAO1 [21]. 5 µg/mL 
concentration of erythromycin was selected as this is both achievable in vivo and substantially 
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beneath a level that inhibits growth. When this concentration was tested in the clinical isolates, 
there was no significant or biologically important impact on growth.  
 
P. aeruginosa readily colonises the mucus, forming protective biofilms depriving the colony of 
oxygen, yet allowing survival [151]. Human sputum is also quite dissimilar in composition to LB. 
Standard culture conditions may therefore not represent the phenotype of the bacteria within the 
lung, simply its potential, if the isolate is able to grow in a non-adapted environment. In order to 
attempt to replicate the conditions in the human lung, partially anaerobic (S) and microaerophilic 
(M) culture conditions were assessed alongside standard aerobic culture. SSM was also adapted 
from constituents and base amino acids found in CF sputum so as to replicate the nutrients available 
to adapted respiratory isolates. When PAO1 was challenged with these conditions and media, it 
consistently demonstrated a down-regulation of phenotype (pyocyanin, elastase and PQS) in LB 
cultured aerobically and partially anaerobically (except PQS) with no change in a microaerophilic 
environment. This is consistent with previously reported investigations assessing the impact of 
azithromycin on quorum sensing in PAO1 [21]. Whilst the demonstration of the impact of 
erythromycin on quorum sensing in P. aeruginosa is novel, it is not unexpected. In SSM there was 
no impact of erythromycin in any culture condition except a down-regulation of pyocyanin in 
stationary conditions and an up-regulation of PQS in aerobic and microaerophilic conditions. PAO1 
produced far less pyocyanin, elastase and PQS in SSM for mechanisms that are unclear except to 
state that, due to the ready availability of free base amino acids [133], there is probably no need to 
produce elastase or pyocyanin for nutrient scavenging purposes or competitive advantage, in this 
media. The assessment of gene expression in PAO1 yielded inconsistent results with regards to the 
quorum sensing genes. The only two genes to be affected by erythromycin were lasI and pqsA. 
LasI, a central quorum sensing gene was down-regulated 2-fold in the presence of erythromycin 
when cultured in LB under aerobic conditions, consistent with previously reported experiments [74] 
and consistent with the demonstrated inhibition of elastase production (Figure 5.27). PqsA was up-
regulated 3 fold in the presence of erythromycin in both condition S and condition M. PqsA is the 
first gene to be activated in the production of PQS, which then goes on to stimulate pyocyanin 
production, and would therefore be expected to be inhibited in the presence of erythromycin. 
Interestingly, PQS production was not altered in the presence of erythromycin in either condition S 
or condition M. This suggests that there may be a degree of post transcriptional modification, prior 
to PQS and pyocyanin production. The production of PQS is complex and involves the activation of 
several genes including pqsA, B, C and D and is modified by pqsE and H. Despite testing for 
changes in the expression of pqsA and pqsR (the PQS regulator gene), no consistent response was 
found in either culture condition suggesting a non-linear relationship with these genes in these 
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conditions. Importantly, mexX, the efflux pump for which erythromycin is the substrate [152], was 
consistently up-regulated in the presence of erythromycin and mexB, a constitutively expressed 
efflux pump [152] remained unchanged across all culture conditions. These genes were therefore 
able to act as both a positive and negative control respectively.  
 
Isolate #181, whilst behaving like PAO1 in LB cultured aerobically at baseline, was quite different 
in its responses to erythromycin. In LB, there was a reduction in pyocyanin and PQS production in 
the presence of erythromycin in condition A, and a reduction in pyocyanin and elastase in the 
presence of erythromycin when cultured in LB in condition S. There was an increase in PQS 
production in the presence of erythromycin in condition S in both LB and SSM and an increase in 
pyocyanin production with erythromycin in SSM cultured under microaerophilic conditions. 
Erythromycin had no impact in any other condition or media. Elastase was poorly produced by 
#181 in all culture conditions as it was in all other isolates tested. This variable response to 
erythromycin was demonstrated across all of the clinical isolates with a trend to a reduction in 
pyocyanin production in the presence of erythromycin when cultured aerobically in LB the most 
consistent response seen. There was also no consistent, significant, change in gene expression in the 
isolates when cultured in LB aerobically.  
 
These data both support and conflict with previously reported investigations [21, 74]. PAO1 is fully 
quorum sensing proficient and behaves, in this study, as expected when cultured aerobically in LB 
and, to a lesser degree in partially anaerobic conditions. There was no response to erythromycin 
when cultured in a microaerophilic environment, however. Differences in the quorum sensing 
phenotypes of the isolates likely reflect mutations in quorum sensing genes, especially LasR, and 
may explain the significantly less elastase measured in this study in these isolates. Most of the 
isolates were able to produce pyocyanin, however, but not all down-regulated pyocyanin production 
in the presence of erythromycin. MexX was up-regulated in some of the isolates tested and may 
explain the difference in quorum sensing phenotype expression, with some isolates being less 
responsive to erythromycin than others due to more aggressive efflux pump activation. It must also 
be considered that, with particular relevance to the respiratory isolates, these bacteria are not 
adapted to grow in laboratory conditions, and, despite efforts to closely replicate the conditions of 
the lung, it is nearly impossible to do so and these factors likely impact on our ability to measure 
the true in vivo effect of erythromycin on these isolates using in vitro techniques. 
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5.5 LIMITATIONS 
This study investigated the effect of erythromycin on quorum sensing in the typed strain, PAO1. 
This strain was used as it is a well-described and extensively studied strain which grows well under 
laboratory testing, and is fully quorum sensing proficient. It is not, however, a strain that was 
originally isolated from the lung and may not be representative of the behaviour of typical 
pulmonary adapted isolates. To overcome this limitation, a selection of P. aeruginosa isolates, 
taken from induced sputum collected as part of the BLESS RCT were also studied. These isolates 
were taken from baseline samples of macrolide naïve subjects randomised to the placebo arm of the 
trial. Six isolates were randomly selected, however, one could argue that several isolates across both 
arms could have been used, as well as multiple isolates from the same subject, which could 
strengthen the data by increasing the denominator. However, as has been made clear from this 
investigation, there is significant intra and inter-isolate variability dependent upon culture condition 
and its response to erythromycin. For the purposes of answering the hypothesised question of 
whether erythromycin inhibits quorum sensing in typed and respiratory isolates, this number was 
adequate. The respiratory isolates were tested in triplicate, which brings into question the possibility 
of a type II error, particularly with the gene expression data. Experiments were repeated however, 
with consistent results. To overcome this, isolate #181 and PAO1 were examined in greater detail, 
multiple times with at least 5 replicates per run in order to strengthen the data. Finally, only a 
relatively limited number of genes were tested, testing further genes may give more insight into the 
complexities of the P. aeruginosa quorum sensing system, suggesting the potential utility of global 
gene expression analysis. 
5.6 SUMMARY 
The analyses described in this chapter demonstrate that there is high baseline phenotypic variability 
between different strains of P. aeruginosa as well as significant variability within strain when 
exposed to different culture conditions. These findings bring into question the validity of in vitro 
data when assessments of P. aeruginosa isolates are obtained and suggests that, when considering 
assessments of bacteria in sputum, molecular tests on whole sputum, rather than isolates, may be 
more representative of the functional characteristics of the pathogens in vivo. 
 
This chapter also aimed to assess the impact of erythromycin on bacterial phenotypes controlled by 
quorum sensing. While in some cases, particularly when assessing PAO1, there was an expected 
inhibition by erythromycin of quorum sensing controlled products, the effect of erythromycin was 
not universal across culture conditions and clinical isolates of P. aeruginosa. In particular, there 
seemed to be no change in quorum sensing-controlled phenotypes in the presence of erythromycin 
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when cultured under microaerophilic conditions, and a very inconsistent effect on the respiratory 
isolates. Again, this questions previous research that has supported an inhibitory effect of macrolide 
on quorum sensing and suggests that the generalizability of these data to in vivo pathophysiology 
needs to be carefully considered. 
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6.1 INTRODUCTION  
The in vitro work described in Chapter 5 indicates that erythromycin can interfere with P. 
aeruginosa quorum sensing. This observation builds upon other in vitro macrolide studies [21, 71, 
74, 124]. However, with differences in isolate phenotypes in vitro, and the impact of growth 
conditions on the expression of pathogenicity traits, the extent to which these data reflect 
microbiological processes in vivo is unclear. This chapter describes the inhibition of P. aeruginosa 
quorum sensing gene expression by erythromycin directly within the airways of non-CF 
bronchiectasis patients, based on an assessment of quorum sensing specific gene expression in 
induced sputum collected as part of a randomised controlled trail (BLESS [7]). This further enables 
changes in gene expression to be linked to the well-described clinical outcomes of the BLESS trial. 
6.2 MATERIALS AND METHODS 
Methods used are summarised here, and provided in detail in Chapter 4. 
6.2.1  Study Population 
Analysis was performed on induced sputum samples collected as part of the BLESS trial [7] in 
patients with non-CF bronchiectasis. Baseline demographic and disease characteristics are outlined 
in section 4.1. Differences between treatment and control arms after 48 weeks of treatment were 
assessed. Subjects who were P. aeruginosa positive by qPCR, with a 48 week sample, were 
included. 
6.2.2  Sample Collection 
Induced sputum samples were collected at baseline and after 48 weeks of low dose erythromycin. 
Sputum induction was performed according to the standardised protocol recommended by the 
European Respiratory Society Task Force [129]. Sputum was further processed and stored in 
RNAProtect prior to DNA and RNA extraction. 
6.2.3 Assessment of P. aeruginosa Load in Induced Sputum 
DNA was extracted from sputum using the QIAamp DNA Mini Kit according to manufacturer’s 
instructions, but with an extended initial lysis step (3 h). P. aeruginosa levels in induced sputum 
were determined by quantitative PCR (qPCR) amplification of the oprL gene using the TaqMan 
assay described in Chapter 4.9.4 [153]. 
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6.2.4 RNA Extraction 
It was necessary to develop a more stringent RNA extraction protocol for induced sputum to ensure 
that bacterial RNA was efficiently extracted, and that any contaminating bacterial DNA was 
removed. RNA was extracted from induced sputum using the High Pure RNA Isolation Kit with 
several modifications. A more stringent lysis process was utilised, whereby sputum cell pellets were 
resuspended in Trizol and subjected to physical cell disruption via repeated passage through a 21G 
then a 23G needle (a detailed protocol is provided in Appendix 2). An extended on column DNase 
step was also required to ensure the absence of contaminating bacterial DNA, as outlined in section 
4.11.  
 
RNA concentration and purity was determined using the NanoDrop 1000 spectrophotometer. 200 
ng of total RNA extract was used as template for cDNA generation, using the SensiFAST cDNA 
Synthesis Kit. The absence of contaminating bacterial genomic DNA was verified by PCR 
amplification of cDNA reactions lacking reverse transcriptase (Figure 6.1). 
 
 
 
Figure 6.1: PCR verification of elimination of contaminating bacterial DNA. Left Panel: The 
amplification plot of 8 randomly selected reverse transcriptase negative samples and two no 
template controls demonstrating absence of amplification after 40 PCR cycles. Right Panel: The 
corresponding melt curve plot of the same samples shown in the left panel demonstrating absence 
of a discernible peak. Both of these confirm the absence of contaminating DNA in these samples. 
 
6.2.5 Quantitative PCR 
QPCR assays were performed in duplicate using Sybr Green (rpoD, rpsL, lasR, lasI, rhlR, rhlI, 
pqsA, mexB, mexX) and a custom TaqMan gene expression assay (oprL) (PCR primers, probes, and 
amplification conditions are detailed in section 4.9).  
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6.2.6 Measurement of In Vivo Quorum Sensing Molecules with Biosensors 
Induced sputum samples were extracted in acidified ethyl acetate as described in section 4.12.1 and 
incubated with the appropriate biosensor at 37oC for 24 h whilst shaking at 200 rpm in a plate 
reader (Pherastar FS). Luminescence (RLU) and absorbance (at OD600) readings were taken every 
30 min. The peak luminescence was recorded and divided by the absorbance at the same time point 
(RLU/OD600) to give a corrected luminescence value. 
6.2.7 Measurement of In Vivo Quorum Sensing Molecules by Mass Spectrometry 
Samples were extracted in ethylacetate and analysed using a Bruker Microtof Q II mass 
spectrometer (section 4.12). All mass spectrometry analyses were supported by Dr Brett Hamilton 
(Mater Health Services OMICS Laboratory, Brisbane, Australia).  
6.2.8 Measurement of Induced Sputum Interleukin Levels  
IL-8 and IL-1β concentrations in induced sputum samples were measured using ELISA as per the 
manufacturer’s instruction (Human IL-8 and IL-1β ELISA Set II). All measurements were 
performed in duplicate. This measurement was performed by Dr Alice Chen, Infection, 
Inflammation and Immunity Program, Mater Research, University of Queensland. 
6.2.9 Determination of Absolute and Percentage Neutrophil Count 
Sputolysin was added to the sputum and the sample homogenised by vortexing and rolling. The 
sample was centrifuged at 500 x g for 10 min, the supernatant removed and the cell pellet 
resuspended in phosphate buffered saline for cell counting in the presence of trypan blue and both 
blue and red Rapi-Diff cell stains [7].  
6.2.10  16HBE Culture 
16HBE cells were expanded from frozen aliquots by washing with 10 mL media (Dulbecco’s 
Modified Eagle Media (DMEM) 4.5 g/L glucose) then pelleting at 500 x g for 5 min at 4oC. The 
pelleted cells were resuspended in fresh media and dispersed into a T-25 flask for expansion. When 
the cells were 80% confluent they were passaged with trypsin and further expanded in T-75 flasks. 
Once 80% confluent they were seeded into a 24 well plate (1.7 x 105 cells per well) and allowed to 
expand. Once confluent, quorum sensing molecules (at varying concentrations) were added to the 
media for 15-24 h along with a vehicle control (DMSO). The media was removed. Lysis buffer was 
added to the cell layer and stored at -80oC to await RNA extraction. 
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6.2.11 Statistical Analysis 
The normality of data distribution was determined by Shapiro-Wilk, D’Agostino, and Pearson 
omnibus normality tests. The significance of variance between placebo and treatment was 
determined using t-tests and Mann-Whitney U tests for parametric and non-parametric data, 
respectively. All analyses were 2-sided and p values <0.05 were considered significant. Statistical 
analyses were performed using GraphPad Prism statistical software (version 6.0, California, USA). 
For the gene expression component, it was estimated that 26 patients would need to be enrolled for 
this sub study to have 80% power to detect a 90% reduction in gene expression assuming a two-
sided α level of 0.05. 
 
6.3  RESULTS 
6.3.1  Patient Selection 
In order to test the hypothesis that erythromycin inhibits P. aeruginosa quorum sensing in vivo, 
BLESS subjects who were positive for P. aeruginosa by PCR after 48 weeks of treatment were 
selected. 
6.3.2  Justification of Samples Used 
Of the 80 patients who provided sputum samples at the final BLESS visit, 41 were positive for P. 
aeruginosa as determined by PCR amplification of the oprL gene from a DNA extraction. Of these, 
20 samples were in the erythromycin treatment group and 21 in the placebo group. RNA was 
extracted from these 41 samples and then screened for sufficient P. aeruginosa RNA content by 
amplification of mRNA from both rpoD and rpsL housekeeping genes. Eleven samples in the 
erythromycin group and 15 samples in the placebo group had amplifiable RNA and were then used 
in the subsequent analysis. Figure 6.2 demonstrates the patient flow through this study. 
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Figure 6.2: Patient flow through the P. aeruginosa gene expression sub-study 
 
6.3.3 Patient Characteristics 
The baseline patient characteristics of the selected group are shown in Table 6.1. There were no 
statistically significant differences between the two groups. The composition of the subgroup was 
also similar to that of the original BLESS cohort, Table 4.1. 
 
 
 
 
 
 
 
	 170 
 Placebo (15) Erythromycin (11) P value 
Age, years, mean (SD) 63.5 (7.9) 63.6 (6.3) 0.95 
Gender, % female, (SD) 47 (51) 63 (50) 0.41 
Ex-smokers, %, (SD) 33 (48) 18 (40) 0.41 
Post BD FEV1, L, mean (SD) 63.5 (19.1) 57.8 (18.4) 0.46 
24 hour sputum weight, g, mean (SD) 17.7 (12.3) 18.4 (10.4) 0.89 
CRP, mg/L, mean (SD) 5.7 (5.6) 5.4 (4.5) 0.86 
 
Table 6.1: Baseline characteristics of the cohort tested. These subjects were P. aeruginosa positive 
and had amplifiable RNA. There was no statistically significant difference between the two groups 
for these measures at trial entry.  
 
6.3.4 Effect of Erythromycin on Clinical Outcomes 
Consistent with the findings in the complete BLESS cohort, in the subset subjected to gene 
expression analysis there was a significant reduction in total exacerbations in the erythromycin 
group (erythromycin: 3 (IQR 4-2), n=11; placebo 6 (IQR 8-4), n=15; p=0.008, Mann-Whitney U 
test); Figure 6.3. 
 
Figure 6.3: Pulmonary exacerbations requiring either intravenous or oral antibiotic therapy 
recorded as part of the BLESS trial in the sub-group selected for gene expression analysis (n=15 
placebo, n=11 erythromycin). Columns represent median values for each set of conditions. Error 
bars represent standard deviation. Significance determined by Mann-Whitney U-test. Significant 
values denoted by an asterisk (*). 
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Similarly, there was a significant reduction in daily sputum production in the erythromycin treated 
group (erythromycin group, baseline: 18.4 +/- 10.4 (SD); week 48: 6.60 +/- 4.67 (SD); p=0.007 
(paired t-test), Figure 6.4), which was not replicated in the placebo arm (p=0.102, paired t-test).  
 
 
 
Figure 6.4: Sputum production at baseline and either after 48 weeks of erythromycin treatment (left 
panel), or after 48 weeks of placebo (right panel) in the sub-group selected for gene expression 
analysis. Lines connect values within individual patients. Significance determined by paired t-test. 
Significant values denoted by an asterisk (*). ns = not significant. 
 
Quality of life, as measured by the St George’s Respiratory Questionnaire (SGRQ), was also 
improved (demonstrated by a >4 point reduction in the SGRQ) in the erythromycin treated arm 
(erythromycin group, week 48: 28.8 +/- 14.5 (SD); baseline: 33.9 +/- 14.5 (SD); p=0.030 (paired t-
test), Figure 6.5), which was not seen in the placebo group (p=0.81). 
 
Figure 6.5: St George Respiratory Questionnaire at baseline and either after 48 weeks of 
erythromycin treatment (left panel), or after 48 weeks of placebo (right panel) in the sub-group 
selected for gene expression analysis (n=15 placebo, n=11 erythromycin). A four-point change 
represents a clinically significant difference. Lines connect values within individual patients. 
Significance determined by paired t-test. Significant values denoted by an asterisk (*). ns = not 
significant. 
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6.3.5  Effect of Erythromycin on P. aeruginosa In Vivo  
6.3.5.1 Effect of Erythromycin on P. aeruginosa Levels 
P. aeruginosa abundance in induced sputum was determined by amplification of the oprL gene 
using the TaqMan assay described in Chapter 4. Bacterial levels were determined by comparison to 
a standard curve generated from known concentrations of cultured P. aeruginosa. The standard 
curve was simultaneously generated in the same PCR reaction. No significant impact on P. 
aeruginosa levels was observed after 48 weeks in patients receiving low dose erythromycin 
compared with placebo, as measured by qPCR (erythromycin: 6.25 +/- 1.48 (SD); placebo 5.38 +/- 
1.32; p = 0.129, unpaired t-test), Figure 6.6. 
 
 
 
Figure 6.6: Pseudomonas aeruginosa bacterial load in sputum derived from patients treated with 
erythromycin or placebo for 48 weeks determined by qPCR amplification of oprL. P. aeruginosa 
levels were determined by comparison to a standard curve which was simultaneously generated in 
the same PCR reaction. Points represent mean Log10 colony forming units per millilitre of sputum 
of duplicate measures. Horizontal bars represent median values, the box represents the interquartile 
range. Significance determined by unpaired t-test. ns = not significant. 
 
Compared to baseline, there was a statistically significant increase in bacterial levels in both 
erythromycin and placebo groups after 48 weeks. This difference was greater in the erythromycin 
group; Erythromycin group: Baseline 3.84 Log10 cfu/mL (IQR, 2.72-6.34) vs. Week 48 6.87 Log10 
cfu/mL (IQR, 3.38-7.25); n=11; p=0.006 (paired t-test); Placebo group: Baseline 4.57 Log10 cfu/mL 
(IQR, 2.47-6.03) vs. Week 48 4.95 Log10 cfu/mL (IQR, 4.16-6.74); n=13; p=0.040 (paired t-test); 
Figure 6.7. Thus, while the erythromycin group showed significant improvements in exacerbation 
frequency and sputum volume, there was no lessening of the P. aeruginosa abundance in sputum. 
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In this case, it can be assumed that the presence of bacterial DNA per se does not contribute to the 
overall benefit seen with erythromycin treatment in vivo. 
 
 
 
Figure 6.7: Pseudomonas aeruginosa bacterial load in sputum derived from patients treated with 
erythromycin (left) or placebo (right) for 48 weeks, compared with baseline bacterial load (n=15 
placebo, n=11 erythromycin). Points represent mean Log10 colony forming units per millilitre of 
duplicate measures. Significance determined by paired t-test. Significant values denoted by an 
asterisk (*). 
 
6.3.5.2 Effect of Erythromycin on P. aeruginosa Gene Expression 
The previous section demonstrated that there was no difference in P. aeruginosa bacterial DNA 
levels in sputum between erythromycin or placebo treated groups after 48 weeks. It also 
demonstrated, that, in this sub-group, there was an overall increase in total P. aeruginosa bacterial 
DNA per volume of sputum in both arms, which was more pronounced in the erythromycin treated 
group. In order to assess whether bacterial activity, rather than bacterial density, is altered in the 
presence of erythromycin, expression of genes central to P. aeruginosa quorum sensing were 
assessed directly in induced sputum. 
 
Firstly, expression of mexX was assessed. MexX is a P. aeruginosa drug efflux pump, up-regulated 
in the presence of erythromycin. An expected increase in the expression of mexX was observed, but 
did not reach statistical significance (erythromycin: fold change 1.55 (IQR, 0.13-4.00), n=11 vs. 
placebo: fold change 1.00 (IQR, 0.10-2.04), n=15; p=0.604, Mann-Whitney U test), Figure 6.8 left 
panel. However, when samples were compared to those collected from the same patient at baseline 
(48 weeks prior), a significant up-regulation in mexX expression over the period of the trial, in the 
presence of erythromycin was seen (baseline: fold change 1.00 (IQR 0.09–6.00) vs. 48 weeks: fold 
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change 73.92 (IQR 7.09-124.50); p=0.016, Wilcoxon matched pairs rank test), Figure 6.8 right 
panel.  
 
Figure 6.8: Left Panel: MexX expression in induced sputum from patients treated with low dose 
erythromycin for 48 weeks compared to placebo determined by RT-PCR (n=15 placebo, n=11 
erythromycin). Right Panel: Paired mexX expression in induced sputum at baseline and after 48 
weeks treatment with low dose erythromycin. Points represent mean fold change of duplicate 
measures, normalised to expression levels of two housekeeping genes (rpoD and rpsL). 
Significance determined by Wilcoxon matched pairs rank test. Significant values denoted by an 
asterisk (*); ns = not significant. 
 
Secondly, MexB, a gene encoding an efflux pump that is not under quorum sensing regulation, and 
which is not involved in removal of erythromycin from the cell, showed no difference in expression 
level in sputum from patients receiving erythromycin when compared to placebo (erythromycin: 
fold change 0.661 (IQR, 0.36-1.64), n=11 vs. placebo: fold change 1.000 (IQR, 0.38-3.60), n=15; 
p=0.349, Mann-Whitney U test), Figure 6.9. 
 
Figure 6.9: MexB expression in induced sputum from patients treated with low dose erythromycin 
for 48 weeks compared to placebo determined by RT-PCR (n=15 placebo, n=11 erythromycin). 
Points represent mean Log10 fold change of duplicate measures, normalised to expression levels of 
two housekeeping genes (rpoD and rpsL). Horizontal bars represent median values. Significance 
determined by Mann-Whitney U-test; ns = not significant.  
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Expression of several quorum sensing controller genes, including lasR, lasI, rhlR, and rhlI were 
assessed in induced sputum samples. Expression of pqsA, the first gene to be activated in the 
synthesis of PQS, was also assessed. A significant reduction was observed in the expression of both 
lasR (erythromycin: fold change 0.066 (IQR, 0.008–0.852) n=11 vs. placebo: fold change 1.00 
(IQR, 0.047-3.052) n=15; p=0.047, Mann-Whitney test), Figure 6.10 left panel, and pqsA 
(erythromycin: fold change 0.065 (IQR, 0.020-0.254) n=11 vs. placebo: fold change 1.00 (IQR, 
0.207-4.311) n=15; p=0.016, unpaired t-test), Figure 6.10 right panel, in patients who had received 
erythromycin, compared to controls.  
 
 
 
Figure 6.10: lasR and pqsA expression in induced sputum from patients treated with low dose 
erythromycin for 48 weeks compared to placebo determined by RT-PCR (n=15 placebo, n=11 
erythromycin). Points represent mean Log10 fold change of duplicate measures, normalised to 
expression levels of two housekeeping genes (rpoD and rpsL). Horizontal bars represent median 
values, the box represents the interquartile range. Significance determined by Mann-Whitney U-test 
(lasR) and unpaired t-test (pqsA). Significant values denoted by an asterisk (*). 
 
 
A trend to a reduction was observed in the expression of both lasI (erythromycin: fold change 0.118 
(IQR, 0.012-1.44) n=11 vs. placebo: fold change 1.00 (IQR, 0.058-3.99) n=15; p=0.121, unpaired t-
test), Figure 6.11 left panel, and rhlR (erythromycin: fold change 0.175 (IQR, 0.073-1.305) n=11 
vs. placebo: fold change 1.00 (IQR, 0.036-7.258) n=15; p=0.574, unpaired t-test), Figure 6.11 right 
panel, in patients who had received erythromycin, compared to controls, but did not reach statistical 
significance. 
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Figure 6.11: lasI and rhlR gene expression in induced sputum from patients treated with low dose 
erythromycin for 48 weeks compared to placebo determined by RT-PCR (n=15 placebo, n=11 
erythromycin). Points represent mean Log10 fold change of duplicate measures, normalised to 
expression levels of two housekeeping genes (rpoD and rpsL). Horizontal bars represent median 
values, the box represents the interquartile range. Significance determined by unpaired t-test; ns = 
not significant. 
 
 
6.3.5.3 Effect of Erythromycin on Inflammation 
In order to determine whether this change in quorum sensing gene expression had any effect on 
inflammation, sputum concentrations of IL-8, IL-1β and neutrophil content were assessed. This 
work was performed in collaboration with Dr Alice Chen, Mater Research, University of 
Queensland. Despite a significant inhibitory effect of erythromycin on P. aeruginosa quorum 
sensing, no effect of macrolide on inflammation was observed in this subgroup. IL-8 (erythromycin: 
298.4 pg/mL (IQR, 89.0-538.7) n=11 vs. placebo: 650.9 pg/mL (IQR, 151.7-805.0) n=15; p=0.384, 
Mann-Whitney U test), Figure 6.12 left panel. IL-1β (erythromycin: 3103 pg/mL (IQR, 813.4-7514) 
n=11 vs. placebo: 4332 pg/mL (IQR, 651.7-25435) n=15; p=0.693, Mann-Whitney U test), Figure 
6.12 right panel.  
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Figure 6.12: IL-8 and IL-1β measured in induced sputum from patients treated with low dose 
erythromycin for 48 weeks compared to placebo determined by ELISA (n=15 placebo, n=11 
erythromycin). Points represent the mean of duplicate measures. Horizontal bars represent median 
values. Significance determined by Mann-Whitney U test; ns = not significant. 
 
Additionally, there was also no difference in absolute neutrophil count (erythromycin: 423.5 
cells/mL (IQR, 396.5-451.0) n=11 vs. placebo: 416.5 cells/mL (IQR, 408.8-442.0) n=15; p=0.838, 
Mann-Whitney U test), Figure 6.13, or percentage neutrophil count in the presence of erythromycin 
in this sub-group. 
 
 
 
Figure 6.13: Absolute neutrophil count as measured in induced sputum from patients treated with 
low dose erythromycin for 48 weeks compared to placebo (n=15 placebo, n=11 erythromycin). 
Horizontal bars represent median values. Significance determined by Mann-Whitney U test; ns = 
not significant. 
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6.3.5.4 Quorum Sensing Gene Expression Levels and Clinical Measures 
To determine whether the level of relative gene expression correlated with specific clinical 
outcomes, levels of quorum sensing genes from the placebo arm were correlated with lung function, 
inflammatory markers, daily sputum production, days of additional antibiotic therapy, 
exacerbations, and quality of life. There was no significant correlation seen between quorum 
sensing gene expression and any of these parameters. Correlations with expression levels of pqsA 
are reported as an example, Figure 6.14. 
 
 
 
Figure 6.14: Correlations between gene expression levels of pqsA (x axis) and clinical variables (y 
axis) including (from top right to bottom left) daily sputum production, CRP, number of 
exacerbations, days of antibiotics, FEV1 % predicted and SGRQ score. The dotted line represents 
the line of linear regression. Assessments were performed on the placebo arm (n=15). 
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6.3.5.5 Effect of Erythromycin on P. aeruginosa Quorum Sensing Molecules 
Despite there being no significant effect on P. aeruginosa bacterial load in the airways of non-CF 
bronchiectasis subjects, a significant reduction in quorum sensing gene expression was found. In 
order to determine whether this reduction in gene expression lead to a similar reduction in the 
production of the P. aeruginosa quorum sensing molecules themselves, sputum levels of quorum 
sensing molecules were measured using both mass spectrometry and biosensors.  
6.3.5.5.1 Justification of Samples Used 
Of the 41 samples which were P. aeruginosa positive after 48 weeks of erythromycin or placebo 
treatment, there were 39 samples with enough material available for further analysis. Samples were 
assessed for quorum sensing molecules in tandem via two different methods, mass spectrometry 
and with the use of specific biosensors. Samples were extracted in ethylacetate and solubilised in 
methanol, as previously described (section 4.12.1), and divided in two before being immediately 
placed on specific biosensors, or stored at -20oC prior to analysis by mass spectrometry. 
6.3.5.5.2 Biosensors 
Duplicate extractions were placed on the relevant biosensor (section 4.12.3) and incubated at 37oC 
for 24 hours. Peak luminescence occurred after 8.5 hours for PQS. Peak luminescence was divided 
by the simultaneously recorded absorbance level (OD600) at the same time-point to standardise the 
data. Samples were analysed in duplicate and mean values for each technical duplicate were 
compared between the treatment and placebo arms. There was no difference in peak luminescence 
between erythromycin and placebo groups after 48 weeks of erythromycin treatment (PQS: 
Erythromycin: 1094 RU/OD600 +/- 196.5 (SD) n=20 vs. Placebo 1093 RU/OD600 +/- 148.7 (SD) 
n=19; p=0.99, unpaired t-test).  
 
It must be noted however that, due to the low volume of the original sample used, all of the values 
were just below the lower limit of the simultaneously assessed standards, making non-extrapolated 
quantification impossible. Therefore the data represented here reflects the peak luminescence 
divided by the absorbance for each sample (Figure 6.15). 
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Figure 6.15: PQS measured by bioluminescence in ethyl acetate extracts of induced sputum from 
patients treated with low dose erythromycin for 48 weeks compared to placebo (n=19 placebo, 
n=20 erythromycin). Points represent mean luminescence/absorbance of duplicate measures. 
Horizontal bars represent median values. Significance determined by unpaired t-test test; ns = not 
significant. 
 
 
6.3.5.5.3 Mass Spectrometry 
From the biosensor data, quorum sensing molecules were detected in low abundance in this group. 
Our mass spectrometry technique, though highly specific, is less sensitive. Additionally, as has been 
previously described [100], quorum sensing molecules are expected to be present in low abundance 
in sputum. Therefore, for mass spectrometric analysis, only those samples with greater than log 6 
cfu/ml P. aeruginosa (as determined by qPCR amplification of the oprL gene) were used. Twenty-
two samples had P. aeruginosa levels above this threshold, 14 of which had an adequate volume 
(>2mL) of 1:3 diluted sputum available for processing.  
 
No difference was observed in peak area measurements between erythromycin and placebo groups 
after 48 weeks of erythromycin treatment (PQS: erythromycin: 6847 peak area (IQR, 5621-7096) 
n=7; placebo 6847 peak area (IQR, 5546-8138) n=7; p=0.71 Mann-Whitney test). Abundance was 
very low, with values bordering on the lower limit of the detection threshold making quantitation 
problematic, Figure 6.16. Thus, quorum sensing molecules were detectible, but not quantifiable in 
this analysis. 
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Figure 6.16: PQS measured by mass spectrometry in ethyl acetate extracts of induced sputum from 
patients treated with low dose erythromycin for 48 weeks compared to placebo (n=7). Points 
represent mean peak area of duplicate measures. Horizontal bars represent median values. 
Significance determined by Mann-Whitney test; ns = not significant. 
 
6.3.6 Interaction of Quorum Sensing Molecules with the Mammalian Host 
The interaction of quorum sensing molecules with the human host is somewhat confusing in the 
literature. When quorum sensing molecules are added to human epithelial cells, there is a potent 
inflammatory response, particularly with regards to IL-8 release, however, when added to immune 
cells (such as macrophages) there appears to be a down regulation of the immune response. Reports 
use a wide range of concentrations of quorum sensing molecules and may explain the difference 
observed in these experiments. In order to determine whether concentration of quorum sensing 
molecules was important in the stimulation if IL-8 from epithelial cells, the well characterised 
human respiratory epithelial cell line (16HBE) was treated with varying concentrations of the 
quorum sensing molecules PQS and 3-oxo-C12. Expression of IL-8 was measured with RT-PCR 
and normalised to the expression of the housekeeping gene β-actin. IL-8 fold change is expressed 
relative to the median of the control group. Importantly there was no increase or decrease in IL-8 
expression in the vehicle control group (V 1:1000, V 1:100000) at either concentration used. With 
100 µM PQS or 3-oxo-C12 HSL, there was a significant increase in IL-8 expression in 16-HBE 
cells (PQS and 3-oxo-C12 HSL: control vs. 100 µM; p<0.001, ANOVA with Tukey’s multiple 
comparison post test). Concentrations of either PQS or 3-oxo-C12 HSL of 10 µM and lower did not 
lead to a significant stimulation of IL-8 expression in 16HBE cells compared with control. IL-8 
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expression was significantly lower with concentrations of 10 µM and less, compared with 100 µM 
PQS or 3-oxo-C12 HSL. Representative data are shown in Figure 6.17. 
 
 
 
Figure 6.17: Log10 IL-8 gene expression in 16HBE cells incubated for 15 hours (overnight) with 
either PQS or 3-oxo-C12 at concentrations varying from 100 to 0.625 µM; n=4). Log10 fold change 
expressed relative to the housekeeper β-actin and normalised to the median of the control group. 
Points represent mean values of duplicate PCR reactions from one well. Horizontal bars represent 
median values, the box represents the interquartile range. Significance determined by ANOVA with 
Tukey’s multiple comparison post test. Significant values denoted by an asterisk (*). 
 
 
	 183 
6.4  DISCUSSION 
The aim of this study was to investigate the inhibition of P. aeruginosa quorum sensing by 
macrolide directly within the airways of non-CF bronchiectasis patients receiving long-term, low 
dose erythromycin. This study has demonstrated that central P. aeruginosa quorum sensing genes 
(lasR and pqsA) are inhibited in the presence of erythromycin, despite there being no reduction in 
total P. aeruginosa bacterial load as measured by qPCR amplification of bacterial DNA. Previous 
investigations have relied on P. aeruginosa isolates taken from clinical samples, cultured and 
assessed in vitro [54]. The use of such approaches raises questions about how representative 
individual isolates are of the wider pseudomonal populations in the airways [42], as well as the 
extent to which the P. aeruginosa phenotype is altered by the artificial conditions of the culture 
environment [18, 149]. The data presented in Chapter 5 demonstrated the significant variability in 
bacterial response to culture condition, media and erythromycin, supporting the fact that in vitro 
assessment of bacterial isolates demonstrates only the potential of the bacteria to exhibit a specific 
phenotype in vivo, not the actual phenotype of that bacterium at a specific time point within the 
airway. This chapter, for the first time in non-CF bronchiectasis, addressed these issues through the 
analysis of gene expression levels based on mRNA transcripts extracted directly from induced 
sputum from patients administered low dose macrolide for an extended period under trial 
conditions. Induced sputa from a sub-group of patients recruited to the well described BLESS trial 
were analysed. Importantly, a similar clinical benefit of erythromycin was seen in this sub-group of 
patients with respect to exacerbations and sputum weight, and these subjects were indistinguishable 
from the original BLESS cohort, supporting the generalizability of these data.  
 
In order to ensure that erythromycin was not affecting P. aeruginosa bacterial load, and potentially 
confounding the results by simply reducing the number of bacteria able to quorum sense, 
quantification of total P. aeruginosa bacterial load by qPCR was performed. There was no 
detectable difference in P. aeruginosa load between the treatment and placebo groups, consistent 
with previously reported data [10], and supportive of the fact that erythromycin is not bactericidal 
to P. aeruginosa. Despite this, erythromycin is relevant to P. aeruginosa physiology, as 
demonstrated by the significant down-regulation of the key quorum sensing genes lasR and pqsA. 
Simultaneously assessed control genes were not affected by erythromycin. These findings support a 
differential and sustained effect of erythromycin on specific patterns of P. aeruginosa gene 
expression in vivo, with a significant inhibitory effect on genes controlled by quorum sensing. 
Azithromycin has previously been shown to selectively inhibit quorum sensing controlled genes in 
vitro [74] (using cultured laboratory strains) and in vivo [17] (directly from tracheal aspirates using 
similar techniques to this study). However, no previous studies have addressed the effect of 
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erythromycin on quorum sensing directly from the sputum of non-CF bronchiectasis subjects. It is 
important to reiterate that this effect on gene expression was independent of an effect on P. 
aeruginosa bacterial density in the airways.  
 
Analysis of this subset of patients demonstrated a lack of a significant difference in airway 
inflammation, as measured by IL-8, IL-1β and neutrophil count, in those patients receiving 
erythromycin compared to controls. This is despite a reduction in exacerbation frequency (in 
keeping with the reduction in exacerbation rate reported in the wider BLESS study) and sputum 
production. This observation suggests that, within the limits of the inflammatory mediators assessed 
as part of this study, a direct anti-inflammatory effect of the drug is unlikely to contribute solely to 
the clinical benefit seen in this study, contrary to previous literature [154]. However, the significant 
reduction in sputum amount is likely to be important and is consistent with previously documented 
suppressive effects of macrolide on sputum production [7, 155]. Whilst there was no difference in 
inflammation and bacterial density per mL of sputum, there was less sputum overall, suggesting 
less total inflammation and bacteria within the lung. Importantly, gene expression data generated 
here is expressed relative to the expression of two intrinsically expressed housekeeping genes and is 
not dependent upon bacterial load nor sputum amount. Thus, in addition to there being less sputum 
overall, the bacteria present in the erythromycin treated sputum display significantly less quorum 
sensing activity than those in the placebo arm. From this data, it can be said that erythromycin not 
only reduces mucus hyper-secretion (potentially by inhibiting exuberant mucin secretion [155]), but 
also inhibits quorum sensing activity, which, in turn, based on previous findings, can also inhibit 
mucin secretion by reducing the 3-oxo-C12-HSL stimulation of MUC5AC secretion [104]. We 
were also able to show that low concentrations of quorum sensing molecules (nM vs. µM) actually 
do not promote significant inflammatory cytokine release from airway epithelial cells. While this is 
contrary to some previous studies [102], it supports the hypothesis that by reducing high 
concentrations of quorum sensing molecules in the airway, the amount of epithelial inflammation is 
less. As described however, we were unable to detect a significant difference in markers of 
inflammation with erythromycin therapy in this sub group. Similarly, and most likely due to their 
low abundance in sputum, we were unable to reliably detect and measure the concentration of 
quorum sensing molecules.  
 
In order to determine whether levels of quorum sensing gene expression were associated with 
important clinical outcomes, specific measures of lung function, sputum, exacerbation frequency 
and CRP were correlated with expression levels of quorum sensing genes in the subjects who 
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received placebo. No significant correlation between quorum sensing gene expression and specific 
clinical outcomes was observed.  
6.5  LIMITATIONS 
The main limitation of this study was the restricted amount of airway sample available for analysis. 
Whilst the number of subjects included was adequate for gene expression analysis, the volume of 
induced sputum was limited, with volumes around 0.25 mL available for analysis. This was 
particularly relevant to the mass spectrometric assessments. A larger volume of sputum may have 
allowed quantification of quorum sensing molecules in the airways. The use of sputum is 
potentially a limitation as there is no absolute guarantee that the whole lung is sampled. However, 
sputum induction is conceptually superior to BAL, where only a discrete area of lung is sampled 
without the ability to accurately determine dilution factors for essential calculations regarding 
bacterial density etc. Secondly, samples were obtained from the BLESS cohort [7], which was 
powered to detect a difference in exacerbation rate, not P. aeruginosa gene expression, nor 
correlates with clinical outcomes. Furthermore, the study cohort necessarily included only the sub-
group of the BLESS cohort positive for P. aeruginosa at the end point of the study. It should be 
noted however, that the BLESS randomisation was stratified for P. aeruginosa and there were no 
demographic or baseline clinical differences between the subgroups analysed here. Further, the 
primary clinical outcomes were the same in this cohort as in BLESS. It is acknowledged that 
alterations in gene expression do not always lead to a relevant change in protein production. 
However, a number of in vitro studies [21, 104], including this study (Chapter 5), have 
demonstrated a strong correlation between down-regulation of gene expression, and an associated 
reduction in pathogenicity traits. This analysis was focused on the expression of a discrete group of 
genes, based on their recognised role in quorum sensing regulation. Global gene expression analysis 
may provide further insight into the complexities of the P. aeruginosa quorum sensing system. 
Finally the analysis of a wider group of inflammatory markers may identify anti-inflammatory 
effects of erythromycin which were not assessed in this study.  
6.6  SUMMARY 
This study has demonstrated the inhibition by macrolide of P. aeruginosa quorum sensing within 
the airways of non-CF bronchiectasis patients receiving long-term, low dose erythromycin with 
ongoing clinical benefit despite no change in total bacterial load. These findings hint at a possible 
mechanism of benefit of macrolide in P. aeruginosa colonised inflammatory airways diseases, 
beyond classical antimicrobial or anti-inflammatory pathways. However, this study was 
underpowered to detect correlations with gene expression levels of central quorum sensing genes 
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and clinical outcomes, nor changes in quorum sensing controlled proteins such as PQS. Although 
we were not able to show a significant correlation between clinical outcomes and gene expression 
measures, these data lend weight to the hypothesis that inhibition of bacterial virulence and 
behaviour may underpin the efficacy of macrolide in the treatment of bronchiectasis and warrants 
further assessment in a larger randomised controlled trial. Exploration of the interaction of quorum 
sensing molecules with activators of mucus production is also important and may help to explain 
the association between reduced sputum volume and the concurrent reduction in quorum sensing 
activity. 
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CHAPTER 7: THE ROLE OF PPARγ  AND ITS INTERACTION WITH P. AERUGINOSA 
IN NON-CF BRONCHIECTASIS 
7.1  INTRODUCTION 
The relationship between P. aeruginosa infection, inflammation, and airway damage is complex. P. 
aeruginosa is known to trigger production of pro-inflammatory mediators and, conversely, there is 
evidence that P. aeruginosa quorum sensing molecules might also contribute to disease through 
dysregulation of host immunity. Acyl-homoserine lactones (AHLs) are chemically analogous to 
human lipidic signalling molecules. Bacterial AHLs have been shown to enter, and function in, 
mammalian cells [61, 107, 108]. One way that P. aeruginosa might interfere with the host immune 
response is through the suppression of PPARγ production and/or action/transcriptional activity. 
PPARγ is a nuclear transcription regulator whose primary function is to bind to exogenous lipid-like 
ligands and then interact with specific PPAR response elements on nuclear DNA to modulate gene 
expression. Inhibition of PPARγ has been shown to produce a pro-inflammatory phenotype by 
interfering with its inhibitory action on the target genes of NFκB [113].  
 
PPARγ production has been shown to be down-regulated in inflammatory airways diseases, 
including COPD [114] and cystic fibrosis [115], suggesting its involvement in the underlying 
pathology. The mechanism by which PPARγ production is suppressed is not known. However, in 
vitro studies have demonstrated that P. aeruginosa AHLs [111, 115, 156] suppress expression of 
PPARγ in various cell types including epithelial and endothelial cells. The paroxinases, particularly 
paroxinase 2 (PON2), generally inhibit the function of AHL’s by breaking them down via 
lactynolysis, and may be relevant in this context [115]. 
 
In this chapter, the hypothesis that expression of PPARγ and PON2 is down-regulated in the 
airways of non-CF bronchiectasis patients is tested. Further, the hypothesis that the relative level of 
expression of PPARγ is inversely correlated to P. aeruginosa bacterial load was also explored. 
Finally, it was also investigated empirically in vitro whether the AHL 3-oxo-C12-HSL, and the 
quinolone, PQS, inhibit immune cell production of PPARγ. 
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7.2  METHODS 
7.2.1  Patient Selection 
Subjects in this study were participants in the BLESS trial [7]. A subgroup of 41 participants 
underwent bronchoscopic sampling at baseline, along with 20 healthy controls. The current analysis 
is based upon the 35 bronchoscopy subjects and 20 healthy controls from whom sufficient 
bronchoalveolar lavage (BAL) sample was obtained for gene expression analysis. Table 7.1 shows 
the baseline clinical characteristics of these two groups.  
 
 Bronchiectasis 
(n=35) 
Control 
(n=20) 
Age, mean (SD), y 62.8 (6.6) 35.8 (11.8) 
Female sex, No. (%) 25 (71.4) 12 (60.0) 
FEV1 (post bronchodilator) % (SD) 75.8 (12.5) 100.2 (12.0) 
P. aeruginosa PCR positive, no. (%) 31 (88.6) 0 (0) 
H. influenzae PCR positive, no (%) 13 (37.1) 0 (0) 
Exacerbations in prior year, mean 
(SD) 
1.9 (1.7) 0 (0) 
Ex-smokers, No. (%) 4 (11.4) 0 (0) 
Pack years, mean (SD) 0.2 (0.6) 0 (0) 
Sputum weight g, mean (SD) 16.2 (10.1) N/A 
 
Table 7.1: Baseline characteristics of the 35 bronchiectasis subjects and 20 healthy control subjects 
included in this analysis. 
 
All 20 healthy control samples were available and were therefore indistinguishable from the 
original cohort. Six subjects in the non-CF bronchiectasis group did not have sufficient BAL sample 
for analysis, however, there was no difference between this group and the original 41 patients 
recruited for bronchoscopy in the trial (Table 7.2). 
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 Bronchiectasis 
(n=35) 
BLESS  
(n=41) 
Age, mean (SD), y 62.8 (6.6) 62.9 (6.9) 
Female sex, No. (%) 25 (71.4) 28 (68.0) 
FEV1 (post bronchodilator) % 
(SD) 
75.8 (12.5) 76.8 (14.4) 
Ex-smokers, No. (%) 4 (11.4) 5 (12) 
Pack years, mean (SD) 0.2 (0.6) 0.2 (0.6) 
Sputum weight g, mean (SD) 16.2 (10.1) 16.8 (11.0) 
 
Table 7.2: Baseline characteristics of the 35 bronchiectasis subjects vs. the original 41 BLESS 
subjects recruited to the bronchoscopy sub group. 
 
7.2.2  Sample Processing 
Gauze-filtered BAL was separated into sterile specimen jars and transported to the laboratory on 
ice. One portion was sent for cell counting. BAL was then further divided into 1 mL aliquots. A 
minimum of 2 aliquots were frozen rapidly as crude suspension and stored at -80oC prior to DNA 
extraction. A minimum of 2 further aliquots were centrifuged at 500 x g for 5 min at 4°C to pellet 
large cellular debris. The pellet was then frozen rapidly and stored at -80oC prior to RNA 
extraction. Matched, spontaneously expectorated sputum was frozen rapidly and stored at -80oC 
until subsequent molecular analysis.  
7.2.3  Cell Counts 
BAL was processed within 60 minutes of collection. After filtration, the sample was centrifuged, 
the supernatant aspirated and the cell pellet resuspended in PBS for cell counting in the presence of 
trypan blue and both Blue and Red Rapi-Diff cell stains. 
7.2.4  DNA Extraction 
DNA extraction for both PCR and microbiome analysis were performed on 200 µL portions of 
paired induced sputum using a combination of physical disruption and a phenol/chloroform-based 
methodology as described previously [10]. This was completed by A/Professor Geraint Rogers at 
Kings College, London. 
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7.2.5  RNA Extraction and cDNA Synthesis 
RNA extraction from BAL was performed using an on-column method as per the manufacturer’s 
instructions for RNeasy RNA Extraction Kit described in detail in section 4.11. cDNA synthesis for 
the non-amplified RNA samples was performed using the iScript cDNA Synthesis Kit as per the 
manufacturer’s instructions. 1 µg RNA from each sample was used as template in each cDNA 
synthesis reaction. 
7.2.6  PPARγ  Gene Expression by RT-PCR 
RT-PCR to determine PPARγ and PON2 gene expression was performed. The total reaction volume 
was 7.5 µL with the following components: Sybr 3.75 µL, Primer (F+R) 200 nM, 0.75 µL, ROX 
0.15 µL, H2O 0.35 µL, Template 2.5 µL. Thermal cycling conditions were as follows: Hold 95oC 2 
min, Cycle (x40), 95oC 30 s, 60oC 30 s, 72oC 30 s, Hold 72oC 2 min. 
 
Each reaction was performed in duplicate and normalized to the expression of the housekeeping 
gene, β-actin, with slightly different cycling conditions: Hold 95oC 2 min, Cycle (x40), 95oC 15 s, 
59oC 45 s, 72oC 20 s, Hold 72oC 20 s. All products underwent melt curve analysis. 
 
Primer sequences were as follows (optimized from Griffin et al 2012 [115]): 
PPARγ forward 5'-AGCTGAACCACCCTGAGTCC-3' 
PPARγ reverse 5'-TCATGTCTGTCTCCGTCTTCTTG-3' 
PON2 forward 5'-GCCAACAATGGGTCTGTTCTCC-3' 
PON2 reverse 5'-CAGCTTCCCATCATACACTGAGGC-3' 
β-actin forward 5'-GGCTGGCCGGGACCTGACTGA-3' 
β-actin reverse 5'-CTTCTCCTTAATGTCACGCACG-3' 
7.2.7  Quantitative PCR For The Determination of Bacterial Load 
Total bacterial levels were determined on paired BAL samples, using a TaqMan assay directed 
against a conserved region of the 16S rRNA gene, as described previously [137]. P. aeruginosa 
levels were determined using a TaqMan assay, in which a 117 bp region between positions 330 to 
447 of the P. aeruginosa oprL gene was amplified, as described previously [131]. H. influenzae 
density was determined using a TaqMan assay, in which a 90-bp region between positions 518 to 
608 of the H. influenzae hel gene was amplified [10].  
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7.2.8  PBMC Extraction and Treatment 
Detailed methods are described in section 4.15.3. Briefly, peripheral blood mononuclear cells 
(PBMCs) were isolated from fresh blood of 4-5 healthy control subjects using a Ficoll-Hypaque 
layering technique. Cells were resuspended in DMEM (low glucose, +pyruvate, +glutamine) + 10% 
FCS + 1% penicillin streptomycin and seeded at 1x105 cells per well of a 24 well plate (at 2x105 
cells/mL).  
 
PBMCs were activated with the addition of 25 ng PMA and 250 ng ionomycin per well, and treated 
with 10 µM 3-oxo-C12-HSL or 10 µM PQS diluted in DMSO (1:10,000 final concentration). 
PBMCs were incubated overnight before harvesting into lysis buffer prior to RNA extraction using 
the High Pure RNA extraction kit as per manufacturer’s protocol. 
7.2.9  Clinical Correlates 
Lung function and assessment of clinical measures were performed at enrolment. Spirometry was 
performed pre and post inhalation of salbutamol bronchodilator. Serum CRP was measured at each 
visit. A 24-hour sputum sample and a spontaneously expectorated sputum sample were collected at 
each visit for volume quantification, microbiology and differential cell count. Symptom and quality 
of life were assessed by standard questionnaires (LCQ and SGRQ).  
7.3  RESULTS 
7.3.1  PPARγ  Gene Expression in the Airways of Non-CF Bronchiectasis Subjects  
PPARγ gene expression in BAL fluid taken from macrolide naïve non-CF bronchiectasis subjects 
was determined by qRT-PCR and compared with healthy controls. Gene expression levels were 
expressed relative to the expression of the stably expressed housekeeping gene, β-actin, and 
normalised to the median of the control group. PPARγ gene expression was significantly lower in 
the airways of non-CF bronchiectasis subjects compared with healthy controls (control: 1.00, IQR 
0.55-1.44, n = 20 vs. Bronchiectasis: 0.49, IQR 0.12–0.89; n = 35; p<0.001, Mann-Whitney U test), 
Figure 7.1.  
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Figure 7.1: Relative PPARγ gene expression, as determined by RT-PCR in BAL -derived cells 
from healthy control volunteers and macrolide naïve non-CF bronchiectasis subjects. Gene 
expression levels were expressed relative to the expression of the housekeeping gene, β actin and 
normalised to the median of the control group. Points represent individual subjects, columns 
represent mean values. Error pars represent the standard deviation. Significance determined by 
Mann-Whitney U test. Significant values denoted by an asterisk (*). 
 
The paroxinases have been shown to increase the degradation of lipid like molecules such as 3-oxo-
C12 [109]. In CF, the paroxinase PON2 has been shown to be expressed in lower levels in subjects 
colonised with P. aeruginosa compared with those without P. aeruginosa infections. It was 
therefore hypothesised that, in non-CF bronchiectasis subjects, PON2 mRNA expression would also 
be lower, however, this was not demonstrated in these subjects, Figure 7.2. 
 
 
Figure 7.2: Relative PON2 gene expression, as determined by RT-PCR in BAL -derived cells from 
healthy control volunteers and macrolide naïve non-CF bronchiectasis subjects. Gene expression 
levels were expressed relative to the expression of the housekeeping gene, β actin and normalised to 
the median of the control group. Points represent individual subjects, columns represent mean 
values. Error pars represent the standard deviation. Significance determined by Mann-Whitney U 
test; ns = not significant. 
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7.3.2  The Effect of Bacteria on the Expression of PPARγ  
To assess whether the down-regulation of PPARγ in non-CF bronchiectasis was due to the presence 
of particular bacterial respiratory pathogens, species-specific RT-PCR was carried out on matched 
BAL samples, and subsequently correlated with the expression of PPARγ. There was a significant 
negative correlation of PPARγ gene expression with total P. aeruginosa bacterial load (r=-0.53, 
n=31; p=0.002; Figure 7.4). 
 
Figure 7.4: PPARγ gene expression levels (y axis) correlated with P. aeruginosa bacterial load (x 
axis) as determined by PCR. There was a significant negative correlation of PPARγ gene expression 
with P. aeruginosa (r = -0.53, n=31; p=0.002). Dotted line represents the line of linear regression. 
 
This correlation with P. aeruginosa was not seen with either total bacterial load (as measured by 
16S qPCR (r=0.24, p=0.194)) or for the other most commonly prevalent microorganism, H. 
influenzae (r=0.30, p=0.325), Figure 7.5. 
 
 
Figure 7.5: PPARγ gene expression levels (y axis) correlated with total bacterial load (panel A, 
n=31) and H. influenzae, as determined by species specific PCR (panel B, n=13), x axis.  
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To further investigate this relationship with P. aeruginosa, PPARγ gene expression was assessed 
relative to the amount of P. aeruginosa in the airways. P. aeruginosa bacterial density was divided 
into 3 groups; <1 cfu/mL (essentially representing absence of P. aeruginosa); 1.1-4 cfu/mL 
(representing low level colonisation with P. aeruginosa) and >4.1 cfu/mL (representing high level 
P. aeruginosa colonisation). There was a significant reduction in PPARγ gene expression in those 
patients with high levels of P. aeruginosa colonisation compared with no or low P. aeruginosa 
(Low 0.953 (IQR 0.336 – 1.17) n = 11 vs. High 0.087 (IQR 0.023 – 0.498) n = 13; p=0.002, Mann-
Whitney U test, Figure 7.6), consistent with the correlation seen above. 
 
Figure 7.6: PPARγ gene expression levels in BAL-derived cells (y axis) divided into no, low and 
high P. aeruginosa bacterial load, as determined by PCR. There is a significant reduction in PPARγ 
gene expression with high levels of P. aeruginosa colonisation. Columns represent median values. 
Error bars represent the standard deviation. Significance determined by Mann-Whitney U test. 
Significant values denoted by an asterisk (*); ns = not significant.  
7.3.3  The Effect of Airway Immune Cells on PPARγ  Gene Expression 
Generally, high levels of P. aeruginosa are associated with dominant airway neutrophilia. PPARγ is 
produced by numerous airway cells, including neutrophils, macrophages, and eosinophils. One 
would expect that if airway immune cells produce PPARγ, PPARγ gene expression would be 
increased during airway inflammation. To determine whether PPARγ gene expression was related 
to airway immune cell counts, PPARγ gene expression was correlated to total neutrophil and 
macrophage levels. No significant correlation was observed between total neutrophil count and 
PPARγ gene expression (r=-0.19, p=0.329), Figure 7.7. However a weak, but significant positive 
correlation was observed between PPARγ gene expression and total macrophage count (r=0.38, 
p=0.044), Figure 7.8.  
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Figure 7.7: Correlation between total neutrophil count in induced sputum against relative PPARγ 
gene expression in BAL-derived cells (n=31). Points represent individual patient values; dotted line 
represents the line of best fit.  
 
Figure 7.8: Correlation between total macrophage count in induced sputum with relative PPARγ 
gene expression in BAL-derived cells (n=31). Points represent individual patient values; dotted line 
represents the line of best fit.  
 
This suggests that perhaps, greater numbers of macrophages in the airway lumen underlie the 
increased PPARγ mRNA expression, and perhaps the presence of P. aeruginosa drives macrophage 
reduction in this group, and thus the PPARγ expression. To investigate this further, total P. 
aeruginosa was correlated with total macrophage count in BAL fluid. As predicted, there was a 
significant, negative correlation between macrophages and P. aeruginosa (r=-0.408, p=0.023), 
Figure 7.9. 
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Figure 7.9: Correlation between total macrophage count in induced sputum against total P. 
aeruginosa bacterial load (n=31). Points represent individual patient values; dotted line represents 
the line of best fit.  
 
7.3.5  The Effect of Quorum Sensing Molecules on PPARγ  Gene Expression in Immune Cells 
The P. aeruginosa quorum sensing molecule, 3-oxo-C12-HSL, has been previously reported to 
down-regulate PPARγ in endothelial cells [111]. In order to determine whether the quorum sensing 
molecules PQS and 3-oxo-C12-HSL down regulated PPARγ in immune cells, whole PBMCs, taken 
from healthy volunteers, were activated with PMA and ionomycin, then treated with 10 µM of 3-
oxo-C12-HSL, and the expression of PPARγ was assessed by qPCR following overnight incubation 
(15 hours). 
 
An initial dose finding experiment was performed using 10 µM and 1 µM concentrations of quorum 
sensing molecules. Previous in vitro studies have tended to examine the effects of very high 
concentrations of quorum sensing molecules. However, there is no clear data on the concentration 
of quorum sensing molecule in the airways, with measured in vivo levels being in the pM-nM range 
[157]. Concentrations at the epithelium are not known. 
 
In this initial dose finding experiment, there was a significant down-regulation in PPARγ gene 
expression in activated PBMCs in the presence of 10 µM 3-oxo-C12-HSL (PMA activated PBMC 
fold change: 4.16 (IQR, 3.46-6.50), n=10 vs. 10 µM 3-oxo-C12-HSL fold change: 2.11 (IQR, 1.29 
– 3.00, n=4, p=0.014, Mann-Whitney U test), but not vs. 1 µM (p=0.181, Mann-Whitney U test). 
Interestingly, there was also a significant down regulation of PPARγ gene expression in activated 
PBMCs in the presence of 10 µM PQS (PMA activated PBMC fold change: 4.16 (IQR, 3.46-6.50), 
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n=10 vs. 10 µM PQS fold change: 1.88 (IQR, 1.32–2.20, n=6, p<0.001, Mann-Whitney U test), and 
vs. 1 µM PQS (p<0.001; Mann-Whitney U test), a molecule not previously associated with PPARγ 
modulation, Figure 7.10. 
 
 
 
 
Figure 7.10: PPARγ gene expression in PBMCs stimulated with PMA and ionomycin (n=10) and 
then treated with 10 µM or 1 µM of 3-oxo-C12 (top) or PQS (bottom) (n=6). PPARγ expressed as 
fold change relative to the expression of β-actin and normalised to the expression of the control 
group (n=6). Significance determined by Mann-Whitney U test. Significant values denoted by an 
asterisk (*).  
 
Both PQS and 3-oxo-C12 are lipophilic molecules and, for this experiment, were solubilised in 
DMSO before being diluted 1:10,000 in growth media. To investigate whether the vehicle (DMSO) 
had an influence on the result, the experiment was repeated with a vehicle control, following PMA 
stimulation. On this occasion, 10 mM quorum sensing molecules were used. There was significant 
inhibition of PPARγ gene expression in stimulated PBMCs with 10 µM PQS vs. the PMA control 
(p=0.002, Mann-Whitney U test), however there was no significant inhibition of PPARγ gene 
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expression with 10 mM 3-oxo-C12-HSL vs. the DMSO-vehicle control (p=0.195, Mann-Whitney U 
test). Surprisingly, there was a significant impact of the vehicle, DMSO, even at 1:10,000 dilution 
(PMA activated PBMC fold change: 9.35 (IQR, 8.43-11.50), n=8; 1:10,000 DMSO fold change: 
7.43 (IQR, 7.08-7.90), n=6; p=0.005, Mann-Whitney U test), questioning the validity of the quorum 
sensing molecule inhibition of PPARg, Figure 7.11. 
 
 
 
Figure 7.11: PPARγ gene expression in PBMCs activated with PMA and ionomycin (n=8) and then 
treated with 1:10,000 DMSO (n=6), 10 µM of 3-oxo-C12 (3 10 µM) or PQS (PQS 10 µM) in 
DMSO (1:10,000) (n=6). PPARγ expressed as fold change relative to the expression of β-actin and 
normalised to the expression of the control group. Significance determined by Mann-Whitney U 
test. Significant values denoted by an asterisk (*).  
 
The experiment was repeated again and the method adjusted such that DMSO was added directly to 
the well and allowed to evaporate before PBMCs were added. Despite this, an effect of the vehicle 
on PPARγ expression was still encountered, Figure 7.12. 
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Figure 7.12: PPARγ gene expression in PBMCs activated with PMA and ionomycin (n=14) and 
then treated with 1:10,000 DMSO (n=15), 10 µM of 3-oxo-C12 or PQS in DMSO (1:10,000) 
(n=15) allowing DMSO to evaporate prior to addition of cells and media. PPARγ expressed as fold 
change relative to the expression of β-actin and normalised to the expression of the control group. 
Significance determined by Mann-Whitney U test. Significant values denoted by an asterisk (*).  
 
7.3.6  The Effect of PPARγ  Gene Expression Levels on Clinical Variables 
To determine whether the alterations in PPARγ were associated with important clinical outcomes, 
correlations with lung function, sputum volume, and exacerbation rate were carried out. FEV1 is 
often used as a marker of severity of lung function. PPARγ gene expression levels in BAL were 
therefore correlated with FEV1 % predicted. There was no significant correlation between PPARγ 
expression and lung function as measured by FEV1 (r=0.082, p=0.225), Figure 7.13. When lung 
function was broken down into centiles, there was still no prominent group associated with PPARγ 
gene expression, Figure 7.14. 
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Figure 7.13: Correlation between PPARγ relative gene expression in BAL-derived cells against per 
cent predicted FEV1 in non-CF bronchiectasis subjects (n=31). Points represent individual patient 
values; dotted line represents the line of best fit.  
 
 
 
Figure 7.14: PPARγ gene expression in BAL-derived cells from non-CF bronchiectasis patients 
divided into FEV1 centiles (>80% (n=13), 70-79% (n=7), 60-69% (n=6) and <50-59% (n=5) 
predicted). Horizontal lines represent median values. Error pars represent the standard deviation. 
Significance determined by Mann-Whitney U test; ns = not significant.  
 
Agonising PPARγ has been implicated in the inhibition of stimulated MUC5AC expression, 
potentially reducing sputum volume in subjects with excessive inflammation [158]. To investigate 
whether airway PPARγ gene expression was related to sputum amount, PPARγ gene expression 
levels were correlated with 24 hour sputum weight. There was a trend to lower PPARγ gene 
expression with increasing sputum volume, suggesting that the more PPARγ expression, the less 
sputum produced, however this did not reach statistical significance (r=-0.190, p=0.276) Figure 
7.15.  
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Figure 7.15: Correlation between PPARγ relative gene expression in BAL-derived cells against 
daily sputum production in non-CF bronchiectasis subjects (n=31). Points represent individual 
patient values; dotted line represents the line of linear regression.  
 
This trend was reflected with measurements of CRP (r=-0.137, p=0.449). However, again, the 
association was weak and non significant, Figure 7.16. 
 
 
 
Figure 7.16: Correlation between PPARγ relative gene expression in BAL-derived cells against 
CRP in non-CF bronchiectasis subjects (n=31). Points represent individual patient values; dotted 
line represents the line of linear regression.  
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No correlation was observed between PPARγ gene expression in BAL and exacerbation frequency, 
either in the 12 months prior to the trial, or in the 12 months on the trial (r=-0.082, p=0.373 - 
measured in the placebo group only, Figure 7.17).  
 
 
Figure 7.17: Correlation between PPARγ relative gene expression in BAL-derived cells against 
protocol defined exacerbation frequency in non-CF bronchiectasis subjects (n=18). Points represent 
individual patient values; dotted line represents the line of linear regression.  
 
There was also no association with PPARγ gene expression and quality of life as measured by both 
the LCQ (r=-0.093, p=0.596) or the SGRQ (r=-0.029, p=0.869), Figure 7.18, although the line of 
linear regression trends with improved quality of life with increasing PPARγ gene expression.  
 
 
Figure 7.18: Correlation between PPARγ relative gene expression in BAL-derived cells against 
SGRQ (left) and LCQ (right) in non-CF bronchiectasis subjects (n=31). Points represent individual 
patient values; dotted line represents the line of linear regression.  
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7.3.7  The Effect of Macrolide on PPARγ  Gene Expression 
In order to determine whether erythromycin has an effect on PPARγ gene expression, PPARγ 
expression levels were assessed in BAL fluid (as above) following 48 weeks of either erythromycin 
or placebo. Erythromycin did not affect PPARγ gene expression levels (placebo: 1.96, IQR 1.25 – 
3.14, n = 16, vs. Bronchiectasis: 1.42, IQR 0.85–2.01, n = 14; p=0.101, Mann-Whitney U test), 
Figure 7.19. 
 
Figure 7.19: Relative PPARγ gene expression, as determined by RT-PCR in BAL-derived cells of 
non-CF bronchiectasis subjects following 48 weeks of either placebo or erythromycin treatment. 
Gene expression levels were expressed relative to the expression of the housekeeping gene, β actin 
and normalised to the median of the original healthy control group. Points represent individual 
subjects. Horizontal lines represent median values. Error pars represent the standard deviation. 
Significance determined by Mann-Whitney U test; ns = not significant. 
  
There was a significant increase in PPARγ gene expression in both the placebo and erythromycin 
treated groups throughout the trial, with a similar magnitude of effect in each group, Figure 7.20. 
 
Figure 7.20: Relative PPARγ gene expression, as determined by RT-PCR in BAL-derived cells of 
non-CF bronchiectasis subjects at baseline and following 48 weeks of treatment. The placebo arm is 
shown on the left (n=16). The erythromycin arm is shown on the right (n=14). Gene expression 
levels were expressed relative to the expression of the housekeeping gene, β actin and normalised to 
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the median of baseline. Points represent individual subjects. Significance determined by paired t-
test. Significant values denoted by an asterisk (*). 
 
Both PPARγ and erythromycin have been shown previously to reduce mucus hyper-secretion in 
inflammatory airway diseases via multiple methods [37, 113, 155]. Quorum sensing molecules have 
been shown to down-regulate PPARγ. Chapter 6 also demonstrated that erythromycin inhibited 
quorum sensing gene expression. Section 7.3.6 has shown a non-significant, but negative 
correlation with PPARγ expression and sputum amount, suggesting that the more PPARγ 
expression, the less sputum produced. It was therefore hypothesised that there would be a stronger 
correlation between PPARγ expression and sputum amount in the erythromycin treated arm (where 
the presence of quorum sensing molecules would be lower) than in the placebo arm. There was a 
non-significant, albeit negative correlation between PPARγ expression and sputum amount in the 
erythromycin arm (r=-0.306, p=0.285 Spearman r), consistent with the hypothesis. Conversely, 
there was a positive correlation between PPARγ and sputum amount in the placebo arm (r=0.196, 
p=0.482 Spearman r), Figure 7.21.  
 
 
Figure 7.21: Correlation between PPARγ relative gene expression in BAL against daily sputum 
production following 48 weeks of either placebo (n=16) or erythromycin treatment (n=14), in non-
CF bronchiectasis subjects divided into the placebo arm (left panel) and the erythromycin arm (right 
panel). Points represent individual patient values; dotted line represents the line of linear regression. 
 
When only those samples with >4 Log10cfu/mL P. aeruginosa were assessed, the direction of the 
correlation still held true in both groups, however these correlations were not statistically significant 
(Erythromycin r=-0.452, p=0.268 Spearman r; Placebo r=1.00, p=0.333 Spearman r), Figure 7.22. 
Importantly, after including only the P. aeruginosa positive subjects, the Placebo arm was only left 
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with three points, making any correlation assessments non-credible. Figures have been included for 
illustrative purposes only.  
 
 
Figure 7.22: Correlation between PPARγ relative gene expression in BAL against daily sputum 
production following 48 weeks of either placebo or erythromycin treatment, in non-CF 
bronchiectasis subjects divided into the placebo arm (left panel, n=3) and the erythromycin arm 
(right panel, n=8). Subjects PCR positive for P. aeruginosa are included. Points represent 
individual patient values; dotted line represents the line of best fit. Note, only three points remain in 
the Placebo group. Figure has been included for illustrative purposes only. 
 
7.4 DISCUSSION 
This chapter aimed to assess the relevance of PPARγ in the context of P. aeruginosa colonisation in 
non-CF bronchiectasis. PPARγ is an anti-inflammatory product of leukocytes, which has been 
shown to inhibit, or switch off NFκB in response to lipids [113], potentially reigning in exuberant 
inflammation. P. aeruginosa quorum sensing molecules are lipid like structures, which easily 
interact with PPARγ and have been shown to be associated with lower level PPARγ gene expression 
in endothelial and other cell lines [111]. Low level PPARγ production may be part of the reason 
why mucus hyper-secretion occurs in inflammatory airway diseases. Macrolides may also enhance 
PPARγ activity via modulation of NFκB, allowing effective switching off of mucin production in 
stimulated airways [159]. 
 
Low level PPARγ expression in the airways has been shown in CF, and may explain the reason why 
excessive inflammation occurs in this context. In CF it has also been shown that the lowest PPARγ 
levels were associated with P. aeruginosa [115]. The data presented in this chapter supports that 
lower levels of PPARγ are also present in the airways of non-CF bronchiectasis subjects, despite an 
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aggressive inflammatory response. This low level PPARγ expression is particularly associated with 
the presence of high levels of P. aeruginosa, suggesting an intrinsic link with this bacterial species, 
perhaps related to the interaction of quorum sensing molecules with PPARγ. Contrary to the 
literature, the paroxinase PON2 was not expressed in lower levels in the airways of non-CF 
bronchiectasis subjects in this study. PON2 degrades 3-oxo-C12-HSL via lactonlysis [112]. 
Previous authors have hypothesised that the lack of PON2 allows 3-oxo-C12-HSL to go unchecked 
in its interaction with PPARγ, suggesting that it is actually the absence of degradation by PON2 that 
allows quorum sensing molecules to inhibit PPARγ. This may not be the case in the non-CF 
bronchiectatic lung however, where one would hypothesise that, after several years of adaptation to 
the airways, a degree of equilibrium has been established between P. aeruginosa and the host. We 
know that in the later stages of CF infection, LasR mutants accumulate [44, 147, 150], 
hypothetically reducing the amount of 3-oxo-C12-HSL produced (as has been demonstrated in 
vitro). An alternate hypothesis is that a normal level of PON2 expression is, in fact, inappropriate to 
the degree of stimulation by 3-oxo-C12-HSL, and that one would expect PON2 expression to be 
increased to prevent PPARγ down-regulation by quorum sensing molecules. Levels of 3-oxo-C12-
HSL were not measured in the bronchoscopy group however, and this hypothesis cannot be tested 
with the data presented.  
 
PPARγ airway gene expression correlated significantly, and negatively, with P. aeruginosa, but not 
with other commonly encountered bacterial species nor total bacteria. This correlation held true 
even when subjects were grouped as per their dominant species, rather than quantified bacterial 
load. This suggests that there is a specific bacterial interaction with regulation of PPARγ or directly 
with the molecule itself.  
 
This investigation measured PPARγ gene expression in cells derived from the airway fluid of 
healthy and non-CF bronchiectasis subjects. Airway fluid comprises mainly immune cells such as 
neutrophils, eosinophils and macrophages. Minimal epithelial cells are collected, and PPARγ RNA 
is highly unlikely to be stable in free airway fluid meaning that the contribution of epithelial derived 
PPARγ is like to be negligible. Airway measures of PPARγ must therefore originate from these 
immune cells, the majority of which, in non-CF bronchiectasis airways, are neutrophils. In order to 
determine whether there was any correlation with PPARγ gene expression and airway immune cells, 
PPARγ was correlated with the absolute and percentage immune cell count. Interestingly there was 
no correlation with airway neutrophils, but there was a weak but significantly positive correlation 
with airway macrophages. This suggests that the more macrophages there are, the more PPARγ, and 
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the more P. aeruginosa, the less PPARγ. Interestingly, there was an inverse correlation between P. 
aeruginosa and macrophages, where the more P. aeruginosa there was in the airways, the fewer 
macrophages were found. Previous in vitro studies have shown that the P. aeruginosa quorum 
sensing molecules HHQ and PQS down-regulate immune responses in monocyte/macrophage cell 
lines, and mouse respiratory lavage-derived cells by interference with NFκB [160]. There is 
evidence that the quorum sensing molecule 3-oxo-12-HSL accelerates apoptosis in macrophages 
[161], suggesting that in the presence of quorum sensing proficient P. aeruginosa there is the 
potential for fewer, less active macrophages. However, whether the reduction in total macrophages 
allows for more P. aeruginosa or the reverse is unclear. In order to investigate the relationship 
between P. aeruginosa and immune cells, whole PBMCs were extracted from healthy human 
controls, treated with quorum sensing molecules and PPARγ gene expression measured. Previous 
investigations on epithelial and endothelial cells have shown that 3-oxo-C12-HSL down-regulates 
PPARγ gene expression [111]. In this experiment, whilst low levels of 3-oxo-C12-HSL reduced the 
expression of PPARγ in activated PBMCs, there was a significant vehicle effect which could not be 
overcome. Interestingly, PQS also reduced the expression of PPARγ in these cells, something which 
has not been shown previously, however, again the vehicle had a significant impact on PPARγ 
expression. If the inhibition of both quorum sensing molecules is to be believed in this context, this 
suggests multiple pathways for P. aeruginosa quorum sensing molecules to interact with immune 
cells to inhibit PPARγ expression (such as interference with IkB) as PQS does not have a lipid-like 
structure and is unlikely to be a direct ligand of PPARγ. From this data, the low level 
PPARγ demonstrated in non-CF bronchiectasis could be a reflection of the presence of P. 
aeruginosa or due to the reduction in total and percentage macrophages in the lung. Further 
research is needed to determine the mechanism in this case. 
 
In order to determine whether PPARγ levels could predict important clinical outcomes, PPARγ gene 
expression levels, measured at baseline, were correlated with matched clinical outcomes. There 
were no significant correlations with specific clinical outcomes, however, there was a trend to 
decreased sputum amount with increasing PPARγ expression, which is consistent with previous 
literature implicating PPARγ agonism with decreased mucus hyper-secretion [158, 162]. Agonising 
PPARγ has been shown in vitro to inhibit MUC5AC secretion by goblet cells by inhibition of NFκB 
[158].  
 
The effect of macrolide on PPARγ activity has not previously been reported. Due to the structure of 
erythromycin it would not be predicted to be a ligand of PPARγ per se, however, in vitro at least, 
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both erythromycin and PPARγ agonists have very similar actions. Both reduce mucus hyper-
secretion [7, 158, 162], both have anti-cytokine properties [37, 39] and both act to rein in 
inflammation by interacting with NFκB [39, 163]. Both are also intrinsically linked to quorum 
sensing, with macrolide inhibiting quorum sensing and PPARγ expression being down-regulated by 
quorum sensing molecules. In order to determine whether erythromycin had an effect on PPARγ 
expression, airway levels of PPARγ were determined after 48 weeks of treatment with erythromycin 
or placebo. No difference between the two groups was noted, however there was a significant 
increase in airway PPARγ gene expression from baseline to week 48 in both treatment arms, but 
most consistently in the erythromycin treated arm. Importantly, when PPARγ gene expression was 
correlated with sputum volume after 48 weeks of erythromycin treatment, there was a non-
significant negative correlation seen only in the erythromycin treated group, which was exaggerated 
in the P. aeruginosa group. This suggests that erythromycin and PPARγ may be working 
synergistically to help reduce sputum volume. We have demonstrated that erythromycin inhibits 
quorum sensing in vivo (Chapter 6) and perhaps it is this inhibition that allows PPARγ gene 
expression to increase in the presence of erythromycin, working synergistically to reduce sputum 
volume, particularly in P. aeruginosa colonised patients. This potential association needs further 
research and will be discussed in Chapter 8 (Discussion and Future Directions), however cannot be 
strongly inferred from the data presented in this thesis.  
7.5 LIMITATIONS 
This study had a number of limitations. Firstly, the basis of this chapter was the investigation of 
PPARγ gene expression rather than its transcriptional activity. PPARγ may be subject to post 
transcriptional modification which could be affected by the complex environment of the human host 
and may vary between cell types. However, previous studies have shown a strong correlation 
between PPARγ gene expression and protein activity suggesting that this method is acceptable 
[164]. Previous studies assessing airway PPARγ expression in association with disease states have 
also arrived at similar conclusions [114, 115], meaning that this study is consistent with the reported 
literature of a down regulation of PPARγ in inflammatory airways diseases. Another limitation 
could be the baseline differences between the healthy control and the bronchiectasis group. The 
samples used for this thesis were not prospectively collected with assessment of PPARγ gene 
expression as the primary end point. Therefore some important differences were not adequately 
controlled for in a prospective manner. The main difference was that the healthy control group was 
significantly younger than the disease group, which may be relevant [165]. The healthy group, by 
its nature, did not have any airway disease, meaning that their lung function was better, they did not 
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have colonising pathogenic airway bacteria, and had no evidence of systemic inflammation, all of 
which necessarily confounded the analysis. From this however, we can say that there is lower 
PPARγ gene expression in a diseased group compared with a non-diseased group, however the 
specific reason for that difference cannot be reliably answered from this data. Within the diseased 
group there were significant correlations between PPARγ gene expression and specific disease 
markers such as presence of P. aeruginosa and abundance of macrophages. Correlation is not 
causation, however. In order to determine whether the correlation with PPARγ gene expression was 
related to quorum sensing molecules, PPARγ gene expression was assessed in vitro in immune cells 
in the presence of quorum sensing molecules. Whilst a significant down-regulation of PPARγ was 
noted in the presence of quorum sensing molecules, an effect of the vehicle was unable to be 
overcome. Measurements of both in vitro and in vivo levels of PPARγ were performed on either 
whole PBMCs or whole BAL, meaning that measurement of PPARγ secretion from individual 
immune cells was not possible. However, the only significant correlation noted in vivo was with 
total macrophage levels, suggesting that this cell, in this case, may be the most relevant to PPARγ 
expression. 
7.6  SUMMARY 
The data presented in this chapter supports that lower levels of PPARγ are expressed in the airways 
of non-CF bronchiectasis subjects, despite an aggressive inflammatory response. This low level 
PPARγ expression is particularly associated with the presence of P. aeruginosa, hinting at a 
possible mechanism involving this bacterial species. P. aeruginosa quorum sensing molecules are 
lipid like structures, which easily interact with PPARγ and may be the explanation for the low-level 
gene expression noted in this group. Erythromycin may work synergistically with PPARγ to help 
reduce inflammation in the airways, inhibit P. aeruginosa quorum sensing and reduce mucus hyper-
secretion in non-CF bronchiectasis. 
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CHAPTER 8: CONCLUSIONS AND FUTURE DIRECTIONS 
This thesis examined the effect of erythromycin on P. aeruginosa in non-CF bronchiectasis. The 
broad aims were to determine the effect of erythromycin on quorum sensing in P. aeruginosa typed 
and clinical isolates; to determine the in vivo effect of erythromycin on quorum sensing by P. 
aeruginosa within the respiratory tract; and to determine whether PPARγ is inhibited by P. 
aeruginosa in the airways of non-CF bronchiectasis subjects. 
 
Central to this thesis was the understanding of the mechanism for clinical benefit of erythromycin in 
non-CF bronchiectasis. Erythromycin has been shown both in BLESS and in the subgroup analysed 
here, to significantly reduce pulmonary exacerbations and sputum volume and improve quality of 
life. A previously published subgroup analysis [10] suggested that the benefit of erythromycin on 
exacerbations was seen in the P. aeruginosa dominant group only; hence it was this group that was 
studied in detail here. The mechanism of the benefit of erythromycin in P. aeruginosa colonised 
non-CF bronchiectasis subjects is unclear. This thesis has shown that, in the presence of 
erythromycin, there is specific reduction in the virulence of P. aeruginosa in the form of an 
inhibition of quorum sensing controlled traits. Associated with this diminution in virulence was a 
reduction in total sputum volume, suggesting an improvement in inflammation. This was 
complemented with the demonstration of low levels of PPARγ (a product associated with 
inflammation reduction) in P. aeruginosa colonised non-CF bronchiectasis patients. 
 
From these observations a potential mechanism can be described and was assessed here: The 
presence of P. aeruginosa contributes to exuberant inflammation in non-CF bronchiectasis subjects, 
contributing to exacerbations and excessive sputum production. This is partly due to the stimulation 
of predominantly neutrophilic inflammation, but also due to the reduction in PPARγ, a traditionally 
anti-inflammatory pathway, which is defective in non-CF bronchiectasis. With erythromycin 
treatment, the virulence of P. aeruginosa is decreased and, along with other known anti-mucin 
properties of erythromycin, contributes to the significant reduction in sputum volume and 
exacerbations. These broad concepts were tested in this thesis. 
 
Firstly, the in vitro effect of erythromycin on cultured isolates of P. aeruginosa was explored. There 
were multiple findings from these experiments including the confirmation of a predominantly 
inhibitory effect of erythromycin on quorum sensing in P. aeruginosa. However, this finding was 
tempered by the discovery that clinical isolates of P. aeruginosa behaved differently in vitro to that 
which would be expected; and that media and oxygen tension had a significant impact both on 
baseline phenotypic expression of quorum sensing-controlled traits, and the effect of erythromycin 
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on those characteristics. This observation questions the appropriateness of in vitro assessments when 
attempting to determine the effect of a drug on P. aeruginosa in vivo. Multiple previous studies have 
confirmed this within patient phenotypic variability in clinical isolates of P. aeruginosa [42, 44, 81, 
166]. However, there have been several other studies which continue to utilise isolate-based 
methods to predict clinical outcomes. The most extensive isolate based study to date assessed the 
phenotypic characteristics of over 2500 P. aeruginosa isolates in 649 children with CF over 5 years 
[167]. This study, using vast numbers of isolates, was able to predict clinical outcomes based on P. 
aeruginosa phenotype, which is useful information when assessing population risk. However, how a 
specific phenotype in a single isolate from a single patient relates to disease risk is unclear. 
Importantly, correlation between P. aeruginosa isolate in vitro phenotype and in vivo measurements 
of quorum sensing related pathogenic traits has not been proven, as exemplified in a study assessing 
the relevance of pyocyanin in the CF airway [50]. In that study, high levels of airway pyocyanin was 
associated with more severe disease (as measured by FEV1) however the cultured isolates 
demonstrated the opposite phenotype in vitro. From this it can be concluded that in vitro 
assessments of bacterial activity determine the potential behaviour that an isolate can exhibit, rather 
than the actual behaviour within the airway.  
 
In order to overcome the difficulty posed by interpreting in vitro culture studies, and to test the 
second hypothesis that erythromycin inhibits P. aeruginosa quorum sensing in vivo, a somewhat 
novel approach was taken. Rather than isolating P. aeruginosa from sputum and subjecting it to 
several in vitro experiments (as in the Chapter 5 studies and as typically used in the field), bacterial 
activity was determined directly from an aliquot of induced sputum. The challenge of this approach 
however, was extracting sufficient high quality bacterial RNA from human sputum and ensuring 
that there was no bacterial DNA contamination that could interfere in the PCR analysis. Several 
optimisation steps were required, however, a final robust method for extracting bacterial RNA from 
sputum was developed and utilised.  
 
The application of this methodology revealed a significant impact of erythromycin on P. aeruginosa 
quorum sensing specific gene expression in sputum, despite there being no impact on P. aeruginosa 
bacterial density. This confirms the hypothesis that quorum sensing is active in non-CF 
bronchiectasis, and that, at a gene expression level at least, it can be inhibited by erythromycin 
therapy. Attempts at translating the change in gene expression to changes in measurable phenotypes 
such as pyocyanin and elastase proved technically difficult and no link could be established. 
However, the patients in the erythromycin group, in this sub-analysis of the BLESS [7] study, had 
less sputum, fewer exacerbations, and better quality of life than those in the placebo arm. Inhibiting 
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quorum sensing in this group of patients therefore plausibly contributes to the complex mechanism 
of action of erythromycin on exacerbation reduction in non-CF bronchiectasis. Whilst this study 
only focussed on the P. aeruginosa infected arm, the clinical benefit on exacerbations in the wider 
BLESS cohort was only seen in the P. aeruginosa dominant group [10], reinforcing the significant 
role of P. aeruginosa in bronchiectasis pathogenesis.  
 
This is the first study to demonstrate the effect of erythromycin on P. aeruginosa quorum sensing 
both in vitro and in vivo. Previous in vivo studies have largely relied on animal models of disease 
[43, 168]. However, there is no currently available good animal model of non-CF bronchiectasis 
and, as such, researchers have necessarily had to rely on “healthy” animals or those with a mutation 
in the CFTR [43]. Assessing clinical effects in humans with the disease is the ideal method of 
investigating mechanisms of effect, however can sometimes be ethically challenging, impractical, 
require large numbers of subjects in order to overcome significant heterogeneity in disease 
presentation, and may only demonstrate an association rather than a direct effect. Despite these 
limitations, the current study was able to demonstrate that quorum sensing is active in non-CF 
bronchiectasis subjects (by way of the measurement of RNA transcripts in the airways of subjects), 
that erythromycin can inhibit airway quorum sensing specific gene expression, and that those 
patients had improved clinical (sputum and exacerbation reduction) and QoL outcomes. Only one 
previous study has specifically investigated the effect of macrolide on airway levels of quorum 
sensing gene expression [17]. That study also demonstrated that quorum sensing gene expression 
was specifically inhibited in the airways of intubated intensive care patients. However, this finding 
was tempered by a reduction in bacterial number and was unable to convincingly associate the 
reduction in quorum sensing activity with a clinically significant outcome, although two patients 
infected with rhamnolipid producing isolates subsequently developed VAP [54]. Taken together, the 
results from this thesis form a convincing association between erythromycin, quorum sensing 
inhibition and improved clinical outcomes, which may be independent of the effect of erythromycin 
on sputum volume reduction and inflammation. 
 
The work presented here provides a foundation for future studies examining the mechanism of 
action of macrolide, and the significance of P. aeruginosa quorum sensing, in the treatment of 
inflammatory airways diseases. In order to progress this, it would be important to first confirm the 
relevance of quorum sensing in the later stages of non-CF bronchiectasis by way of assessment of 
the accumulation of quorum sensing mutants. It has been previously shown that in the late stages of 
CF, quorum sensing mutants accumulate, whereby isolates mutate and therefore do not possess the 
LasR gene (so called quorum sensing cheats) [147]. What is not clear however, is how this 
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accumulation of quorum sensing cheats is relevant in the context of a mature, multi-phenotype 
bacterial colony, whereby only a small number of bacteria retain quorum sensing ability, to the 
benefit of the many cheats [18]. It is important to understand the proportion of quorum sensing 
proficient isolates present within the lung during the late stages of disease, because targeting this, 
even in the late stages of disease, could prove an important therapeutic option. One method may 
include deep sequencing the LasR gene region from bacteria in “whole sputum” and assessing the 
relative proportion of P. aeruginosa quorum sensing proficient sequences (as determined by 
presence of a functional LasR) to the whole. Further, refining airway gene expression analysis and 
airway assessment of quorum sensing related virulence traits (such as pyocyanin) would be vital to 
the understanding of how this pathogen relates to disease progression. Finally, linking these changes 
in quorum sensing phenotypes, in the presence of macrolide, with important clinical outcomes 
would help to provide further insight into the complex relationship between airway bacterial 
manipulation and specific disease outcomes. This would require a large prospective placebo-
controlled, randomised controlled trial, powered to detect changes in quorum sensing activity in the 
context of changes in clinically relevant outcomes such as sputum volume, lung function and 
exacerbation. Such a study would be much harder to perform now that macrolide is so widely used 
in the treatment of inflammatory airways diseases, however would be an important tool to further 
delineate this relationship. 
 
Finally, this thesis has demonstrated a low level of PPARγ gene expression in the airways of non-CF 
bronchiectasis subjects, compared with healthy controls, and correlated this with the presence of P. 
aeruginosa. This finding is consistent with published literature reporting low level PPARγ 
expression in other inflammatory airways diseases [114, 115, 163], but this is the first time this 
phenomenon has been reported in non-CF bronchiectasis. Macrolide antibiotics and PPARγ agonists 
have similar mechanisms of action in vitro, probably related to the common final pathway of NFκB 
inhibition [155, 163]. Nonetheless, the use of macrolide in P. aeruginosa colonised subjects in this 
study was associated with an increase in PPARγ gene expression, as well as a reduction in sputum 
volume suggesting a possible synergistic relationship between these two molecules which could be 
exploited clinically. PPARγ agonists have been developed for the treatment of Type 2 Diabetes 
Mellitus and it would be an informative randomised trial to assess the potential for augmentation of 
PPARγ in the treatment of inflammatory airways diseases. This trial would need to be done in a 
prospective, randomised, double blind, placebo-controlled manner in non-CF bronchiectasis 
subjects. A combination of macrolide exposed and macrolide naïve subjects should be recruited (to 
ensure adequate recruitment), however randomisation would need to be stratified for macrolide use. 
The primary end point would be clinical outcomes such as exacerbation frequency and quality of 
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life, however measurements of airway inflammation, such as sputum amount, airway cytokines and 
bacterial colonisation would also be important to measure. There is sufficient in vitro and in vivo 
data to support a positive effect of PPARγ augmentation on inflammation [111, 114, 158, 162], 
however, due to the reported potential adverse effects on cardiovascular outcomes in the elderly 
with the glitazones [169], careful patient selection and drug choice would be essential. 
 
This study has clearly determined a role for interference of bacterial virulence by macrolide directly 
within the airways of subjects with non-CF bronchiectasis, colonised with P. aeruginosa and may, 
in part, explain some of the mechanism for benefit of macrolide in this population. This is 
significant as it lends support to the importance of personalised medicine, particularly in this 
heterogeneous group of patients, where stratification dependent upon microbiology is an important 
consideration. Macrolides are not without their side effects and it is important to ensure that the 
benefit of treatment outweighs the risks. This study has supported a role for macrolide in P. 
aeruginosa colonised patients with bronchiectasis and has demonstrated that the possible benefit of 
macrolide may be due to specific inhibition of P. aeruginosa quorum sensing directly within the 
airways. This thesis has confirmed that, even at what is considered to be sub-inhibitory doses of 
macrolide, a non-bactericidal effect on bacteria in the lower airways does occur and should not be 
ignored. 
 
In summary, this thesis has examined the complex relationship between macrolide, P. aeruginosa 
and anti-inflammatory molecules in non-CF bronchiectasis, and has found that macrolide 
specifically inhibits P. aeruginosa quorum sensing both in vitro and in vivo. Erythromycin may also 
work synergistically with endogenous anti-inflammatory molecules to rein in inflammation in vivo, 
both directly (by down regulating NFκB) and indirectly (by inhibiting quorum sensing and therefore 
bacterial pathogenicity), furthering our understanding of the mechanism of benefit of macrolide in 
P. aeruginosa infected non-CF bronchiectasis subjects.  		  
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APPENDICES 
APPENDIX 1: QIAamp Mini DNA Kit extraction protocol 	
1. Pellet bacteria by centrifugation for 10min at 10,000 x g 
2. Resuspend bacterial pellet in 180mL Buffer ATL 
3. Add 20mL proteinase K, mix by vortexing and incubate at 56oC until the tissue is 
completely lysed (3 hours). Vortex occasionally during incubation to disperse the sample or 
place in a shaking water bath or on a rocking platform. 
4. Briefly centrifuge the 1.5 mL microcentrifuge tube to remove drops form the inside of the 
lid 
5. Add 200mL Buffer AL to the sample, mix by pulse vortexing for 15 sec and incubate at 
70oC for 10 min. Briefly centrifuge the 1.5 mL microcentrifuge tube to remove drops from 
inside the lid. 
6. Add 200 µL 100% ethanol to the sample, and mix by pulse-vortexing for 15 sec. After 
mixing, briefly centrifuge the 1.5 mL microcentrifuge tube to remove drops from inside the 
lid. 
7. Carefully apply the mixture from step 6 (including the precipitate) to the QIAamp Mini spin 
column without wetting the rim. Close the cap and centrifuge at 6000 x g for 1 min. Place 
the QIAamp Mini spin column in a clean 2ml collection tube (provided) and discard the tube 
containing the filtrate. 
8. Carefully open the QIAamp Mini spin column and add 500mL Buffer AW1 without wetting 
the rim. Close the cap and centrifuge at 6000 x g for 1 min. Place the QIAamp Mini spin 
column in a clean 2 mL collection tube (provided) and discard the tube containing the 
filtrate. 
9. Carefully open the QIAamp Mini spin column and add 500 mL Buffer AW2 without 
wetting the rim. Close the cap and centrifuge at 20,000 x g for 3 min. 
10. Place the QIAamp Mini spin column into a new 2ml collection tube and discard the old 
collection tube with the filtrate. Centrifuge at full speed for 1 min. 
11. Place the QIAamp Mini spin column into a 1.5 mL microcentrifuge tube and discard the old 
collection tube with the filtrate. Carefully open the QIAamp Mini spin column and add 
100mL Buffer AE. Incubate at room temperature for 1 min then centrifuge at 6000 x g for 1 
min. 
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APPENDIX 2: High Pure RNA Isolation Kit protocol 
1. Pellet the sample by centrifugation at 10,000 x g 
2. Resuspend the cells in 200µL PBS 
3. Add 400 µL Lysis/Binding Buffer and vortex for 15 s 
4. To transfer the sample to a High Pure Filter Tube: 
a. Insert one High Pure Filter Tube into one collection tube 
b. Pipet the entire sample into the upper reservoir of the Filter Tube (max 700 µL 
5. Insert the entire High Pure Filter Tube assemble into a standard table-top centrifuge 
a. Centrifuge the tube assembly 15 s at 8,000 x g 
6. After centrifugation 
a. Remove the Filter Tube from the Collection Tube; discard the flow-through, and again 
combine the Filter Tube and the used Collection Tube 
7. After re-inserting the Filter Tube 
a. For each sample, pipet 90 µL DNase I Incubation buffer into a sterile reaction tube, add 10 
µL DNase I, mix, and pipet the solution onto the glass fibre fleece in the upper reservoir of 
the filter tube 
b. Incubate for 15 min at +15 to +25oC 
8. Add 500 µL Wash Buffer I to the upper reservoir of the Filter Tube assembly and centrifuge 15 s at 
8,000 x g. 
a. Discard the flow-through and combine to Filter Tube with the used Collection Tube 
9. Add 500 µL Wash Buffer II to the upper reservoir of the Filter Tube assembly and centrifuge 15 s at 
8,000 x g. 
a. Discard the flow-through and combine to Filter Tube with the used Collection Tube 
10. Add 200 µL Wash Buffer II to the upper reservoir of the Filter Tube assembly and centrifuge for 2 
min at maximum speed (approx. 13,000 x g) to remove any residual Wash Buffer. 
11. Discard the Collection Tube and insert the Filter Tube into a clean sterile 1.5mL microcentrifuge 
tube. 
12. To elute the RNA 
a. Add 50-100 µL Elution Buffer to the upper reservoir of the Filter Tube. 
b. Centrifuge the tube assembly for 1min at 8,000 x g. 
13. The microcentrifuge tube contains the eluted, purified RNA, which can be used directly in RT-PCT 
or stored at -80oC for later analysis. 	
